Clinical Trials

Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers

Conditions:   Cervical Cancer;   Endometrial Cancer;   Ovarian Cancer;   Vaginal Cancer;   Carcinoma of the Vulva
Intervention:   Drug: Avastin
Sponsors:   Dana-Farber Cancer Institute;   Genentech, Inc.;   Brigham and Women's Hospital;   Beth Israel Deaconess Medical Center;   Massachusetts General Hospital;   Lowell General Hospital;   Saint Anne's Hospital
Completed

Wed, 17 Oct 2007 12:00:00 EDT

Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Vestibular Schwannoma

Condition:   Vestibular Schwannoma
Intervention:   Drug: Bevacizumab (Avastin)
Sponsors:   Northwell Health;   Feinstein Institute for Medical Research;   Hofstra North Shore
Suspended

Wed, 10 Mar 2010 12:00:00 EST

Phase II Study of Bevacizumab (Avastin®) in Myelofibrosis

Condition:   Myelofibrosis
Intervention:   Drug: bevacizumab (Avastin)
Sponsors:   Ronald Hoffman;   Myeloproliferative Disorders-Research Consortium;   National Cancer Institute (NCI)
Terminated

Mon, 28 Apr 2008 12:00:00 EDT

Avastin in Combination With Temozolomide for Unresectable or Multifocal GBMs and Gliosarcomas

Conditions:   Glioblastoma;   Gliosarcoma
Intervention:   Drug: Avastin and Temozolomide
Sponsors:   Duke University;   Genentech, Inc.;   Schering-Plough
Completed

Mon, 11 Feb 2008 12:00:00 EST

Topical Avastin for Treatment of Corneal Neovascularization

Condition:   Corneal Neovascularization
Intervention:   Drug: Topical Avastin 1%
Sponsor:   Massachusetts Eye and Ear Infirmary
Completed

Fri, 16 Nov 2007 12:00:00 EST

Observational Study to Evalute the Efficacy and Safety of Avastin (Bevacizumab) in Addition to Platinum-Based Chemotherapy for First-Line Treatment of Participants With Non-Small Cell Lung Cancer

Condition:   Carcinoma, Non-Small-Cell Lung
Intervention:   Drug: Bevacizumab
Sponsor:   Hoffmann-La Roche
Completed

Wed, 31 May 2017 12:00:00 EDT

Avastin/FOLFIRI in Combination With Curcumin in Colorectal Cancer Patients With Unresectable Metastasis

Condition:   Colorectal Cancer
Interventions:   Drug: Avastin/FOLFIRI;   Dietary Supplement: Curcumin
Sponsors:   Gachon University Gil Medical Center;   Aju Pharm
Completed

Fri, 08 May 2015 12:00:00 EDT

Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer

Conditions:   Ovarian Cancer;   Primary Peritoneal Serous Cancer;   Fallopian Tube Cancer
Intervention:   Drug: bevacizumab
Sponsors:   Beth Israel Deaconess Medical Center;   Dana-Farber Cancer Institute;   Massachusetts General Hospital;   Genentech, Inc.
Terminated

Fri, 20 Mar 2009 12:00:00 EDT

Avastin as an Adjunct to Diode Laser in the Treatment of Neovascular Glaucoma

Condition:   Neovascular Glaucoma
Intervention:   Procedure: Diode laser cyclophotocoagulation enhanced by intravitreal injection of Avastin
Sponsors:   Cairo University;   AL-Nour Eye Hospital;   Kasr El Aini Hospital
Completed

Mon, 18 Jan 2010 12:00:00 EST

Safety and Efficacy Study of Avastin in Locally Advanced Metastatic or Recurrent Non-small Lung Cancer (NSLC) Participants

Condition:   Non-Squamous Non-Small Cell Lung Cancer
Intervention:   Drug: Bevacizumab
Sponsor:   Hoffmann-La Roche
Completed

Wed, 04 Nov 2015 12:00:00 EST

Bioequivalence and Safety Study of Bevacizumab-biosimilar (RPH-001) Compared to Bevacizumab-innovator

Condition:   Healthy
Interventions:   Biological: RPH001;   Biological: Avastin®
Sponsor:   TRPHARM
Withdrawn

Thu, 27 Apr 2017 12:00:00 EDT

Pharmacokinetic Equivalence and Safety Study of RPH-001 and Avastin®

Condition:   Healthy
Interventions:   Biological: RPH-001;   Biological: Avastin
Sponsors:   R-Pharm;   Almedis
Completed

Thu, 06 Sep 2018 12:00:00 EDT

Atezolizumab Plus Bevacizumab in First Line NSCLC Patients

Condition:   Non Small Cell Lung Cancer
Intervention:   Drug: Atezolizumab-Bevacizumab
Sponsor:   Fundación GECP
Active, not recruiting

Mon, 11 Feb 2019 12:00:00 EST

Neuradiab® Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme

Condition:   Brain Tumors
Intervention:   Drug: Neuradiab in combination with Bevacizumab (Avastin)
Sponsor:   Bradmer Pharmaceuticals Inc.
Unknown status

Thu, 21 May 2009 12:00:00 EDT

Bevacizumab Treatment For Posterior Zone I ROP

Condition:   Retinopathy of Prematurity
Intervention:   Drug: Bevacizumab
Sponsors:   Jaeb Center for Health Research;   Pediatric Eye Disease Investigator Group;   National Eye Institute (NEI)
Not yet recruiting

Wed, 18 Nov 2020 12:00:00 EST

Bevacizumab Plus Modified FOLFOX6 Regimen as the Salvage Treatment in Metastatic Breast Cancer (MBC) Patients

Condition:   Metastatic Breast Cancer
Intervention:   Drug: Avastin + mFOLFOX6
Sponsor:   Fudan University
Completed

Mon, 06 Aug 2012 12:00:00 EDT

A Study Examining Maintenance Bevacizumab (Avastin®) Monotherapy in Participants With Advanced Lung Adenocarcinoma

Condition:   Lung Adenocarcinoma
Intervention:   Drug: Bevacizumab
Sponsor:   Hoffmann-La Roche
Completed

Thu, 20 Mar 2014 12:00:00 EDT

Evaluation of the Effect of Intravitreal Injections of Anti-VEGF on Macular Perfusion in Diabetic Patients Using OCTA

Conditions:   Diabetic Macular Edema;   Ischemic Maculopathy
Intervention:   Drug: Bevacizumab
Sponsor:   Cairo University
Completed

Fri, 11 Aug 2017 12:00:00 EDT

Bevacizumab and BKM-120 in Patients With Metastatic Renal Cell Carcinoma

Condition:   Renal Cell Carcinoma
Intervention:   Drug: BKM-120 Bevacizumab
Sponsors:   Toni Choueiri, MD;   Beth Israel Deaconess Medical Center
Completed

Tue, 25 Jan 2011 12:00:00 EST

Evaluation of Retinal and Vascular Features in Macular Degeneration After Intravitreal Injections of Bevacizumab

Condition:   Exudative Age-related Macular Degeneration
Intervention:   Drug: Bevacizumab Injection
Sponsor:   Federico II University
Completed

Thu, 24 Oct 2019 12:00:00 EDT

The Effects of Preoperative Bevacizumab on Perioperative Complications

Conditions:   Colorectal Cancer;   Lung Cancer;   Operation Wound; Infection;   Bevacizumab
Intervention:   Drug: Bevacizumab
Sponsor:   Second Affiliated Hospital, School of Medicine, Zhejiang University
Not yet recruiting

Tue, 09 Mar 2021 12:00:00 EST

Bevacizumab-containing Regimen for Metastatic Colorectal Cancer Failed to Cytotoxic Treatment

Conditions:   Neoplasm;   Colorectal Cancer;   Metastatic Neoplasm
Intervention:   Drug: Bevacizumab
Sponsor:   Sixth Affiliated Hospital, Sun Yat-sen University
Not yet recruiting

Wed, 27 Aug 2014 12:00:00 EDT

Therapy for Locally Advanced Breast Cancer Using Doxil, Paclitaxel, and Cyclophosphamide With Avastin

Condition:   Invasive Breast Cancer
Intervention:   Drug: Doxil, Paclitaxel, Cyclophosphamide, Avastin
Sponsors:   University of Alabama at Birmingham;   Ortho Biotech, Inc.;   Genentech, Inc.
Completed

Thu, 13 Mar 2008 12:00:00 EDT

Intrapleural Bevacizumab Injection for Malignant Effusion in Lung Cancer

Conditions:   Non-small Cell Lung Cancer;   Malignant Pleural Effusion
Intervention:   Drug: Bevacizumab
Sponsor:   Haihong Yang, MD, Pricipal investigator
Completed

Tue, 04 Feb 2014 12:00:00 EST

Submucosal Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)

Condition:   Hereditary Hemorrhagic Telangiectasia (HHT)
Intervention:   Drug: Submucosal Bevacizumab
Sponsor:   University of California, San Diego
Completed

Tue, 26 Jul 2011 12:00:00 EDT

Intravitreal Avastin in Proliferative Retinopathies

Condition:   Retinal Neovascularization
Intervention:   Drug: Avastin
Sponsor:   Ophthalmological Association Edelweiss
Completed

Tue, 27 Nov 2007 12:00:00 EST

Efficacy and Safety Study of Bevacizumab Plus Chemotherapy in EGFR-TKI Resistant Non-Squamous Non-Small Cell Lung Cancer

Condition:   Lung, Carcinoma
Intervention:   Drug: Bevacizumab
Sponsors:   Sun Yat-sen University;   First Affiliated Hospital, Sun Yat-Sen University;   Second Affiliated Hospital, Sun Yat-Sen University
Unknown status

Thu, 15 May 2014 12:00:00 EDT

AMG 102 and Avastin for Recurrent Malignant Glioma

Conditions:   Glioblastoma Multiforme;   Gliosarcoma
Interventions:   Drug: AMG 102;   Drug: Avastin
Sponsors:   Katy Peters;   Amgen
Completed

Thu, 29 Apr 2010 12:00:00 EDT

An Observational Study on Bevacizumab (Avastin) as First-Line Treatment in Colorectal Cancer Participants With Potentially Resectable Liver Metastases

Condition:   Colorectal Cancer
Intervention:   Drug: Bevacizumab
Sponsor:   Hoffmann-La Roche
Completed

Thu, 28 Apr 2011 12:00:00 EDT

Bevacizumab 0.500MG Intravitreal There Isn't Lower Than 0.625MG in the Treatment of ROP Type 1

Condition:   Retinopathy of Prematurity
Intervention:   Procedure: Injection of bevacizumab intravitreal (Avastin)
Sponsor:   Universidad Autonoma de San Luis Potosí
Unknown status

Tue, 18 Mar 2014 12:00:00 EDT

Bevacizumab for the Treatment of Corneal Neovascularization

Condition:   Corneal Neovascularization
Intervention:   Drug: Bevacizumab
Sponsor:   Chang Gung Memorial Hospital
Unknown status

Fri, 09 Oct 2009 12:00:00 EDT

Intravitreal Bevacizumab for Low Vision in Neovascular Age-related Macular Degeneration (AMD)

Condition:   Age Related Macular Degeneration
Intervention:   Drug: Bevacizumab
Sponsor:   IRCCS San Raffaele
Completed

Fri, 01 Apr 2011 12:00:00 EDT

A Study of Subcutaneous Bevacizumab in Relapsed / Progressive Glioblastoma

Condition:   Glioblastoma
Intervention:   Drug: Bevacizumab 25 mg in 1 ml subcutaneously daily
Sponsor:   Emory University
Completed

Thu, 05 Jun 2014 12:00:00 EDT

Effectiveness and Safety of Adding Bevacizumab to First Line Chemotherapy in Lung Cancer Patients With Stable Disease

Condition:   Non-small Cell Lung Cancer Metastatic
Intervention:   Drug: bevacizumab
Sponsor:   Beijing Hospital
Unknown status

Mon, 07 Aug 2017 12:00:00 EDT

Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy

Conditions:   Vitreous Hemorrhage;   Proliferative Diabetic Retinopathy
Intervention:   Drug: intravitreal injection of bevacizumab
Sponsor:   Khon Kaen University
Completed

Fri, 09 Nov 2012 12:00:00 EST

Avastin (Bevacizumab) Plus Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) for Advanced Stage Hodgkin Lymphoma

Condition:   Hodgkin Lymphoma
Intervention:   Drug: Avastin
Sponsors:   Massachusetts General Hospital;   Genentech, Inc.
Terminated

Mon, 28 Jul 2008 12:00:00 EDT

MYL-1402O Compared With Avastin®, in Patients With Stage IV nsNSCLC

Condition:   NSCLC Stage IV
Interventions:   Biological: Bevacizumab as MYL-1402O;   Biological: Bevacizumab as Avastin
Sponsor:   Mylan Inc.
Completed

Wed, 18 Nov 2020 12:00:00 EST

A Study of Bevacizumab to Prevent Malignant Ascites

Condition:   Malignant Ascites
Intervention:   Drug: Bevacizumab
Sponsors:   Baylor College of Medicine;   Genentech, Inc.
Withdrawn

Mon, 25 May 2009 12:00:00 EDT

Bevacizumab Therapy for Brain Arteriovenous Malformation

Condition:   Brain Arteriovenous Malformation
Intervention:   Drug: Bevacizumab
Sponsor:   University of California, San Francisco
Completed

Thu, 11 Dec 2014 12:00:00 EST

Phase 1 Trial of Bevacizumab Treatment for Severe Retinopathy of Prematurity

Condition:   Retinopathy of Prematurity
Intervention:   Drug: Bevacizumab
Sponsors:   Jaeb Center for Health Research;   Pediatric Eye Disease Investigator Group;   National Eye Institute (NEI)
Active, not recruiting

Tue, 17 Mar 2015 12:00:00 EDT

Super-Selective Intraarterial Intracranial Infusion of Bevacizumab (Avastin) for Glioblastoma Multiforme

Condition:   Glioblastoma Multiforme
Intervention:   Drug: Bevacizumab
Sponsor:   Global Neurosciences Institute
Recruiting

Fri, 07 Nov 2014 12:00:00 EST

Subconjunctival Bevacizumab and Recurrent Pterygium

Condition:   Recurrent Pterygium
Intervention:   Drug: Bevacizumab
Sponsor:   Instituto de Olhos de Goiania
Completed

Fri, 07 Dec 2012 12:00:00 EST

Avastin in Combination With Chemotherapy for RAS Mutant Unresectable Colorectal Liver-limited Metastases

Condition:   Colorectal Neoplasms
Interventions:   Drug: avastin;   Drug: mFOLFOX6
Sponsor:   Xu jianmin
Completed

Wed, 30 Oct 2013 12:00:00 EDT

Intralesional Bevacizumab for Treating AIDS-associated Kaposi´s Sarcoma of the Larynx, Pharynx and Oral Cavity

Condition:   Kaposi´s Sarcoma
Intervention:   Drug: Bevacizumab
Sponsor:   Centro de Investigación en. Enfermedades Infecciosas, Mexico
Completed

Wed, 16 Feb 2011 12:00:00 EST

Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations

Conditions:   Neuromyelitis Optica;   Neuromyelitis Optica Spectrum Disorder
Intervention:   Drug: Bevacizumab
Sponsors:   Johns Hopkins University;   Genentech, Inc.;   Guthy Jackson Charitable Foundation
Completed

Mon, 28 Jan 2013 12:00:00 EST

To Demonstrate Similarity of Pharmacokinetics and Evaluate Safety of CT-P16, EU-Approved Avastin and US-licensed Avastin

Condition:   Healthy
Interventions:   Drug: CT-P16;   Drug: EU-approved Avastin;   Drug: US-licensed Avastin
Sponsor:   Celltrion
Completed

Mon, 14 Aug 2017 12:00:00 EDT

Observation of Patients With Metastatic Colorectal Cancer Starting Chemotherapy Combined With Bevacizumab (Avastin)

Condition:   Metastatic Colorectal Cancer
Interventions:   Other: Observational Chemotherapy;   Drug: Concomitant Bevacizumab
Sponsor:   Hoffmann-La Roche
Completed

Mon, 23 Nov 2015 12:00:00 EST

Branch Retinal Vein Occlusion (BRVO) Treatment With Bevacizumab and Dexamethasone or Bevacizumab Only.

Condition:   Branch Retinal Vein Occlusion
Interventions:   Drug: Bevacizumab Ophthalmic and Intravitreal Dexamethasone;   Drug: Bevacizumab Ophthalmic
Sponsor:   He Eye Hospital
Not yet recruiting

Mon, 26 Oct 2020 12:00:00 EDT

Observational Studies of the Application of Bevacizumab in HER2-negative Breast Cancer Neoadjuvant Chemotherapy

Conditions:   Breast Cancer;   Bevacizumab;   Neoadjuvant Chemotherapy;   Molecular Targeted Therapy
Intervention:   Drug: bevacizumab
Sponsors:   LiNanlin,Ph.D, Chief Physician,Clinical Professor;   Roche Pharma AG
Unknown status

Mon, 30 Jul 2012 12:00:00 EDT

Bevacizumab in the Treatment of Malignant Pleural Effusions of Non-squamous Non-small Cell Lung Cancer

Condition:   Malignant Pleural Effusion
Intervention:   Drug: Bevacizumab
Sponsors:   Beijing Cancer Hospital;   Peking University First Hospital;   Peking University Third Hospital
Unknown status

Fri, 21 Oct 2016 12:00:00 EDT

DYNAmic Immune Microenvironment of HCC Treated With atezolIzumab Plus bevaCizumab

Condition:   Hepatocellular Carcinoma
Intervention:   Drug: Aatezolizumab plus Bevacizumab
Sponsor:   Tae Won Kim
Not yet recruiting

Thu, 08 Jul 2021 12:00:00 EDT

Phase II Study of Doxorubicin and Avastin® in Sarcoma.

Conditions:   Sarcoma;   Soft Tissue Sarcoma
Interventions:   Drug: Avastin;   Drug: Doxorubicin
Sponsor:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Terminated

Thu, 18 Sep 2008 12:00:00 EDT

First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC

Conditions:   Metastatic Breast Cancer;   Advanced Breast Cancer;   Triple Negative Breast Cancer
Interventions:   Drug: Atezolizumab;   Drug: Paclitaxel;   Drug: Bevacizumab
Sponsors:   MedSIR;   Hoffmann-La Roche
Recruiting

Fri, 29 May 2020 12:00:00 EDT

Central Retinal Vein Occlusion (CRVO) Treatment With Bevacizumab and Dexamethasone or Bevacizumab Only.

Condition:   Central Retinal Vein Occlusion
Interventions:   Drug: Bevacizumab Ophthalmic and Intravitreal Dexamethasone.;   Drug: Bevacizumab Ophthalmic.
Sponsor:   He Eye Hospital
Recruiting

Mon, 26 Oct 2020 12:00:00 EDT

A Study of Avastin (Bevacizumab) in Patients With Multiple Myeloma

Condition:   Multiple Myeloma
Intervention:   Drug: Bevacizumab
Sponsor:   Hoffmann-La Roche
Terminated

Wed, 05 Mar 2014 12:00:00 EST

High-dose Bevacizumab in Advanced Renal Carcinoma Patients

Conditions:   Renal Cancer;   Kidney Cancer
Intervention:   Drug: Bevacizumab
Sponsors:   SCRI Development Innovations, LLC;   Genentech, Inc.
Completed

Wed, 04 Apr 2007 12:00:00 EDT

Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed GBM

Conditions:   Glioblastoma Multiforme;   Brain Tumor
Intervention:   Drug: Bevacizumab
Sponsors:   Northwell Health;   Feinstein Institute for Medical Research
Active, not recruiting

Thu, 14 Mar 2013 12:00:00 EDT

Intravitreal Bevacizumab for the Treatment of CNV in VKH Disease - A Prospective Study

Condition:   Choroidal Neovascularization
Intervention:   Drug: bevacizumab
Sponsors:   University of Sao Paulo;   Fundação de Amparo à Pesquisa do Estado de São Paulo
Unknown status

Thu, 19 Dec 2013 12:00:00 EST

A Proof of Concept Study of the Safety, Tolerability, and Efficacy of Avastin (Bevacizumab) in Patients With Chemo-naive Chronic Lymphocytic Leukemia

Condition:   Lymphocytic Leukemia, Chronic
Intervention:   Drug: Bevacizumab
Sponsor:   Hoffmann-La Roche
Completed

Thu, 18 Sep 2008 12:00:00 EDT

A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM)

Conditions:   Malignant Glioma;   Glioblastoma Multiforme;   Gliosarcoma
Intervention:   Drug: Gliadel/Avastin/CPT-11
Sponsors:   Duke University;   Eisai Inc.;   Genentech, Inc.
Terminated

Fri, 15 Aug 2008 12:00:00 EDT

Study of Gemcitabine+Platinum Salt+Bevacizumab Combination for Metastatic Collecting Duct Carcinoma (GETUG-AFU 24)

Condition:   Collecting Duct Carcinoma (Kidney)
Intervention:   Drug: Bevacizumab
Sponsor:   UNICANCER
Completed

Mon, 16 Feb 2015 12:00:00 EST

Treatment With Intravitreal Avastin for Large Uveal Melanomas

Condition:   Uveal Melanoma
Intervention:   Drug: AVASTIN
Sponsor:   Memorial Sloan Kettering Cancer Center
Completed

Thu, 17 Jan 2008 12:00:00 EST

Intra-articular Bevacizumab for Recurrent Hemarthroses at Target Joints With Chronic Hemophilic Synovitis

Conditions:   Hemophilia;   Synovitis
Intervention:   Drug: Bevacizumab intra-articular injection
Sponsor:   National Taiwan University Hospital
Terminated

Wed, 12 Feb 2014 12:00:00 EST

To Demonstrate Equivalent Pharmacokinetic Properties of HD204 and Bevacizumab (Avastin®) in Healthy Male Subjects

Condition:   Healthy Volunteers
Interventions:   Drug: HD204;   Drug: Avastin
Sponsor:   Prestige Biopharma Ltd
Completed

Thu, 04 Jan 2018 12:00:00 EST

Avastin Plus Rituximab for Patients With B-Cell Non-Hodgkin's Lymphoma

Condition:   Lymphoma
Interventions:   Drug: Avastin;   Drug: Rituximab
Sponsors:   M.D. Anderson Cancer Center;   Genentech, Inc.
Completed

Tue, 27 Apr 2004 12:00:00 EDT

Study of Avastin (Bevacizumab) to Reverse Acquired Estrogen Independence in Previously Hormone Responsive Metastatic Breast Ca.

Condition:   Metastatic Breast Cancer
Interventions:   Drug: Avastin;   Drug: Hormonal therapy
Sponsors:   University of Alabama at Birmingham;   Genentech, Inc.
Completed

Mon, 17 Oct 2005 12:00:00 EDT

Safety and Effectiveness of Bevacizumab Intravitreal Injections in the Treatment of Macular Edema Secondary to Retinal Vein Occlusion

Conditions:   Macular Edema;   Retinal Vein Occlusion
Interventions:   Drug: Avastin Intravitreal Injection;   Drug: Sham Avastin Intravitreal Injection
Sponsor:   Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA
Completed

Thu, 03 Sep 2009 12:00:00 EDT

Avastin Plus Radiotherapy in Elderly Patients With Glioblastoma

Condition:   Glioblastoma
Interventions:   Drug: Bevacizumab;   Radiation: Radiation therapy
Sponsor:   University of Zurich
Completed

Fri, 30 Sep 2011 12:00:00 EDT

Bevacizumab In Hereditary Hemorrhagic Telangiectasia

Condition:   Hereditary Hemorrhagic Telangiectasia
Intervention:   Drug: Bevacizumab
Sponsor:   Hanny Al-Samkari, MD
Recruiting

Thu, 28 May 2020 12:00:00 EDT

Intravitreous Bevacizumab and Standard Metabolic Control for Diabetic Macular Edema - A Contrast Sensitivity Study

Condition:   Diabetic Macular Edema
Intervention:   Drug: intravitreal bevacizumab injection(1.25mg)
Sponsor:   University of Sao Paulo
Completed

Thu, 04 Dec 2014 12:00:00 EST

Phase I Trial of Intraperitoneal Bevacizumab in Refractory Malignant Ascites

Condition:   Refractory Malignant Ascites
Intervention:   Drug: bevacizumab
Sponsor:   Peking University
Unknown status

Mon, 13 May 2013 12:00:00 EDT

Comparison of Changes of Inflammatory Proteins in Aqueous Humour of Subjects Treated With Avastin vs Lucentis

Condition:   Proliferative Diabetic Retinopathy (PDR)
Intervention:   Other: Injection of Avastin / Lucentis, sampling aqueous humour
Sponsor:   University of British Columbia
Completed

Fri, 04 Jan 2013 12:00:00 EST

Bevacizumab and Radiation Therapy for Sarcomas

Conditions:   Soft Tissue Sarcoma;   Fibrous Histiocytoma;   Liposarcoma;   Leiomyosarcoma;   Fibrosarcoma;   Synovial Sarcoma
Interventions:   Drug: Bevacizumab;   Radiation: Radiation Therapy;   Procedure: Surgery
Sponsors:   Massachusetts General Hospital;   National Institutes of Health (NIH);   National Cancer Institute (NCI)
Completed

Tue, 25 Jul 2006 12:00:00 EDT

Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma

Condition:   Glioblastoma Multiforme
Interventions:   Drug: TPI 287;   Drug: Bevacizumab
Sponsor:   Cortice Biosciences, Inc.
Suspended

Mon, 02 Sep 2013 12:00:00 EDT

The ELLIPSE Study: A Phase-1 Study Evaluating the Tolerance of Bevacizumab Nasal Spray to Treat Epistaxis in Hereditary Hemorrhagic Telangiectasia

Condition:   Hemorrhagic Hereditary Telangiectasia
Intervention:   Drug: Bevacizumab
Sponsor:   Hospices Civils de Lyon
Completed

Wed, 11 Jan 2012 12:00:00 EST

Bevacizumab (Avastin) Into the Tumor Resection Cavity in Subjects With Glioblastoma Multiforme at First Recurrence

Condition:   Glioblastoma Multiforme
Intervention:   Drug: Avastin
Sponsor:   Brain & Spine Surgeons of New York
Terminated

Mon, 06 Feb 2012 12:00:00 EST

Safety/Biomarker Study of CNTO 95 and Avastin in Solid Tumors

Condition:   Solid Tumors
Intervention:   Drug: CNTO 95 and avastin
Sponsors:   Herbert Hurwitz, MD;   Centocor, Inc.;   Genentech, Inc.
Completed

Fri, 24 Apr 2009 12:00:00 EDT

Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer

Conditions:   Ovarian Cancer;   Epithelial Ovarian Cancer;   Fallopian Tube Carcinoma;   Primary Peritoneal Carcinoma
Interventions:   Drug: Lenalidomide, Liposomal Doxorubicin, Bevacizumab;   Drug: Revlimid, Doxil, Avastin
Sponsors:   New Mexico Cancer Care Alliance;   Celgene Corporation
Terminated

Thu, 16 Sep 2010 12:00:00 EDT

Anti Cancer Stem Cell Activity of Pre-operative Bevacizumab and Chemotherapy in Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: bevacizumab;   Drug: no bevacizumab
Sponsor:   Institut Paoli-Calmettes
Completed

Fri, 27 Aug 2010 12:00:00 EDT

Pilot Study Using Avastin and Gleevec to Treat the Progression of Intraluminal Pulmonary Vein Stenosis

Condition:   Pulmonary Veno Occlusive Disease
Intervention:   Drug: Bevacizumab (Avastin) and Imatinib Mesylate (Gleevec)
Sponsor:   Boston Children's Hospital
Completed

Fri, 01 May 2009 12:00:00 EDT

Trial of Chemotherapy and Avastin as Treatment for Women With Breast Cancer at High Risk for Relapse

Condition:   Breast Cancer
Intervention:   Drug: Gemcitabine and Capecitabine and Avastin
Sponsors:   Brown University;   Women and Infants Hospital of Rhode Island;   Rhode Island Hospital;   The Miriam Hospital;   Memorial Hospital of Rhode Island;   University of New Mexico Cancer Center
Terminated

Thu, 19 Apr 2007 12:00:00 EDT

Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma

Condition:   Kidney Cancer
Interventions:   Drug: bevacizumab;   Drug: RAD001
Sponsors:   SCRI Development Innovations, LLC;   Genentech, Inc.;   Novartis
Completed

Tue, 09 May 2006 12:00:00 EDT

Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy

Condition:   Glioblastoma Multiforme
Interventions:   Drug: TPI 287;   Drug: Bevacizumab
Sponsor:   Cortice Biosciences, Inc.
Terminated

Tue, 28 Jan 2014 12:00:00 EST

Avastin in Combination With Docetaxel in Ovarian/Fallopian Tube/Peritoneum Carcinoma

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Malignant Tumor of Peritoneum
Interventions:   Drug: Avastin;   Drug: Docetaxel
Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   National Cancer Institute (NCI);   Genentech, Inc.;   Sanofi
Completed

Thu, 19 Jul 2007 12:00:00 EDT

TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma

Condition:   Astrocytoma
Interventions:   Drug: Bevacizumab;   Drug: TVB-2640
Sponsor:   The University of Texas Health Science Center at San Antonio
Active, not recruiting

Thu, 26 Jan 2017 12:00:00 EST

Intrapleural Bevacizumab After Pleural Drainage in the Context of Breast Cancer

Conditions:   Pleural Effusion, Malignant;   Breast Cancer
Intervention:   Drug: Bevacizumab
Sponsors:   Institut Curie;   Henri Mondor University Hospital
Terminated

Fri, 26 Sep 2014 12:00:00 EDT

Therapeutic Study of Bevacizumab Injection Directly Inside the Keloid Tissue

Condition:   Keloid
Intervention:   Biological: bevacizumab
Sponsor:   Tirgan, Michael H., M.D.
Terminated

Wed, 03 Aug 2011 12:00:00 EDT

A Study of Avastin (Bevacizumab) and Transarterial Chemoembolisation (TACE) Treatment in Patients With Liver Cancer

Condition:   Liver Cancer
Interventions:   Drug: Bevacizumab;   Procedure: Transarterial chemoembolisation (TACE)
Sponsor:   Hoffmann-La Roche
Completed

Wed, 19 Dec 2007 12:00:00 EST

Ranibizumab Vs Bevacizumab for Type 1 Retinopathy of Prematurity

Condition:   Retinopathy of Prematurity Both Eyes
Intervention:   Drug: Bevacizumab, Ranibizumab
Sponsors:   Zagazig University;   Cairo University
Recruiting

Thu, 02 Sep 2021 12:00:00 EDT

Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer

Conditions:   Thyroid Neoplasms;   Carcinoma;   Thyroid Cancer;   Metastatic Cancer
Intervention:   Drug: Bevacizumab
Sponsor:   Region Skane
Terminated

Tue, 09 Dec 2008 12:00:00 EST

A Study of Bevacizumab (Avastin) in Combination With Chemotherapy in Participants With Metastatic Cancer of the Colon or Rectum.

Condition:   Colorectal Cancer
Interventions:   Drug: Bevacizumab;   Drug: Fluoropyrimidine-based Chemotherapy
Sponsor:   Hoffmann-La Roche
Completed

Mon, 26 Jul 2010 12:00:00 EDT

Eye Injections of Bevacizumab for Lowering Risk of Scar Tissue in the Retina and Repeated Retinal Detachment.

Conditions:   Retinal Detachment;   Vitreoretinopathy Proliferative
Intervention:   Drug: Bevacizumab
Sponsor:   Wills Eye
Completed

Wed, 22 May 2013 12:00:00 EDT

A Study Comparing SB8 and Avastin® in Patients With Advanced Non-squamous Non-small Cell Lung Cancer

Conditions:   Lung Cancer;   Non-small Cell Lung Cancer
Interventions:   Drug: Bevacizumab;   Drug: SB8;   Drug: Carboplatin;   Drug: Paclitaxel
Sponsor:   Samsung Bioepis Co., Ltd.
Completed

Thu, 28 Apr 2016 12:00:00 EDT

Radiosurgery and Avastin for Recurrent Malignant Gliomas

Condition:   Malignant Glioma
Interventions:   Radiation: Stereotactic Radiosurgery (SRS);   Drug: Bevacizumab
Sponsors:   Duke University;   Genentech, Inc.
Completed

Fri, 20 Nov 2009 12:00:00 EST

Abraxane and Avastin as Therapy for Patients With Malignant Melanoma, a Phase II Study

Condition:   Metastatic Malignant Melanoma
Interventions:   Drug: Avastin;   Drug: Abraxane
Sponsors:   Lynn E. Spitler, MD;   Celgene Corporation;   Genentech, Inc.
Completed

Thu, 19 Apr 2007 12:00:00 EDT

Avastin for PDR (Proliferative Diabetic Retinopathy)

Conditions:   Retinal Detachment;   Diabetic Retinopathy
Interventions:   Drug: Avastin (bevacizumab);   Other: Sham injection
Sponsor:   University of Southern California
Completed

Wed, 05 Jan 2011 12:00:00 EST

Efficacy of PreOperative Bevacizumab for Diabetic Eye Disease

Condition:   Proliferative Diabetic Retinopathy
Intervention:   Drug: Bevacizumab
Sponsor:   Cairo University
Completed

Fri, 01 Jan 2010 12:00:00 EST

Post-First Progression Use of Bevacizumab in Metastatic Colorectal Cancer (mCRC)

Condition:   Metastatic Colorectal Cancer
Intervention:   Drug: Bevacizumab (Avastin)
Sponsor:   Asan Medical Center
Completed

Mon, 16 Mar 2009 12:00:00 EDT

Bevacizumab in Metastatic Renal Cancer

Condition:   Renal Cell Cancer
Interventions:   Drug: Bevacizumab;   Drug: Interferon alpha-2a
Sponsor:   Hoffmann-La Roche
Completed

Thu, 10 Dec 2015 12:00:00 EST

Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma

Conditions:   Renal Cell Carcinoma;   Kidney Cancer
Interventions:   Drug: bevacizumab;   Drug: temsirolimus
Sponsors:   Beth Israel Deaconess Medical Center;   Genentech, Inc.;   Dana-Farber Cancer Institute;   Brigham and Women's Hospital;   Vanderbilt University Medical Center
Completed

Fri, 31 Oct 2008 12:00:00 EDT

Bevacizumab and Peripheral Retinal Changes on Wide Field Angiography in Diabetic Macular Edema

Conditions:   Non-proliferative Diabetic Retinopathy;   Proliferative Diabetic Retinopathy;   Diabetic Macular Edema
Intervention:   Drug: Bevacizumab
Sponsor:   King Khaled Eye Specialist Hospital
Unknown status

Wed, 26 Mar 2014 12:00:00 EDT

To Compare Efficacy and Safety of CT-P16 and EU-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer

Condition:   Adenocarcinoma of Lung
Interventions:   Drug: CT-16;   Drug: Avastin
Sponsor:   Celltrion
Active, not recruiting

Tue, 18 Sep 2018 12:00:00 EDT

Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated

Condition:   Adult Solid Tumor
Intervention:   Drug: TRC105 and Bevacizumab
Sponsor:   Tracon Pharmaceuticals Inc.
Completed

Mon, 11 Apr 2011 12:00:00 EDT

Efficacy Study of Avastin® With Pemetrexed +/- Carboplatin to Treat Elderly Patients With Non-small Cell Lung Cancer

Condition:   Non-squamous Non-small Cell Lung Cancer
Interventions:   Drug: Bevacizumab + Pemetrexed;   Drug: Bevacizumab + Pemetrexed + Carboplatin
Sponsors:   PD Dr. med. Wolfgang Schuette;   Roche Pharma AG;   Eli Lilly and Company
Completed

Mon, 14 Sep 2009 12:00:00 EDT

Compare IBI305 and Bevacizumab on Pharmacokinetics/Safety/Immunogenicity on Healthy Male

Condition:   Healthy
Interventions:   Biological: IBI305(Bevacizumab Biosimilar);   Drug: Avastin(Bevacizumab)
Sponsor:   Innovent Biologics (Suzhou) Co. Ltd.
Completed

Mon, 20 Mar 2017 12:00:00 EDT

Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma

Condition:   Neuroendocrine Carcinoma
Interventions:   Drug: Avastin;   Drug: RAD001
Sponsors:   M.D. Anderson Cancer Center;   Novartis;   Genentech, Inc.
Completed

Tue, 05 Feb 2008 12:00:00 EST

Biomarkers for Apatinib and Bevacizumab in Second-line Therapy for Colorectal Cancer(BABST-C)

Condition:   Colorectal Neoplasms
Interventions:   Drug: Apatinib Mesylate Tablets;   Drug: Bevacizumab Injection
Sponsor:   Shenzhen People's Hospital
Recruiting

Fri, 16 Nov 2018 12:00:00 EST

INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme

Conditions:   Glioblastoma Multiforme;   Gliosarcoma;   Colorectal Cancer;   Renal Cell Carcinoma
Interventions:   Drug: INC280;   Biological: bevacizumab
Sponsors:   SCRI Development Innovations, LLC;   Novartis
Active, not recruiting

Thu, 12 Mar 2015 12:00:00 EDT

Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer

Conditions:   Metastatic Triple Negative Breast Cancer;   Safety Issues;   Efficacy
Intervention:   Drug: Bevacizumab
Sponsor:   Assiut University
Completed

Thu, 05 Jul 2018 12:00:00 EDT

Erlotinib and Avastin in Patients With Cancer of the Esophagus or Gastroesophageal Junction

Conditions:   Esophageal Neoplasms;   Esophageal Diseases
Interventions:   Drug: Erlotinib;   Drug: Avastin
Sponsor:   Washington University School of Medicine
Terminated

Fri, 02 Mar 2007 12:00:00 EST

Safety Study of Bevacizumab (Avastin) With Thoracic Radiation in Non-small Cell Cell Lung Cancer

Condition:   Toxicity
Intervention:   Biological: bevacizumab
Sponsor:   VU University Medical Center
Terminated

Tue, 18 Sep 2007 12:00:00 EDT

A Study of FOLFOX6 With Bevacizumab for Biliary System Carcinoma

Condition:   Biliary Tract Cancer
Intervention:   Drug: "Bevacizumab" in combination with "modified FOLFOX6".
Sponsors:   Georgetown University;   Sanofi
Terminated

Wed, 15 Apr 2009 12:00:00 EDT

Intrapleural Bevacizumab and Cisplatin Therapy for Malignant Pleural Effusion Caused by Non-small Cell Lung Cancer

Condition:   Malignant Pleural Effusion
Interventions:   Drug: Bevacizumab;   Drug: Cisplatin
Sponsors:   Chinese PLA General Hospital;   Roche Pharma AG
Completed

Fri, 10 Aug 2012 12:00:00 EDT

A Randomized Trial of Low-Dose Bevacizumab vs Laser for Type 1 ROP

Condition:   Retinopathy of Prematurity
Interventions:   Drug: Bevacizumab;   Procedure: Laser
Sponsors:   Jaeb Center for Health Research;   Pediatric Eye Disease Investigator Group;   National Eye Institute (NEI)
Not yet recruiting

Wed, 18 Nov 2020 12:00:00 EST

The Role of Bevacizumab in the Treatment of Radiation Necrosis in Children With Central Nervous System Tumors

Condition:   Radiation Necrosis
Intervention:   Drug: Bevacizumab (Avastin®)
Sponsors:   University of Colorado, Denver;   Genentech, Inc.
Terminated

Wed, 15 Sep 2010 12:00:00 EDT

Photodynamic Therapy Alone Versus Combined With Intravitreal Bevacizumab for Age-related Macular Degeneration

Condition:   Age-related Macular Degeneration
Intervention:   Drug: Bevacizumab
Sponsor:   Kumamoto University
Completed

Tue, 15 Dec 2009 12:00:00 EST

Reduction of Plasma Free VEGF-A Using Low-dose Bevacizumab in Hemodialysis Patients

Conditions:   End Stage Renal Disease;   Hemodialysis Vascular Access Failure
Interventions:   Drug: 1.25mg bevacizumab;   Drug: 2.50mg bevacizumab
Sponsor:   Mayo Clinic
Withdrawn

Tue, 01 Mar 2016 12:00:00 EST

Pilot Study of Taxol, Carboplatin, and Bevacizumab in Advanced Stage Ovarian Carcinoma Patients

Condition:   Ovarian Neoplasms
Intervention:   Drug: Avastin
Sponsors:   Gynecologic Oncology Associates;   Genentech, Inc.
Completed

Tue, 09 Aug 2005 12:00:00 EDT

Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery

Conditions:   Malignant Neoplasms of Female Genital Organs;   Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Cancer
Intervention:   Drug: Bevacizumab
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Unknown status

Wed, 31 Aug 2016 12:00:00 EDT

Use of Bevacizumab to Modulate the Outcomes of Trabeculectomy Surgery

Condition:   Glaucoma
Intervention:   Drug: Bevacizumab
Sponsor:   Nova Scotia Health Authority
Unknown status

Wed, 27 Oct 2010 12:00:00 EDT

Intranasal Bevacizumab for HHT-Related Epistaxis

Conditions:   HHT;   Hereditary Hemorrhagic Telangiectasia;   Epistaxis;   Nose Bleeds;   Nasal Bleeding
Interventions:   Drug: Bevacizumab;   Drug: Placebo (Saline)
Sponsor:   Stanford University
Completed

Tue, 17 Mar 2015 12:00:00 EDT

Pilot Study of Abemaciclib With Bevacizumab in Recurrent Glioblastoma Patients With Loss of CDKN2A/B or Gain or Amplification of CDK4/6

Conditions:   GBM;   Glioblastoma;   Brain Tumor;   Brain Tumor, Recurrent
Interventions:   Drug: Abemaciclib;   Drug: Bevacizumab
Sponsor:   Edward Pan
Recruiting

Fri, 30 Aug 2019 12:00:00 EDT

Bevacizumab and Long Acting Gas in Diabetic Vitrectomy

Condition:   Proliferative Diabetic Retinopathy
Intervention:   Drug: Bevacizumab
Sponsor:   National Taiwan University Hospital
Completed

Fri, 11 Apr 2008 12:00:00 EDT

Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme

Conditions:   Glioblastoma Multiforme;   Gliosarcoma
Interventions:   Drug: Avastin;   Drug: Temozolomide;   Drug: Irinotecan
Sponsors:   Katy Peters;   Genentech, Inc.
Completed

Thu, 17 Sep 2009 12:00:00 EDT

Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer

Conditions:   Ovarian Neoplasms;   Fallopian Tube Neoplasms;   Endocrine Gland Neoplasms;   Neoplasms by Site;   Neoplasms;   Genital Neoplasms, Female;   Urogenital Neoplasms;   Neoplasms, Glandular and Epithelial;   Neoplasms by Histologic Type;   Carcinoma, Ovarian Epithelial;   Ovarian Diseases;   Adnexal Diseases;   Genital Diseases, Female;   Endocrine System Diseases;   Gonadal Disorders;   Carcinoma;   Bevacizumab;   Enzyme Inhibitors;   Antineoplastic Agents;   Molecular Mechanisms of Pharmacological Action;   Angiogenesis;   BRCA1 Mutation;   BRCA2 Mutation;   Homologous Recombination Deficiency
Interventions:   Drug: Niraparib;   Drug: Bevacizumab
Sponsor:   Xiaoxiang Chen
Recruiting

Mon, 21 Sep 2020 12:00:00 EDT

Study of Bevacizumab/Doxil in Treatment of Platinum-Resistant/Refractory Ovarian Cancer (CA)

Condition:   Ovarian Cancer
Interventions:   Drug: Doxil;   Drug: Avastin
Sponsors:   New Mexico Cancer Care Alliance;   Genentech, Inc.;   NYU Langone Health
Completed

Thu, 23 Jul 2009 12:00:00 EDT

Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)

Conditions:   Gestational Trophoblastic Neoplasia;   Choriocarcinoma;   Placental Site Trophoblastic Tumor;   Epithelioid Trophoblastic Tumor
Interventions:   Drug: TRC105;   Drug: Bevacizumab
Sponsor:   Tracon Pharmaceuticals Inc.
Terminated

Wed, 27 Jan 2016 12:00:00 EST

A Study of Bevacizumab (Avastin) in Combination With Dacarbazine in Participants With Unresectable/Metastatic Melanoma

Condition:   Malignant Melanoma
Interventions:   Drug: Bevacizumab;   Drug: Dacarbazine
Sponsor:   Hoffmann-La Roche
Completed

Fri, 16 Jul 2010 12:00:00 EDT

Bevacizumab Against Recurrent Retinal Detachment

Conditions:   Retinal Detachment;   Proliferative Vitreoretinopathy
Intervention:   Drug: Bevacizumab
Sponsor:   University of Wisconsin, Madison
Completed

Thu, 17 Jul 2014 12:00:00 EDT

Bevacizumab and Trabectedin +/- Carboplatin in Advanced Ovarian Cancer

Condition:   Ovarian Epithelial Cancer Recurrent
Interventions:   Drug: bevacizumab and trabectedin;   Drug: bevacizumab, trabectedin and carboplatin
Sponsors:   Mario Negri Institute for Pharmacological Research;   PharmaMar;   Hoffmann-La Roche
Completed

Wed, 28 Nov 2012 12:00:00 EST

Combined Alternating Sunitinib and Bevacizumab (Avastin®) in Advanced Renal Cell Carcinoma (CASA)

Condition:   Renal Cell Carcinoma
Interventions:   Drug: Sunitinib;   Drug: Bevacizumab
Sponsor:   King Faisal Specialist Hospital & Research Center
Recruiting

Thu, 29 Sep 2016 12:00:00 EDT

Neoadjuvant Treatment in Rectal Cancer With Radiotherapy Followed by Atezolizumab and Bevacizumab (TARZAN)

Condition:   Rectal Cancer
Interventions:   Drug: Atezolizumab;   Drug: Bevacizumab
Sponsors:   The Netherlands Cancer Institute;   Hoffmann-La Roche
Recruiting

Fri, 12 Jul 2019 12:00:00 EDT

Anti-VEGF Therapy for Subfoveal Hemorrhage in Patients With Neovascular Age-Related Macular Degeneration

Conditions:   Submacular Hemorrhage;   Wet Macular Degeneration;   Neovascular Age-related Macular Degeneration
Interventions:   Drug: Anti-VEGF;   Other: Hemorrhage displacement + Anti-VEGF
Sponsor:   Johns Hopkins University
Terminated

Tue, 09 Oct 2018 12:00:00 EDT

Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer

Condition:   Urothelial Carcinoma
Interventions:   Drug: Atezolizumab;   Drug: Bevacizumab
Sponsors:   Arjun Balar, MD;   Roche-Genentech;   Hoosier Cancer Research Network
Active, not recruiting

Tue, 05 Sep 2017 12:00:00 EDT

French Evaluation Group Avastin Versus Lucentis

Condition:   Age Related Macular Degeneration
Interventions:   Drug: Avastin;   Drug: Lucentis
Sponsor:   Hospices Civils de Lyon
Completed

Tue, 27 Jul 2010 12:00:00 EDT

Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors

Conditions:   Renal Cell Carcinoma;   Colorectal Adenocarcinoma;   Non-squamous Non-small Cell Lung Cancer;   Platinum-refractory Ovarian Carcinoma;   Cervical Carcinoma
Interventions:   Drug: Nintedanib;   Drug: Bevacizumab
Sponsors:   University of Alabama at Birmingham;   Boehringer Ingelheim
Completed

Mon, 18 Jul 2016 12:00:00 EDT

Efficacy and Safety of Bevacizumab Versus Pulvis Talci in Malignant Pleural Effusion

Condition:   Malignant Pleural Effusion
Interventions:   Drug: Bevacizumab;   Drug: Pulvis talci
Sponsor:   Tang-Du Hospital
Unknown status

Tue, 04 Feb 2014 12:00:00 EST

Bevacizumab and Docetaxel in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Condition:   Lung Cancer
Interventions:   Biological: bevacizumab;   Drug: docetaxel
Sponsors:   Barbara Ann Karmanos Cancer Institute;   National Cancer Institute (NCI)
Completed

Mon, 08 Oct 2007 12:00:00 EDT

Systemic Avastin Therapy in Age-Related Macular Degeneration

Condition:   Macular Degeneration
Interventions:   Drug: Bevacizumab;   Drug: Sodium Chloride
Sponsor:   The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
Completed

Tue, 18 Sep 2007 12:00:00 EDT

Pharmacokinetic Study of Avastin and Doxil in Ovarian Cancer

Condition:   Ovarian Cancer
Interventions:   Drug: Doxil;   Drug: Bevacizumab (Avastin)
Sponsors:   NYU Langone Health;   Genentech, Inc.;   University of New Mexico Cancer Center
Completed

Thu, 19 Feb 2009 12:00:00 EST

Bevacizumab Plus Ixabepilone to Treat Patients With Advanced Kidney Cancer

Condition:   Renal Cell Carcinoma
Interventions:   Drug: Bevacizumab;   Drug: Ixabepilone
Sponsor:   National Cancer Institute (NCI)
Completed

Thu, 18 Jun 2009 12:00:00 EDT

Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22

Conditions:   Glioblastoma Multiforme;   Fibrillary Astrocytoma of Brain;   Glioma of Brainstem;   Anaplastic Astrocytoma;   Pilomyxoid Astrocytoma;   Mixed Oligodendroglioma-Astrocytoma;   Brain Stem Glioma;   Diffuse Intrinsic Pontine Glioma
Intervention:   Drug: SIACI of Erbitux and Bevacizumab
Sponsor:   Weill Medical College of Cornell University
Recruiting

Mon, 24 Jun 2013 12:00:00 EDT

Phase II Avastin + Bortezomib for Patients With Recurrent Malignant Glioma

Conditions:   Glioblastoma;   Gliosarcoma
Interventions:   Drug: Avastin;   Drug: Bortezomib
Sponsors:   Duke University;   Millennium Pharmaceuticals, Inc.;   Genentech, Inc.
Completed

Fri, 08 Feb 2008 12:00:00 EST

A Phase I/II Study of XELOXIRI and Bevacizumab as First-line Treatment in Metastatic Colorectal Cancer

Conditions:   Metastatic Cancer;   Colorectal Cancer;   Colorectal Adenocarcinoma
Intervention:   Drug: XELOXIRI/Bevacizumab
Sponsor:   Chinese Academy of Medical Sciences
Recruiting

Fri, 08 May 2020 12:00:00 EDT

Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer

Conditions:   Hormone-Sensitive Breast Cancer;   Breast Cancer
Interventions:   Drug: Letrozole;   Drug: Bevacizumab
Sponsors:   Yale University;   Novartis;   Genentech, Inc.
Terminated

Wed, 18 Apr 2007 12:00:00 EDT

Low-dose Intra-arterial Bevacizumab for Edema and Radiation Necrosis Therapeutic Intervention (LIBERTI)

Condition:   Radiation Necrosis
Interventions:   Drug: 25% Mannitol;   Drug: Low-dose Intra-arterial Bevacizumab
Sponsors:   Norton Healthcare;   University of Kentucky
Completed

Thu, 30 Jun 2016 12:00:00 EDT

Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer

Conditions:   MSI;   ColoRectal Cancer;   Chemotherapy;   Resistance, APC
Interventions:   Drug: Atezolizumab;   Drug: Bevacizumab
Sponsors:   Vall d'Hebron Institute of Oncology;   European Organisation for Research and Treatment of Cancer - EORTC
Recruiting

Mon, 05 Dec 2016 12:00:00 EST

Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival

Conditions:   Corneal Neovascularization;   Corneal Graft Failure
Interventions:   Drug: Avastin® (bevacizumab);   Drug: 0.9% NaCl & Refresh Liquigel
Sponsor:   Reza Dana, MD
Completed

Mon, 22 Feb 2010 12:00:00 EST

Neoadjuvant Pemetrexed, Carboplatin and Bevacizumab in Unresectable, Locally Advanced Lung Adenocarcinoma

Condition:   Lung Cancer
Intervention:   Drug: Neoadjuvant Bevacizumab
Sponsor:   Si-Yu Wang
Completed

Tue, 01 May 2012 12:00:00 EDT

Subconjunctival Bevacizumab Effect on Bleb Vascularity

Conditions:   Bleb Vascularity;   Bleb Fibrosis;   Trabeculectomy Failure
Intervention:   Drug: Bevacizumab
Sponsor:   Rabin Medical Center
Unknown status

Tue, 03 Mar 2009 12:00:00 EST

Effect of Ranibizumab Versus Bevacizumab on the Macular Perfusion in Diabetic Macular Edema

Conditions:   Diabetic Macular Edema;   Macular Ischemia;   Diabetic Retinopathy;   Vascular Endothelial Growth Factor Overexpression
Interventions:   Drug: Intravitreal ranibizumab;   Drug: Intravitreal bevacizumab
Sponsor:   Cairo University
Not yet recruiting

Thu, 05 Aug 2021 12:00:00 EDT

Pre- and Intra-operative Intravitreal Bevacizumab Injection in Diabetic Vitrectomy

Conditions:   Proliferative Diabetic Retinopathy;   Vitreous Hemorrhage
Intervention:   Drug: Bevacizumab
Sponsor:   Seoul National University Bundang Hospital
Completed

Wed, 03 Sep 2008 12:00:00 EDT

Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme

Condition:   Glioblastoma Multiforme
Interventions:   Drug: Bevacizumab;   Drug: BKM120
Sponsors:   SCRI Development Innovations, LLC;   Novartis
Completed

Fri, 06 May 2011 12:00:00 EDT

Fractionated Stereotactic Radiosurgery With Concurrent Bevacizumab for Brain Metastases: A Phase I Dose-escalation Trial

Condition:   Brain Neoplasm
Interventions:   Radiation: Fractionated stereotactic radiosurgery;   Drug: bevacizumab
Sponsor:   National Taiwan University Hospital
Unknown status

Wed, 03 Feb 2016 12:00:00 EST

Postoperative Adjuvant Chemotherapy With Bevacizumab and Maintenance Bevacizumab After Neoadjuvant Chemotherapy for Ovarian Cancer

Condition:   Epithelial Ovarian Cancer
Intervention:   Drug: Bevacizumab
Sponsors:   Chang Gung Memorial Hospital;   Hoffmann-La Roche;   Asian Gynecologic Oncology Group;   Taiwanese Gynecolgic Oncology Group
Completed

Mon, 30 Dec 2013 12:00:00 EST

BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Bevacizumab;   Drug: Standard adjuvant chemotherapy
Sponsor:   Hoffmann-La Roche
Completed

Wed, 12 Sep 2007 12:00:00 EDT

A Pilot Study of Bevacizumab for Neoplastic Meningitis

Condition:   Neoplastic Meningitis
Intervention:   Drug: Bevacizumab
Sponsors:   M.D. Anderson Cancer Center;   Genentech, Inc.
Completed

Fri, 19 Jun 2009 12:00:00 EDT

Organ-specific Responses to Atezolizumab Plus Bevacizumab in Advanced HCC

Condition:   Advanced Hepatocellular Carcinoma
Intervention:   Drug: Atezolizumab plus bevacizumab
Sponsors:   CHA University;   Hoffmann-La Roche
Recruiting

Wed, 28 Apr 2021 12:00:00 EDT

89Zr-bevacizumab PET Scan in Patients With Relapsing Multiple Myeloma

Condition:   Multiple Myeloma
Intervention:   Drug: 89Zr-bevacizumab
Sponsor:   University Medical Center Groningen
Unknown status

Tue, 21 May 2013 12:00:00 EDT

A Study of Avastin (Bevacizumab) Plus Crossover Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer.

Condition:   Colorectal Cancer
Interventions:   Drug: Chemotherapy;   Drug: Bevacizumab
Sponsor:   Hoffmann-La Roche
Completed

Wed, 18 Jun 2008 12:00:00 EDT

Atezolizumab Plus Bevacizumab With HCC and HBV Infection

Condition:   Carcinoma, Hepatocellular
Interventions:   Drug: Atezolizumab;   Drug: Bevacizumab
Sponsors:   National Health Research Institutes, Taiwan;   National Taiwan University Hospital;   Taipei Veterans General Hospital, Taiwan;   Mackay Memorial Hospital;   Changhua Christian Hospital;   China Medical University Hospital;   National Cheng-Kung University Hospital;   Kaohsiung Medical University Chung-Ho Memorial Hospital;   Taichung Veterans General Hospital
Recruiting

Wed, 27 Nov 2019 12:00:00 EST

Apatinib Versus Bevacizumab in Second-line Therapy for Colorectal Cancer(ABST-C)

Conditions:   Colorectal Neoplasms;   Intestinal Neoplasms;   Gastrointestinal Neoplasms;   Digestive System Neoplasms
Interventions:   Drug: Apatinib Mesylate Tablets;   Drug: Bevacizumab Injection
Sponsor:   Shenzhen People's Hospital
Recruiting

Tue, 05 Sep 2017 12:00:00 EDT

Bevacizumab and Nimustine in Patients With Recurrent High Grade Glioma

Condition:   Glioblastoma
Interventions:   Drug: Bevacizumab;   Drug: Nimustine
Sponsor:   Huashan Hospital
Completed

Thu, 03 Mar 2016 12:00:00 EST

Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer

Conditions:   Ovarian Endometrioid Tumor;   Fallopian Tube Cancer;   Primary Peritoneal Cancer;   TP53 Mutation
Interventions:   Drug: Atezolizumab;   Drug: Bevacizumab
Sponsor:   University Health Network, Toronto
Not yet recruiting

Wed, 12 Aug 2020 12:00:00 EDT

A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Condition:   Ovarian Neoplasms
Interventions:   Drug: Niraparib;   Biological: Bevacizumab
Sponsor:   Tesaro, Inc.
Active, not recruiting

Tue, 31 Oct 2017 12:00:00 EDT

Study of VGX-100 Administered Alone and Co-administered With Bevacizumab in Adult Subjects With Advanced Solid Tumors

Conditions:   Neoplasms;   Cancer
Interventions:   Drug: VGX-100;   Drug: Bevacizumab
Sponsor:   Circadian Technologies Ltd.
Completed

Fri, 20 Jan 2012 12:00:00 EST

A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival

Conditions:   Corneal Neovascularization;   Corneal Graft Failure
Interventions:   Drug: Avastin® (bevacizumab);   Drug: 0.9% NaCl & Refresh Liquigel
Sponsors:   Reza Dana, MD;   United States Department of Defense;   Bascom Palmer Eye Institute;   New York Presbyterian Hospital
Completed

Wed, 27 Nov 2013 12:00:00 EST

A Safety and Efficacy Study of BCD-021 With Paclitaxel and Carboplatin Compared to Avastin With Paclitaxel and Carboplatin in Non-Small Cell Lung Cancer

Condition:   Non-small Cell Lung Cancer
Interventions:   Drug: Bevacizumab;   Drug: Paclitaxel;   Drug: Carboplatin
Sponsor:   Biocad
Completed

Wed, 09 Jan 2013 12:00:00 EST

Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and Neck

Condition:   Head and Neck Neoplasms
Interventions:   Drug: Atezolizumab;   Drug: Bevacizumab
Sponsor:   Centre Leon Berard
Recruiting

Mon, 28 Jan 2019 12:00:00 EST

Transarterial Chemoembolisation Plus Bevacizumab for Treatment of Hepatocellular Carcinoma

Condition:   Hepatocellular Carcinoma
Intervention:   Drug: bevacizumab
Sponsor:   Medical University of Vienna
Terminated

Fri, 20 Jan 2006 12:00:00 EST

Trial of Switching Between Intravitreal Bevacizumab (Avastin®)& Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema

Conditions:   Diabetes;   Diabetic Macular Oedema;   Diabetic Macular Edema;   Diabetic Retinopathy
Interventions:   Drug: Avastin (Bevacizumab);   Drug: Ozurdex (dexamethasone)
Sponsors:   University of Sydney;   Allergan
Completed

Fri, 08 Feb 2013 12:00:00 EST

Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM

Condition:   Glioblastoma
Interventions:   Drug: Nivolumab;   Drug: Standard Dose Bevacizumab;   Drug: Low Dose Bevacizumab
Sponsor:   Case Comprehensive Cancer Center
Active, not recruiting

Fri, 02 Mar 2018 12:00:00 EST

mFOLFOX6+Bevacizumab+PD-1 Monoclonal Antibody in Local Advanced MSS CRC

Conditions:   Colorectal Cancer;   Immunotherapy
Intervention:   Drug: mFOLFOX6+Bevacizumab+PD-1 monoclonal antibody treatment combinations
Sponsor:   Sixth Affiliated Hospital, Sun Yat-sen University
Recruiting

Thu, 20 May 2021 12:00:00 EDT

Bevacizumab and Temozolomide Following Radiation and Chemotherapy for Newly Diagnosed Glioblastoma Multiforme

Condition:   Glioblastoma Multiforme
Intervention:   Drug: Bevacizumab and Temozolomide
Sponsors:   University of Chicago;   Genentech, Inc.
Completed

Fri, 11 Jan 2008 12:00:00 EST

A Study of Avastin (Bevacizumab) in Combination Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum

Condition:   Colorectal Cancer
Interventions:   Drug: Bevacizumab [Avastin];   Drug: Capecitabine;   Drug: Irinotecan
Sponsor:   Hoffmann-La Roche
Completed

Wed, 26 May 2010 12:00:00 EDT

Observational Post-authorization Studies Carboplatin, Paclitaxel and Bevacizumab

Condition:   Nonsquamous Nonsmall Cell Neoplasm of Lung
Intervention:   Drug: paclitaxel, carboplatin and bevacizumab
Sponsor:   Spanish Lung Cancer Group
Completed

Tue, 19 Mar 2013 12:00:00 EDT

Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia

Condition:   Coronavirus Infections
Intervention:   Drug: Bevacizumab Injection
Sponsors:   Qilu Hospital of Shandong University;   Renmin Hospital of Wuhan University;   Moriggia-Pelascini Gravedona Hospital
Completed

Wed, 19 Feb 2020 12:00:00 EST

Avastin and Tarceva for Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer

Condition:   Lung Cancer
Interventions:   Drug: Avastin;   Drug: Tarceva
Sponsors:   M.D. Anderson Cancer Center;   Genentech, Inc.;   Vanderbilt-Ingram Cancer Center
Completed

Thu, 15 Aug 2002 12:00:00 EDT

A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista

Condition:   Carcinoma, Hepatocellular
Interventions:   Drug: Atezolizumab;   Drug: Bevacizumab
Sponsor:   Hoffmann-La Roche
Active, not recruiting

Mon, 27 Jul 2020 12:00:00 EDT

An Observational Study of Bevacizumab in Chinese Patients With Metastatic Colorectal Cancer

Condition:   Metastatic Colorectal Cancer
Intervention:   Drug: Bevacizumab
Sponsor:   Peking University
Unknown status

Wed, 22 May 2013 12:00:00 EDT

Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer

Condition:   Metastatic Colorectal Cancer
Interventions:   Drug: TAS-102;   Drug: Bevacizumab
Sponsor:   Georgetown University
Terminated

Wed, 13 Jan 2016 12:00:00 EST

Radiosensitization of AVASTIN® (Bevacizumab) With Stereotactic Body Radiotherapy for Colorectal Liver Metastasis

Condition:   Colorectal Cancer.
Intervention:   Radiation: Stereotactic body radiotherapy
Sponsors:   Dr. Yoo-Joung Ko;   Roche Pharma AG
Completed

Tue, 03 Apr 2012 12:00:00 EDT

Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer

Condition:   Kidney Cancer
Intervention:   Biological: bevacizumab
Sponsors:   Paul Monk;   Genentech, Inc.
Terminated

Mon, 28 Jan 2008 12:00:00 EST

Efficacy and Safety of Intravitreal Bevacizumab for Threshold ROP.

Condition:   Stage 2+ or Stage 3+ Retinopathy of Prematurity in Zone I or Zone II.
Intervention:   Procedure: Intravitreal Bevacizumab
Sponsor:   Sivakami A Pai
Unknown status

Tue, 16 Oct 2012 12:00:00 EDT

Chemoembolization and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed With Surgery

Condition:   Liver Cancer
Intervention:   Biological: bevacizumab
Sponsors:   Jonsson Comprehensive Cancer Center;   National Cancer Institute (NCI);   Genentech, Inc.
Completed

Mon, 27 Jan 2003 12:00:00 EST

Ph II Bevacizumab + Etoposide for Pts w Recurrent MG

Conditions:   Glioblastoma;   Gliosarcoma
Intervention:   Drug: Bevacizumab and Etoposide
Sponsors:   Duke University;   Genentech, Inc.
Completed

Mon, 11 Feb 2008 12:00:00 EST

Bevacizumab Versus Ranibizumab for the Treatment of Diabetic Macular Edema

Conditions:   Diabetic Retinopathy;   Macular Edema
Interventions:   Drug: Bevacizumab;   Drug: Ranibizumab
Sponsors:   University of Sao Paulo;   Fundação de Amparo à Pesquisa do Estado de São Paulo
Unknown status

Wed, 07 Dec 2011 12:00:00 EST

A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer

Condition:   Carcinoma, Non-Small-Cell Lung
Interventions:   Drug: Atezolizumab;   Drug: Bevacizumab
Sponsor:   Hoffmann-La Roche
Active, not recruiting

Thu, 11 Jun 2020 12:00:00 EDT

Bevacizumab in Combination With Metronomic Temozolomide for Recurrent Malignant Glioma

Condition:   Glioblastoma Multiforme
Interventions:   Drug: Bevacizumab;   Drug: Metronomic Temozolomide
Sponsors:   Duke University;   Genentech, Inc.;   Schering-Plough
Completed

Mon, 16 Jul 2007 12:00:00 EDT

An Interventional Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer

Conditions:   Ovarian Neoplasms;   Peritoneal Neoplasms;   Fallopian Tube Neoplasms
Intervention:   Drug: Bevacizumab
Sponsor:   Hoffmann-La Roche
Recruiting

Fri, 30 Aug 2013 12:00:00 EDT

Efficacy and Safety of TC+AVASTIN Versus TC in Patients With Metastatic Nasopharyngeal Carcinoma

Condition:   Nasopharyngeal Neoplasms
Interventions:   Drug: Paclitaxel;   Drug: Bevacizumab;   Drug: Carboplatin
Sponsor:   Sun Yat-sen University
Unknown status

Fri, 26 Sep 2014 12:00:00 EDT

A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy

Condition:   Carcinoma, Hepatocellular
Interventions:   Drug: Atezolizumab;   Drug: Bevacizumab
Sponsor:   Hoffmann-La Roche
Recruiting

Mon, 01 Feb 2021 12:00:00 EST

Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors

Condition:   Malignant Solid Tumour
Interventions:   Drug: Bevacizumab;   Biological: NK immunotherapy
Sponsors:   Fuda Cancer Hospital, Guangzhou;   Shenzhen Hank Bioengineering Institute
Completed

Fri, 05 Aug 2016 12:00:00 EDT

Open-label Study in Patients With Metastatic NSLC Treated With Cisplatin, Gemcitabine and Bevacizumab

Condition:   Non-Small Cell Lung Cancer (NSCLC)
Intervention:   Drug: gemcitabine, cisplatin and bevacizumab
Sponsor:   Fundacion Clinic per a la Recerca Biomédica
Completed

Fri, 12 Dec 2014 12:00:00 EST

A Phase I Study of ABT-510 in Combination With Bevacizumab in Advanced Solid Tumors

Condition:   Solid Tumors
Intervention:   Drug: bevacizumab, ABT-510
Sponsors:   Herbert Hurwitz;   Genentech, Inc.;   Abbott
Completed

Fri, 04 Jan 2008 12:00:00 EST

Bevacizumab in Treating Patients With Angiosarcoma

Condition:   Sarcoma
Intervention:   Biological: Bevacizumab
Sponsors:   Northwestern University;   Genentech, Inc.
Completed

Tue, 07 Feb 2006 12:00:00 EST

Bloodstream Absorption of Avastin and Lucentis After Injection Into the Eye

Condition:   Diabetic Macular Edema
Interventions:   Drug: Bevacizumab;   Drug: Ranibizumab
Sponsors:   Queen's University;   The Physicians' Services Incorporated Foundation
Completed

Fri, 10 Aug 2012 12:00:00 EDT

Neoadjuvant Clinical Trial to Evaluate the Efficacy of Bevacizumab for Renal Cell Carcinoma

Conditions:   Renal Cell Carcinoma;   Kidney Cancer
Intervention:   Drug: Bevacizumab
Sponsors:   M.D. Anderson Cancer Center;   Genentech, Inc.
Completed

Tue, 07 Jun 2005 12:00:00 EDT

Ocular Growth Factors Profile in Proliferative Retinopathies Before and After Intravitreal Bevacizumab

Conditions:   Proliferative Diabetic Retinopathy;   Age Related Macular Degeneration
Intervention:   Drug: Avastin intravitreal injection
Sponsors:   Ophthalmological Association Edelweiss;   University of Cologne
Completed

Tue, 21 Oct 2008 12:00:00 EDT

A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma

Condition:   Renal Cell Carcinoma
Interventions:   Drug: Atezolizumab;   Drug: Bevacizumab
Sponsor:   Hoffmann-La Roche
Withdrawn

Wed, 03 Oct 2018 12:00:00 EDT

Safety and Effectiveness of Subconjunctival Injection of Bevacizumab in the Treatment of Corneal Neovasculization

Conditions:   Lipid Keratopathy;   Penetrating Keratoplasty;   Herpetic Keratopathy;   Rosacea
Intervention:   Drug: subconjunctival injection of bevacizumab ( 1.25 to 2.50 mg)
Sponsor:   National Taiwan University Hospital
Completed

Wed, 21 May 2008 12:00:00 EDT

Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab)

Conditions:   Glioblastoma Multiforme;   Anaplastic Astrocytoma
Intervention:   Drug: Super-Selective Intraarterial Intracranial Infusion of BEVACIZUMAB
Sponsor:   Northwell Health
Completed

Fri, 28 Aug 2009 12:00:00 EDT

Pemetrexed and S-1 in Combination With Bevacizumab in Refractory Colorectal Cancer

Condition:   Colorectal Neoplasms
Interventions:   Drug: Pemetrexed;   Drug: S-1;   Drug: Bevacizumab
Sponsors:   The First Affiliated Hospital with Nanjing Medical University;   Jiangsu HanSoh Tharmaceutical Group Co., Ltd
Not yet recruiting

Mon, 18 Feb 2019 12:00:00 EST

Safety and Efficacy Study of Eribulin in Combination With Bevacizumab for Second-line Treatment HER2- MBC Patients

Conditions:   Metastatic Breast Cancer;   Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Intervention:   Drug: Bevacizumab and eribulin
Sponsors:   Consorzio Oncotech;   Clinical Research Technology S.r.l.
Unknown status

Thu, 26 Jun 2014 12:00:00 EDT

An Observational Study of Continued Bevacizumab Plus Chemotherapy Until First Progression in Participants With Metastatic Colorectal Cancer (CRC)

Condition:   Colorectal Cancer
Interventions:   Other: Bevacizumab;   Combination Product: Chemotherapy
Sponsor:   Hoffmann-La Roche
Completed

Tue, 02 Dec 2014 12:00:00 EST

Bevacizumab for Primary Pterygium Treatment

Condition:   Pterygium
Interventions:   Procedure: Autoconjunctival grafting;   Drug: Subconjuntival bevacizumab injection
Sponsor:   Instituto de Oftalmología Fundación Conde de Valenciana
Completed

Tue, 18 Sep 2012 12:00:00 EDT

Phase II Study of Carboplatin and Bevacizumab (Avastin) for ER Neg, PR Neg, and HER2/Neu Neg Metastatic Breast Cancer

Condition:   Metastatic Breast Cancer
Interventions:   Drug: carboplatin;   Drug: bevacizumab
Sponsors:   University of Chicago;   Genentech, Inc.
Terminated

Thu, 16 Aug 2007 12:00:00 EDT

A Study to Evaluate the Safety and Efficacy of Bevacizumab in Combination With Chemotherapy in Previously Treated Metastatic Breast Cancer (RIBBON 2)

Condition:   Metastatic Breast Cancer
Interventions:   Drug: Bevacizumab;   Drug: Placebo;   Drug: Standard chemotherapy
Sponsor:   Genentech, Inc.
Completed

Wed, 25 Jan 2006 12:00:00 EST

ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab

Condition:   Ovarian Cancer
Interventions:   Drug: atezolizumab + avastin + platinum-based chemotherapy;   Drug: placebo + avastin + platinum-based chemotherapy
Sponsors:   ARCAGY/ GINECO GROUP;   Hoffmann-La Roche
Active, not recruiting

Thu, 08 Sep 2016 12:00:00 EDT

A Study of Avastin (Bevacizumab) in Combination With Docetaxel and Cisplatin in Patients With Metastatic or Locally Advanced Non-small Cell Lung Cancer

Condition:   Non-small Cell Lung Cancer
Interventions:   Drug: Bevacizumab;   Drug: Cisplatin;   Drug: Docetaxel
Sponsor:   Hoffmann-La Roche
Completed

Fri, 18 Apr 2008 12:00:00 EDT

Impact of Pre-operative Bevacizumab on Complications After Resection of Colorectal Liver Metastases

Condition:   Colorectal Liver Metastases
Intervention:   Drug: bevacizumab
Sponsor:   University of Zurich
Completed

Fri, 03 Apr 2009 12:00:00 EDT

Intravitreal Dexamethasone vs Bevacizumab in Aboriginal People With DMO

Conditions:   Diabetic Macular Edema;   Diabetic Retinopathy
Interventions:   Drug: Dexamethasone intravitreal implant;   Drug: Bevacizumab Injectable Product
Sponsors:   Lions Eye Institute, Perth, Western Australia;   Lions Outback Vision;   Allergan
Completed

Fri, 06 Nov 2020 12:00:00 EST

Bevacizumab in Treating Patients Who Have Undergone First-Line Therapy for Metastatic Colorectal Cancer

Condition:   Colorectal Cancer
Interventions:   Biological: bevacizumab;   Other: no maintenance
Sponsor:   Swiss Group for Clinical Cancer Research
Terminated

Tue, 16 Oct 2007 12:00:00 EDT

Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Diabetic Macular Edema (BRDME)

Condition:   Diabetic Macular Edema
Interventions:   Drug: Ranibizumab;   Drug: Bevacizumab
Sponsors:   Prof. dr. R.O. Schlingemann;   University Medical Center Groningen;   Free University Medical Center;   Erasmus Medical Center;   Radboud University;   Leiden University Medical Center;   UMC Utrecht
Unknown status

Tue, 10 Jul 2012 12:00:00 EDT

An Observational Study of First-Line Bevacizumab (Avastin) With Fluoropyrimidine-Based Chemotherapy in Participants With Metastatic Colorectal Cancer

Condition:   Colorectal Cancer
Interventions:   Drug: Bevacizumab;   Drug: Chemotherapy
Sponsor:   Hoffmann-La Roche
Completed

Tue, 23 Oct 2012 12:00:00 EDT

Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab

Conditions:   Epithelial Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Cancer
Interventions:   Drug: Ixabepilone;   Drug: Bevacizumab
Sponsors:   Yale University;   R-Pharm-US, LLC
Active, not recruiting

Tue, 28 Mar 2017 12:00:00 EDT

Results of Adjunctive Intraoperative Bevacizumab Injection on Trabeculectomy Outcome

Condition:   Glaucoma
Interventions:   Drug: Bevacizumab;   Drug: Mitomycin C
Sponsor:   Prince of Songkla University
Completed

Tue, 21 Dec 2010 12:00:00 EST

Ozurdex as Adjunct to Avastin Compared to Avastin Alone in Treatment of Patients With Diabetic Macular Edema

Condition:   Diabetic Macular Edema
Interventions:   Drug: Bevacizumab;   Drug: dexamethasone intravitreal implant
Sponsor:   Maturi, Raj K., M.D., P.C.
Completed

Mon, 07 Mar 2011 12:00:00 EST

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Breast Cancer

Condition:   Breast Cancer
Intervention:   Drug: Bevacizumab
Sponsor:   Hoffmann-La Roche
Completed

Wed, 06 Oct 2010 12:00:00 EDT

Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD

Condition:   Age-related Macular Degeneration
Intervention:   Drug: Fovista® (anti-PDGF BB) plus anti-VEGF
Sponsor:   Ophthotech Corporation
Terminated

Tue, 12 Aug 2014 12:00:00 EDT

Pilot Study of Bevacizumab (Avastin) in Patients With Septic Shock

Condition:   Septic Shock
Interventions:   Drug: Bevacizumab;   Drug: Placebo
Sponsors:   Beth Israel Deaconess Medical Center;   The Cooper Health System;   Carolinas Medical Center
Withdrawn

Fri, 05 Feb 2010 12:00:00 EST

Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + Irinotecan

Conditions:   Glioblastoma;   Gliosarcoma
Interventions:   Drug: Temo + Avastin;   Drug: VP-16 + Avastin
Sponsors:   Duke University;   Genentech, Inc.
Completed

Tue, 12 Feb 2008 12:00:00 EST

Expanded Cohort for Metastatic Colorectal Cancer (MCRC) Using Bevacizumab + Everolimus

Condition:   Colorectal Adenocarcinoma
Interventions:   Drug: Bevacizumab;   Drug: Everolimus
Sponsors:   Herbert Hurwitz;   Novartis Pharmaceuticals;   Genentech, Inc.
Completed

Fri, 18 Jan 2008 12:00:00 EST

Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Retinal Vein Occlusions (BRVO)

Condition:   Retinal Vein Occlusion
Interventions:   Drug: Bevacizumab;   Drug: Ranibizumab
Sponsors:   Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA);   Leiden University Medical Center;   Free University Medical Center;   Erasmus Medical Center;   Radboud University;   UMC Utrecht;   University Medical Center Groningen
Unknown status

Tue, 10 Jul 2012 12:00:00 EDT

Low -Dose-bevacizumab and Pemetrexed Versus TPC in Metastatic HER2-negative Breast Cancer Patients

Condition:   Metastatic Breast Cancer
Interventions:   Drug: low-dose-bevacizumab/pemetrexed;   Drug: Treatment of physician's choice
Sponsor:   Chinese Academy of Medical Sciences
Unknown status

Tue, 12 Jul 2016 12:00:00 EDT

Preoperative Injection of Bevacizumab Prior to Vitreoretinal Surgery in Diabetic Tractional Retinal Detachment

Conditions:   Intravitreal Bevacizumab Injection;   Pars Plana Vitrectomy;   Tractional Retinal Detachment;   Diabetic Retinopathy
Intervention:   Drug: Bevacizumab
Sponsor:   Iran University of Medical Sciences
Completed

Tue, 23 Oct 2007 12:00:00 EDT

An Observational Study of Avastin in Participants With Metastatic Colorectal Cancer (KORALLE)

Condition:   Colorectal Cancer
Intervention:   Drug: Bevacizumab
Sponsor:   Hoffmann-La Roche
Completed

Fri, 25 Jan 2013 12:00:00 EST

Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma

Conditions:   Brain Neoplasms;   Central Nervous System Neoplasms
Interventions:   Drug: TPI287;   Drug: Bevacizumab
Sponsors:   M.D. Anderson Cancer Center;   Cortice Biosciences, Inc.
Terminated

Fri, 20 Apr 2012 12:00:00 EDT

Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)

Conditions:   Glioblastoma;   Gliosarcoma
Intervention:   Drug: Bevacizumab and Erlotinib
Sponsors:   Duke University;   Genentech, Inc.
Completed

Tue, 06 May 2008 12:00:00 EDT

Bevacizumab Plus Somatostatin Analogue and Metronomic Capecitabine in Patients With Advanced Neuroendocrine Tumors

Condition:   Neuroendocrine Carcinomas
Intervention:   Drug: bevacizumab + octreotide LAR + capecitabine
Sponsor:   University of Turin, Italy
Unknown status

Thu, 16 Sep 2010 12:00:00 EDT

Neoadjuvant Chemoradiation With RHUMAB VEGF (Avastin) for Rectal Cancer

Condition:   Rectal Cancer
Interventions:   Drug: Avastin (Bevacizumab, RHUMAB VEGF);   Drug: Capecitabine;   Radiation: Radiation Therapy
Sponsors:   M.D. Anderson Cancer Center;   Genentech, Inc.
Completed

Tue, 07 Jun 2005 12:00:00 EDT

Trial of Bevacizumab and Ixabepilone for Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

Condition:   Non-squamous Non-small Cell Lung Cancer
Interventions:   Drug: ixabepilone;   Drug: bevacizumab
Sponsors:   Providence Health & Services;   Genentech, Inc.;   Bristol-Myers Squibb
Terminated

Wed, 27 Jan 2010 12:00:00 EST

A Pharmacokinetic Study Comparing MB02 And US And EU Avastin® In Healthy Male Volunteers

Condition:   Healthy Volunteers
Interventions:   Drug: MB02;   Drug: US licenced Avastin®;   Drug: EU approved Avastin®
Sponsor:   mAbxience S.A
Completed

Tue, 26 Sep 2017 12:00:00 EDT

Carboplatin and Bevacizumab for Recurrent Ependymoma

Conditions:   Ependymoma;   Anaplastic Ependymoma
Interventions:   Drug: Carboplatin;   Drug: Bevacizumab
Sponsor:   National Cancer Institute (NCI)
Completed

Tue, 15 Feb 2011 12:00:00 EST

Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM)

Conditions:   Glioblastoma Multiforme;   Gliosarcoma
Interventions:   Drug: Gliadel;   Radiation: Radiation Therapy;   Drug: Avastin;   Drug: Temodar
Sponsors:   Duke University;   Genentech, Inc.;   Eisai Inc.
Terminated

Mon, 23 Aug 2010 12:00:00 EDT

The Sahlgrenska Anti-VEGF Study

Condition:   Neovascular Age-related Macular Degeneration
Interventions:   Drug: Bevacizumab Injection;   Drug: Aflibercept Injection
Sponsor:   Vastra Gotaland Region
Recruiting

Tue, 24 Sep 2019 12:00:00 EDT

Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer

Conditions:   Advanced Ovarian Carcinoma;   Primary Peritoneal Carcinoma;   Ovarian Carcinosarcoma
Interventions:   Drug: Avastin;   Drug: Paclitaxel;   Drug: Cisplatin
Sponsors:   University of Oklahoma;   Genentech, Inc.
Completed

Mon, 06 Aug 2007 12:00:00 EDT

To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in Study of QL1101 and Avastin® in Patients With Non-squamous Non-small Cell Lung Cancer

Condition:   Non Small Cell Lung Cancer
Interventions:   Drug: QL1101;   Drug: Avastin®;   Drug: Paclitaxel;   Drug: Carboplatin
Sponsors:   Qilu Pharmaceutical Co., Ltd.;   Tianjin Medical University Cancer Institute and Hospital
Unknown status

Thu, 22 Jun 2017 12:00:00 EDT

A Study of Tarceva vs. Avastin+Tarceva for Advanced NSCLC With EGFR m(+)

Condition:   EGFR Positive Non-small Cell Lung Cancer
Interventions:   Drug: Erlotinib plus Bevacizumab;   Drug: Erlotinib
Sponsors:   National Cancer Center, Korea;   Roche Korea co.,Ltd.
Unknown status

Mon, 24 Apr 2017 12:00:00 EDT

An Extension Study to Provide Continued Bevacizumab Therapy to Participants With Solid Tumors Who Were Previously Enrolled in a Roche/Genentech Sponsored Study

Condition:   Neoplasms
Intervention:   Drug: Bevacizumab
Sponsor:   Hoffmann-La Roche
Completed

Mon, 30 Apr 2012 12:00:00 EDT

Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer

Conditions:   Ovarian Neoplasm;   Fallopian Tube Cancer;   Primary Peritoneal Cancer
Interventions:   Drug: Bevacizumab;   Drug: BAY 43-9006
Sponsor:   National Cancer Institute (NCI)
Completed

Mon, 19 Feb 2007 12:00:00 EST

Effect of Bevacizumab on Radiation-induced Brain Necrosis in Patients With Nasopharyngeal Carcinoma

Conditions:   Nasopharyngeal Carcinoma;   Adverse Effect of Radiation Therapy;   Brain Necrosis
Interventions:   Drug: bevacizumab;   Drug: Corticosteroid
Sponsor:   Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Completed

Mon, 18 Jun 2012 12:00:00 EDT

Phase I - Pharmacokinetic Comparability Study in Healthy Male Volunteers

Condition:   Healthy
Interventions:   Drug: MYL-1402O;   Drug: US marketed Avastin(R);   Drug: EU marketed Avastin(R)
Sponsors:   Mylan Inc.;   Mylan GmbH
Unknown status

Fri, 12 Jun 2015 12:00:00 EDT

A Study of Bevacizumab (Avastin) in Women With HER2 Negative Metastatic Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Docetaxel;   Drug: Placebo to bevacizumab;   Drug: Bevacizumab
Sponsor:   Hoffmann-La Roche
Completed

Tue, 06 Jun 2006 12:00:00 EDT

Lower Dose Chemotherapy Given More Frequent With Avastin to Treat Advanced Non-Squamous Non-Small Cell Lung Cancer

Condition:   Non-Small Cell Lung Cancer
Interventions:   Drug: Paclitaxel;   Drug: Gemcitabine;   Biological: Avastin
Sponsors:   University of Alabama at Birmingham;   Genentech, Inc.
Completed

Thu, 10 Apr 2008 12:00:00 EDT

Safety Study of Avastin Used as Adjunctive Therapy in Pterygium Surgery

Condition:   Pterygium
Interventions:   Drug: Bevacizumab;   Drug: Mitomycin C
Sponsors:   The University of Texas Health Science Center, Houston;   Hermann Eye Center
Completed

Tue, 04 May 2010 12:00:00 EDT

LUCAS (Lucentis Compared to Avastin Study)

Condition:   Exudative Age-related Macular Degeneration
Interventions:   Drug: Bevacizumab;   Drug: Ranibizumab
Sponsor:   Oslo University Hospital
Completed

Thu, 20 May 2010 12:00:00 EDT

Search for a Link Between Response to Treatment and Circulating Leucocytes in High Grade Glioma Patients

Conditions:   Glioblastoma;   Glioma
Intervention:   Drug: Bevacizumab standard of care
Sponsor:   Center Eugene Marquis
Completed

Mon, 22 Apr 2013 12:00:00 EDT

Efficacity of Weekly Paclitaxel in Association or Not With Bevacizumab in Metastatic or Locally Advanced Angiosarcomas

Condition:   Angiosarcoma
Interventions:   Drug: Paclitaxel;   Drug: Bevacizumab
Sponsors:   Centre Oscar Lambret;   French Sarcoma Group;   Study Group of Bone Tumors
Completed

Thu, 24 Feb 2011 12:00:00 EST

Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion (CRVO)

Conditions:   Macular Edema;   Central Retinal Vein Occlusion
Interventions:   Drug: Ozurdex;   Drug: Avastin
Sponsor:   Long Island Vitreoretinal Consultants
Completed

Mon, 01 Nov 2010 12:00:00 EDT

Efficacy/Safety Study of Bevacizumab,Capecitabine,Oxaliplatin to Metastatic Colorectal Adenocarcinoma Elderly Patients.

Condition:   Metastatic Colorectal Cancer
Intervention:   Drug: bevacizumab, capecitabine, oxaliplatin
Sponsor:   Grupo Espanol Multidisciplinario del Cancer Digestivo
Unknown status

Thu, 11 Feb 2010 12:00:00 EST

A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Condition:   Glioblastoma
Interventions:   Drug: DSP-7888 Dosing Emulsion;   Drug: Bevacizumab
Sponsor:   Sumitomo Dainippon Pharma Oncology, Inc
Recruiting

Thu, 11 May 2017 12:00:00 EDT

A Study of Bevacizumab With Taxane Therapy in Participants With Triple Negative Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Bevacizumab;   Drug: Paclitaxel;   Drug: Docetaxel
Sponsor:   Hoffmann-La Roche
Completed

Fri, 26 Mar 2010 12:00:00 EDT

Topotecan and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Did Not Respond to Previous Systemic Chemotherapy

Condition:   Lung Cancer
Interventions:   Biological: bevacizumab;   Drug: topotecan hydrochloride
Sponsor:   Masonic Cancer Center, University of Minnesota
Completed

Thu, 17 Aug 2006 12:00:00 EDT

Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III

Conditions:   Glioblastoma;   Recurrence;   Progression
Interventions:   Drug: Temozolomide;   Drug: Bevacizumab
Sponsors:   Kyorin University;   Japan Clinical Oncology Group
Recruiting

Wed, 04 May 2016 12:00:00 EDT

Acute Changes in Intraocular Cytokines After Intravitreal Bevacizumab

Condition:   Complications of Diabetes Mellitus
Intervention:   Drug: Intravitreal Avastin injection
Sponsor:   Seoul St. Mary's Hospital
Unknown status

Fri, 23 Sep 2011 12:00:00 EDT

A Real World Study to Evaluate Effectiveness of Avastin (Bevacizumab) for First Line Treatment of Patients With Metastatic Colorectal Cancer and Known KRAS Status

Condition:   Colorectal Cancer
Interventions:   Drug: Anti-EGFR-Containing Regimen;   Drug: Bevacizumab-containing regimen;   Drug: Chemotherapy
Sponsor:   Hoffmann-La Roche
Completed

Wed, 13 Jul 2016 12:00:00 EDT

Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma

Conditions:   Glioblastoma;   Glioma;   Gliosarcoma
Interventions:   Drug: Bevacizumab;   Device: TTFields Therapy
Sponsors:   RTOG Foundation, Inc.;   NovoCure Ltd.
Terminated

Tue, 19 Apr 2016 12:00:00 EDT

A Study Comparing MB02 and Avastin® in Subjects With Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Condition:   Non-small Cell Lung Cancer
Interventions:   Drug: MB02 (Bevacizumab Biosimilar Drug);   Drug: EU-approved Avastin®;   Drug: Carboplatin;   Drug: Paclitaxel
Sponsor:   mAbxience S.A
Completed

Thu, 28 Sep 2017 12:00:00 EDT

Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma

Conditions:   Malignant Glioma;   Recurrent Glioblastoma
Interventions:   Drug: vorinostat;   Drug: bevacizumab
Sponsors:   National Cancer Institute (NCI);   M.D. Anderson Cancer Center;   Genentech, Inc.;   Merck Sharp & Dohme Corp.;   Brain Tumor Trials Collaborative;   Ohio State University Wexner Medical Center;   Northwestern University Feinberg School of Medicine;   UF Health Cancer Center at Orlando Health;   Baylor Health Care System;   MUSC Hollings Cancer Center;   University of Utah Health System;   University of Washington;   Henry Ford Health System;   Columbia University;   Rush University Medical Center;   NorthShore University HealthSystem;   The Cleveland Clinic;   University of North Carolina, Chapel Hill;   Washington University School of Medicine;   Texas Oncology-Austin
Completed

Fri, 24 Dec 2010 12:00:00 EST

Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M (BOOSTER)

Condition:   Non Small Cell Lung Cancer Metastatic
Interventions:   Drug: Osimertinib;   Drug: Bevacizumab
Sponsors:   European Thoracic Oncology Platform;   AstraZeneca;   Hoffmann-La Roche
Active, not recruiting

Fri, 28 Apr 2017 12:00:00 EDT

Compare Bevacizumab in Combination With Erlotinib Versus Erlotinib Alone in NSCLC Patients Activating EGFR Mutations

Condition:   NSCLC
Interventions:   Drug: Bevacizumab;   Drug: Erlotinib
Sponsor:   Guangdong Association of Clinical Trials
Unknown status

Tue, 03 May 2016 12:00:00 EDT

BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC)

Condition:   Lung Cancer
Interventions:   Drug: Erlotinib;   Drug: Bevacizumab
Sponsors:   European Thoracic Oncology Platform;   Spanish Lung Cancer Group
Completed

Fri, 23 Mar 2012 12:00:00 EDT

Avastin/[18-F]-5-fluorouracil PET/CT Imaging Feasibility Project

Conditions:   Colorectal Neoplasms;   Colon Cancer;   Rectal Cancer;   Anal Cancer
Intervention:   Drug: Bevacizumab
Sponsors:   Stanford University;   Genentech, Inc.
Completed

Fri, 18 Apr 2008 12:00:00 EDT

A Study of Low Dose Bevacizumab With Conventional Radiotherapy Alone in Diffuse Intrinsic Pontine Glioma

Condition:   DIPG
Interventions:   Drug: Bevacizumab Injection;   Radiation: Ultra-low-dose RT
Sponsor:   Tata Memorial Centre
Recruiting

Fri, 31 Jan 2020 12:00:00 EST

Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy

Condition:   Liver Cancer
Interventions:   Drug: Bevacizumab;   Drug: Erlotinib
Sponsors:   M.D. Anderson Cancer Center;   Genentech, Inc.;   OSI Pharmaceuticals
Completed

Thu, 12 Aug 2010 12:00:00 EDT

A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma

Conditions:   Clinical Stage III Cutaneous Melanoma AJCC v8;   Stage IV Melanoma;   Unresectable Stage III Cutaneous Melanoma;   Unresectable Stage IV Cutaneous Melanoma
Interventions:   Drug: Atezolizumab;   Drug: Bevacizumab
Sponsors:   Elizabeth Buchbinder;   Genentech, Inc.
Recruiting

Wed, 22 Apr 2020 12:00:00 EDT

The Effect of Bevacizumab (Avastin) on Pterygium

Condition:   Pterygium
Intervention:   Drug: local injection of bevacizumab
Sponsor:   University of Alabama at Birmingham
Completed

Fri, 11 Jan 2008 12:00:00 EST

A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation

Condition:   Carcinoma, Hepatocellular
Interventions:   Drug: Atezolizumab;   Drug: Bevacizumab
Sponsor:   Hoffmann-La Roche
Recruiting

Wed, 25 Sep 2019 12:00:00 EDT

Efficacy and Safety of Bevacizumab for the Treatment Hemorrhagic Hereditary Telangiectasia (HHT) Associated With Severe Hepatic Vascular Malformations. Phase II Study

Condition:   Hemorrhagic Hereditary Telangiectasia
Intervention:   Drug: Bevacizumab
Sponsor:   Hospices Civils de Lyon
Completed

Fri, 13 Feb 2009 12:00:00 EST

Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients

Condition:   Metastatic Colorectal Cancer (mCRC)
Interventions:   Drug: Bevacizumab biosimilar (BEVZ92);   Drug: Avastin® (bevacizumab, reference product)
Sponsors:   mAbxience S.A;   Laboratorio Elea Phoenix S.A.;   Libbs Farmacêutica LTDA
Completed

Mon, 24 Feb 2014 12:00:00 EST

TH-302 in Combination With Bevacizumab for Glioblastoma

Condition:   Glioblastoma
Interventions:   Drug: Bevacizumab;   Drug: TH-302
Sponsor:   The University of Texas Health Science Center at San Antonio
Completed

Mon, 19 Jan 2015 12:00:00 EST

Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients

Conditions:   Glioblastoma Multiforme;   Glioblastoma;   Glioma;   Brain Tumor;   Neoplasms;   Neoplasms, Nerve Tissue
Interventions:   Device: NaviFUS System;   Drug: Bevacizumab
Sponsors:   NaviFUS Corporation;   Chang Gung Memorial Hospital
Recruiting

Wed, 24 Jun 2020 12:00:00 EDT

Bevacizumab Combined With Fractionated Stereotactic Radiotherapy for 1 to 10 Brain Metastases From Non-squamous NSCLC

Condition:   Non-squamous Non-small Cell Lung Cancer
Intervention:   Combination Product: FSRT combined with Bevacizumab
Sponsor:   Sun Yat-sen University
Recruiting

Tue, 14 Apr 2020 12:00:00 EDT

Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma

Condition:   Glioma
Interventions:   Drug: bevacizumab;   Drug: carmustine
Sponsors:   University of California, Davis;   National Cancer Institute (NCI);   Genentech, Inc.
Completed

Fri, 21 Nov 2008 12:00:00 EST

A Pharmacokinetic Study Comparing MB02 And EU Avastin® In Healthy Male Volunteers

Conditions:   Healthy Volunteers;   Male;   Japanese
Interventions:   Drug: MB02 (Bevacizumab Biosimilar);   Drug: EU approved Avastin®
Sponsor:   mAbxience S.A
Completed

Thu, 23 Jan 2020 12:00:00 EST

Combination of Erlotinib and Bevacizumab as Second-line Treatment in Patients With Non-small Cell Lung Cancer

Condition:   Non-small-cell Lung Cancer
Interventions:   Drug: Erlotinib;   Drug: Bevacizumab
Sponsors:   Hellenic Oncology Research Group;   University Hospital of Crete
Terminated

Tue, 09 Sep 2008 12:00:00 EDT

Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients

Conditions:   Recurrent Glioblastoma Multiforme;   Malignant Glioma;   Adult Brain Tumor
Interventions:   Drug: Vorinostat;   Drug: Bevacizumab
Sponsors:   Duke University;   Genentech, Inc.;   Merck Sharp & Dohme Corp.
Completed

Fri, 30 Nov 2012 12:00:00 EST

Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer

Condition:   Non-Small Cell Lung Cancer (NSCLC)
Interventions:   Drug: Alectinib;   Drug: Bevacizumab
Sponsors:   Massachusetts General Hospital;   Genentech, Inc.
Recruiting

Thu, 13 Aug 2015 12:00:00 EDT

Border Zone Stereotactic Radiosurgery With Bevacizumab in Patients With Glioblastoma Multiforme

Conditions:   Glioblastoma Multiforme;   Glioblastoma - Category
Interventions:   Drug: Bevacizumab;   Procedure: Magnetic Resonance Spectroscopy (MRS);   Procedure: Border Zone Stereotactic Radiosurgery (BZ-SRS)
Sponsors:   Ajay Niranjan;   Genentech, Inc.
Completed

Tue, 22 Apr 2014 12:00:00 EDT

Bevacizumab in Treating Patients With Advanced Solid Tumors

Condition:   Unspecified Adult Solid Tumor, Protocol Specific
Intervention:   Biological: Bevacizumab (Avastin)
Sponsors:   Herbert Hurwitz, MD;   National Cancer Institute (NCI)
Completed

Thu, 28 Dec 2006 12:00:00 EST

Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer

Conditions:   Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Carcinoma
Interventions:   Drug: RAD001;   Drug: bevacizumab
Sponsors:   University of Pittsburgh;   Novartis Pharmaceuticals;   Genentech, Inc.
Completed

Mon, 14 Dec 2009 12:00:00 EST

Prospective Randomized Controlled Study of Intravitreal Injection of Bevacizumab for Proliferative Diabetic Retinopathy

Conditions:   Proliferative Diabetic Retinopathy;   Diabetic Traction Retinal Detachment;   Vitreous Hemorrhage
Interventions:   Drug: Bevacizumab;   Procedure: Vitrectomy;   Device: Sham injection
Sponsor:   Nihon University
Completed

Wed, 15 May 2013 12:00:00 EDT

Preoperative Bevacizumab for Vitreous Hemorrhage

Conditions:   Diabetic Retinopathy;   Vitreous Hemorrhage
Interventions:   Drug: bevacizumab;   Procedure: pars plana vitrectomy
Sponsor:   University of Sao Paulo
Completed

Wed, 16 Jan 2008 12:00:00 EST

Study of Gemcitabine/Carboplatin/Bevacizumab to Treat Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Conditions:   Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer
Interventions:   Drug: Bevacizumab;   Drug: Gemcitabine;   Drug: Carboplatin
Sponsors:   Ohio State University Comprehensive Cancer Center;   Genentech, Inc.;   Eli Lilly and Company
Completed

Wed, 21 Dec 2005 12:00:00 EST

Efficacy of Bevacizumab in Preventing Acute Respiratory Distress Syndrome (ARDS)

Conditions:   Severe Sepsis;   Acute Respiratory Distress Syndrome
Interventions:   Drug: Bevacizumab;   Drug: Placebo
Sponsor:   Weill Medical College of Cornell University
Withdrawn

Mon, 14 Mar 2011 12:00:00 EDT

Treatment of Bevacizumab Followed by Steroid in RN

Conditions:   Nasopharyngeal Carcinoma;   Adverse Effect of Radiation Therapy;   Brain Injuries
Interventions:   Drug: Bevacizumab and steroid;   Drug: Bevacizumab and placebo
Sponsor:   Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Recruiting

Thu, 17 Sep 2020 12:00:00 EDT

Bendamustine and Bevacizumab for Advanced Cancers

Condition:   Advanced Cancer
Interventions:   Drug: Bendamustine;   Drug: Bevacizumab
Sponsors:   M.D. Anderson Cancer Center;   Cephalon;   National Comprehensive Cancer Network
Completed

Tue, 29 Jun 2010 12:00:00 EDT

Bevacizumab as a Palliative Treatment for Patients With Symptomatic Malignant Ascites Due to Advanced-stage Gastrointestinal Cancers

Conditions:   Malignant Ascites;   Gastrointestinal Cancers
Interventions:   Drug: Bevacizumab;   Other: Placebo
Sponsor:   AIO-Studien-gGmbH
Completed

Mon, 13 Sep 2010 12:00:00 EDT

Avastin/Docetaxel/Carboplatin in Non-Small Cell Lung Cancer

Condition:   Non-Small Cell Lung Cancer
Interventions:   Drug: Bevacizumab (Avastin);   Drug: Carboplatin;   Drug: Docetaxel
Sponsors:   M.D. Anderson Cancer Center;   Genentech, Inc.
Completed

Mon, 02 Jan 2006 12:00:00 EST

A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy

Condition:   Age-Related Macular Degeneration
Interventions:   Drug: E10030;   Drug: bevacizumab or aflibercept;   Drug: E10030 sham injection
Sponsor:   Ophthotech Corporation
Terminated

Thu, 12 Sep 2013 12:00:00 EDT

Bevacizumab Versus Cidofovir for the Treatment of Recurrent Respiratory Papillomatosis

Condition:   Recurrent Respiratory Papillomatosis
Interventions:   Drug: Bevacizumab;   Drug: Cidofovir;   Other: Placebo
Sponsor:   Centro de Investigación en. Enfermedades Infecciosas, Mexico
Unknown status

Tue, 22 Sep 2015 12:00:00 EDT

Pilot Study to Evaluate the Safety and Efficacy of Treatment With ORA102 Combined With Avastin (Bevacizumab) Versus Avastin Alone, in Patients With Neovascular Age Related Macular Degeneration (AMD)

Condition:   Macular Degeneration
Interventions:   Drug: ORA102 and Avastin;   Drug: Avastin
Sponsor:   Ora Bio Ltd.
Unknown status

Wed, 03 Sep 2008 12:00:00 EDT

Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease

Conditions:   Hemangioblastomas;   Von Hippel Lindau Disease
Intervention:   Drug: Avastin
Sponsors:   Dartmouth-Hitchcock Medical Center;   Genentech, Inc.
Terminated

Wed, 18 Nov 2009 12:00:00 EST

Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab

Condition:   Ovarian Cancer
Interventions:   Drug: Bevacizumab;   Drug: Paclitaxel;   Drug: Carboplatin
Sponsors:   National Cancer Institute, Naples;   Mario Negri Institute for Pharmacological Research
Active, not recruiting

Mon, 15 Oct 2012 12:00:00 EDT

Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas

Conditions:   Neurofibromatosis Type 2;   Progressive Vestibular Schwannomas
Intervention:   Drug: Bevacizumab
Sponsors:   University of Alabama at Birmingham;   Genentech, Inc.
Completed

Mon, 14 Jan 2013 12:00:00 EST

Satraplatin and Bevacizumab in Treating Patients With Metastatic Prostate Cancer Previously Treated With Docetaxel

Condition:   Prostate Cancer
Interventions:   Biological: bevacizumab;   Drug: satraplatin
Sponsors:   Barbara Ann Karmanos Cancer Institute;   National Cancer Institute (NCI)
Completed

Wed, 11 Jul 2007 12:00:00 EDT

Atezolizumab in Combination With Bevacizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma

Condition:   Melanoma
Interventions:   Drug: Atezolizumab;   Drug: Bevacizumab
Sponsor:   Hoffmann-La Roche
Active, not recruiting

Mon, 16 Sep 2019 12:00:00 EDT

Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma

Conditions:   Malignant Glioma;   Glioblastoma;   Gliosarcoma
Interventions:   Drug: Bevacizumab;   Drug: Temozolomide;   Radiation: Radiation Therapy (XRT);   Drug: Topotecan
Sponsors:   Duke University;   Genentech, Inc.;   GlaxoSmithKline
Active, not recruiting

Fri, 30 Oct 2009 12:00:00 EDT

A Study of Bevacizumab (Avastin) in Combination With Capecitabine (Xeloda) in Elderly Patients With Metastatic Colorectal Cancer

Condition:   Colorectal Cancer
Interventions:   Drug: Bevacizumab;   Drug: Capecitabine
Sponsor:   Hoffmann-La Roche
Completed

Tue, 12 Jun 2007 12:00:00 EDT

Pemetrexed and TAS-102 in Combination With Bevacizumab in Refractory Colorectal Cancer

Condition:   Colorectal Neoplasms
Interventions:   Drug: Pemetrexed;   Drug: TAS-102;   Drug: Bevacizumab
Sponsors:   The First Affiliated Hospital with Nanjing Medical University;   Jiangsu HanSoh Tharmaceutical Group Co., Ltd
Not yet recruiting

Thu, 24 Dec 2020 12:00:00 EST

Bevacizumab and Erlotinib in Lung Cancer With Brain Metastases, a Phase II Trial

Conditions:   Carcinoma, Non-Small-Cell Lung;   Brain Neoplasms
Interventions:   Drug: Bevacizumab plus erlotinib;   Drug: Erlotinib
Sponsor:   National Taiwan University Hospital
Unknown status

Thu, 14 Jan 2016 12:00:00 EST

Intralesional Bevacizumab Injection on Primary Pterygium

Conditions:   Pterygium;   Inflammation
Interventions:   Drug: Intralesional injection of bevacizumab;   Drug: Topical antihistamine and vasoconstrictor
Sponsor:   Khon Kaen University
Unknown status

Mon, 27 Jun 2011 12:00:00 EDT

A Study of Bevacizumab (Avastin) in Neoadjuvant Therapy in Participants With International Federation of Gynecology and Obstetrics (FIGO) Stage IIIC/IV Ovarian, Tubal, or Peritoneal Cancer, Initially Unresectable

Condition:   Ovarian Cancer
Interventions:   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Bevacizumab
Sponsor:   Hoffmann-La Roche
Completed

Mon, 03 Dec 2012 12:00:00 EST

Adjuvant Intravitreal Bevacizumab in Pars Plana Vitrectomy for Vitreous Hemorrhage

Condition:   Vitreous Hemorrhage Secondary to PDR
Interventions:   Drug: Bevacizumab;   Drug: bevacizumab
Sponsor:   University of Sao Paulo
Unknown status

Wed, 24 Mar 2010 12:00:00 EDT

Cisplatin and Gemcitabine With or Without Bevacizumab in EGFR Wild-type Non-Small Cell Lung Cancer

Condition:   Lung Cancer
Interventions:   Drug: cisplatin and gemcitabine combination with Bevacizumab;   Drug: Gemcitabine combined with cisplatin chemotherapy
Sponsor:   Sichuan Cancer Hospital and Research Institute
Unknown status

Tue, 19 Jun 2012 12:00:00 EDT

Comparing Efficacy and Safety of Stivant (AryoGen Bevacizumab) Versus Avastin in Metastatic Colorectal Cancer

Condition:   Metastatic Colorectal Cancer
Intervention:   Drug: Bevacizumab + FOLFIRI-3
Sponsor:   AryoGen Pharmed Co.
Completed

Wed, 20 Sep 2017 12:00:00 EDT

DRCR.Net Aflibercept vs. Bevacizumab + Deferred Aflibercept for the Treatment of CI-DME

Condition:   Diabetic Macular Edema
Interventions:   Drug: intravitreous aflibercept;   Drug: Bevacizumab + Deferred Aflibercept Group
Sponsor:   Jaeb Center for Health Research
Active, not recruiting

Wed, 25 Oct 2017 12:00:00 EDT

A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer

Conditions:   Head and Neck Cancer;   Squamous Cell Carcinoma
Interventions:   Drug: Cetuximab;   Drug: Bevacizumab
Sponsor:   National Cancer Institute (NCI)
Completed

Mon, 11 Dec 2006 12:00:00 EST

A Study of Bevacizumab (Avastin) in Combination With Chemotherapy in Participants With Metastatic Cancer of the Colon or Rectum

Condition:   Colorectal Cancer
Interventions:   Drug: 5-Fluorouracil;   Drug: Bevacizumab;   Drug: Irinotecan;   Drug: Oxaliplatin
Sponsor:   Hoffmann-La Roche
Completed

Wed, 21 Oct 2015 12:00:00 EDT

A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1)

Condition:   Metastatic Breast Cancer
Interventions:   Drug: Bevacizumab;   Drug: Placebo;   Drug: Chemotherapy
Sponsor:   Genentech, Inc.
Unknown status

Tue, 06 Dec 2005 12:00:00 EST

Raltitrexed-based Chemotherapy Plus Bevacizumab in Retreated Patients With Advanced Colorectal Cancer

Condition:   Advanced Colorectal Cancer
Interventions:   Drug: Raltitrexed;   Drug: Irinotecan;   Drug: Oxaliplatin;   Drug: Bevacizumab
Sponsor:   Jiangsu Cancer Institute & Hospital
Recruiting

Mon, 24 Apr 2017 12:00:00 EDT

Does Adding Bevacizumab Therapy in Glaucoma Surgery Improve the Success of Needle Bleb Revisions?

Condition:   Glaucoma
Interventions:   Drug: bevacizumab;   Other: balanced salt solution
Sponsor:   Wills Eye
Completed

Fri, 27 Feb 2009 12:00:00 EST

MAAM Study: Avastin and Macugen Versus Avastin Versus Macugen

Condition:   Macular Degeneration
Interventions:   Drug: intravitreal injection of Bevacizumab (Avastin);   Drug: Pegaptanib (Macugen)
Sponsor:   The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery
Completed

Tue, 18 Sep 2007 12:00:00 EDT

Pars Plana Vitrectomy (PPV) Versus Preoperative Intravitreal Bevacizumab Plus PPV to Treat Diabetic Tractional Retinal Detachment (IBETRA)

Conditions:   Diabetic Retinopathy;   Retinal Detachment
Interventions:   Drug: Bevacizumab;   Procedure: pars plana vitrectomy
Sponsor:   University of Sao Paulo
Completed

Thu, 05 Jun 2008 12:00:00 EDT

Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme

Conditions:   Recurrent Glioblastoma Multiforme;   Recurrent Gliosarcoma
Intervention:   Drug: temozolomide and bevacizumab
Sponsors:   Center for Neurosciences, Tucson;   Genentech, Inc.
Completed

Fri, 17 Apr 2009 12:00:00 EDT

OSI-774 and Bevacizumab in the Treatment of Patients With Metastatic Renal Cell Carcinoma

Condition:   Kidney Cancer
Interventions:   Drug: OSI-774;   Drug: Bevacizumab
Sponsors:   SCRI Development Innovations, LLC;   AstraZeneca;   Genentech, Inc.
Completed

Mon, 19 Sep 2005 12:00:00 EDT

Safety and Efficacy of Bevacizumab in Combination With Carboplatin and Paclitaxel for Metastatic, Recurrent or Persistent Cervical Cancer

Condition:   Cervical Cancer
Interventions:   Drug: Bevacizumab;   Drug: Carboplatin;   Drug: Paclitaxel
Sponsor:   Hoffmann-La Roche
Completed

Wed, 10 Jun 2015 12:00:00 EDT

INCMGA00012 and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas

Conditions:   Glioma;   Glioblastoma
Interventions:   Drug: Epacadostat;   Drug: Bevacizumab;   Radiation: Radiation therapy;   Procedure: Peripheral blood draw
Sponsors:   Washington University School of Medicine;   Incyte Corporation
Recruiting

Tue, 22 May 2018 12:00:00 EDT

A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenecity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer Patients

Conditions:   Lung Cancer;   Non-small Cell Lung Cancer
Interventions:   Drug: Bevacizumab;   Drug: HD204;   Drug: Carboplatin;   Drug: Paclitaxel
Sponsor:   Prestige Biopharma Ltd
Recruiting

Thu, 04 Jan 2018 12:00:00 EST

Paclitaxel-Carboplatin-Bevacizumab +/- Nitroglycerin in Metastatic Non-Squamous-Non-Small Cell Lung Cancer

Condition:   Non Small Cell Lung Cancer
Interventions:   Drug: carboplatin paclitaxel bevacizumab;   Drug: Standard treatment plus nitroglycerin
Sponsor:   Dutch Society of Physicians for Pulmonology and Tuberculosis
Completed

Wed, 28 Jul 2010 12:00:00 EDT

Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma

Condition:   Advanced Non-Clear Cell Kidney Cancer
Interventions:   Drug: Bevacizumab;   Drug: Atezolizumab
Sponsors:   Dana-Farber Cancer Institute;   Genentech, Inc.
Active, not recruiting

Thu, 31 Mar 2016 12:00:00 EDT

A Study of Bevacizumab Plus 5-Flurouracil (5-FU) Based Doublet Chemotherapy as Neoadjuvant Therapy for Participants With Previously Untreated Unresectable Liver-Only Metastases From Colorectal Cancer

Condition:   Colorectal Cancer
Interventions:   Drug: 5-FU based doublet chemotherapy;   Drug: bevacizumab
Sponsor:   Hoffmann-La Roche
Completed

Fri, 28 Sep 2012 12:00:00 EDT

Intraperitoneal Paclitaxel and Carboplatin With IV Avastin Therapy in Patients With Carcinomas of Mullerian Origin

Conditions:   Ovarian Cancer;   Peritoneal Cancer;   Fallopian Tube Cancer
Interventions:   Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Avastin
Sponsors:   Massachusetts General Hospital;   Genentech, Inc.;   National Cancer Institute (NCI)
Active, not recruiting

Thu, 03 Apr 2008 12:00:00 EDT

Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors

Condition:   Germ Cell Tumor
Interventions:   Drug: Brentuximab Vedotin;   Drug: Bevacizumab
Sponsor:   Masonic Cancer Center, University of Minnesota
Terminated

Fri, 09 Dec 2016 12:00:00 EST

Bevacizumab Injection for Recurrent Pterygium

Condition:   Recurrent Pterygium
Interventions:   Drug: Bevacizumab;   Drug: Medical Treatment;   Procedure: Argon laser treatment
Sponsors:   Instituto de Oftalmología Fundación Conde de Valenciana;   National Council of Science and Technology, Mexico
Completed

Tue, 10 Dec 2013 12:00:00 EST

MIL60 Versus Bevacizumab in Patients With Treatment-naïve Non-squamous Non-small Cell Lung Cancer

Condition:   Non-small Cell Lung Cancer
Interventions:   Drug: MIL60;   Drug: Bevacizumab
Sponsors:   Beijing Mabworks Biotech Co., Ltd.;   Betta Pharmaceuticals Co., Ltd.
Unknown status

Fri, 23 Jun 2017 12:00:00 EDT

Longterm Efficiency and Safety of Intravitreal Injections With Bevacizumab in Patients With Neovascularisation or Macular Edema

Conditions:   Retinal Neovascularization;   Macular Edema
Intervention:   Drug: Bevacizumab Injection [Avastin]
Sponsor:   University Hospital, Ghent
Recruiting

Fri, 07 Jul 2017 12:00:00 EDT

A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT)

Conditions:   Non-Small Cell Lung Cancer;   Brain Neoplasms
Interventions:   Drug: bevacizumab;   Drug: First-Line Chemotherapy Agents;   Drug: Second-Line Chemotherapy Agents
Sponsor:   Genentech, Inc.
Completed

Tue, 11 Apr 2006 12:00:00 EDT

A Phase I/II Study of IXO With Bevacizumab in Patients With Metastatic Colorectal Cancer

Condition:   Metastatic Colorectal Cancer
Intervention:   Drug: IXO regimen + bevacizumab
Sponsors:   Ottawa Hospital Research Institute;   Hoffmann-La Roche;   Pfizer;   Sanofi;   Ottawa Regional Cancer Foundation
Terminated

Fri, 09 Jan 2009 12:00:00 EST

Abraxane With Bevacizumab Biosimilar in Patients With Recurrent, Platinum-resistant Epithelial Ovarian Cancer

Condition:   Objective Response Rate
Intervention:   Drug: albumin-bound paclitaxe combined with bevacizumab biosimilar
Sponsor:   Shandong University
Recruiting

Thu, 17 Dec 2020 12:00:00 EST

Phase I/II Trial of Radiation, Avastin and Tarceva for Pancreatic Adenocarcinoma

Condition:   Pancreatic Cancer
Interventions:   Drug: Avastin;   Drug: Tarceva;   Radiation: Radiation Therapy
Sponsors:   Duke University;   Genentech, Inc.
Completed

Thu, 14 Aug 2008 12:00:00 EDT

Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial

Condition:   Age Related Macular Degeneration
Interventions:   Drug: ranibizumab;   Drug: bevacizumab
Sponsors:   University of Pennsylvania;   National Eye Institute (NEI)
Completed

Tue, 15 Jan 2008 12:00:00 EST

Laser vs Bevacizumab Injection Alone in Treatment of Diabetic Macular Edema

Condition:   Diabetic Macular Edema
Interventions:   Drug: bevacizumab;   Device: PASCAL Endpoint Management (EpM) laser treatment
Sponsor:   University of California, San Francisco
Withdrawn

Mon, 01 Sep 2014 12:00:00 EDT

Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis

Conditions:   Leptomeningeal Metastasis;   Non-small Cell Lung Cancer;   EGFR Activating Mutation
Interventions:   Drug: Osimertinib;   Drug: Bevacizumab
Sponsors:   Second Affiliated Hospital of Nanchang University;   Nanchang University
Unknown status

Mon, 04 Nov 2019 12:00:00 EST

Neoadjuvant FOLFOX Plus Bevacizumab Chemotherapy in Patients With Locally Advanced Colon Cancer

Condition:   Colon Cancer
Intervention:   Drug: FOLFOX and bevacizumab
Sponsors:   Memorial Sloan Kettering Cancer Center;   Genentech, Inc.
Terminated

Thu, 22 Jan 2009 12:00:00 EST

Efficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver Cancer That Cannot be Removed By Surgery

Conditions:   Hepatocellular Carcinoma;   Liver Cancer
Interventions:   Drug: Bevacizumab (Avastin);   Drug: Erlotinib
Sponsors:   M.D. Anderson Cancer Center;   Genentech, Inc.
Completed

Thu, 20 Oct 2005 12:00:00 EDT

First Line Ovarian Cancer Treatment - Cohort Study

Condition:   Epithelial Ovarian Cancer
Intervention:   Drug: Bevacizumab
Sponsors:   ARCAGY/ GINECO GROUP;   Roche Pharma AG
Completed

Tue, 16 Apr 2013 12:00:00 EDT

Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas

Condition:   Malignant Glioma
Interventions:   Radiation: Hypofractionated Stereotactic Irradiation (HFSRT);   Drug: Pembrolizumab;   Drug: Bevacizumab
Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   Merck Sharp & Dohme Corp.
Completed

Wed, 10 Dec 2014 12:00:00 EST

A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer

Condition:   Ovarian Cancer
Interventions:   Drug: Paclitaxel;   Drug: Bevacizumab;   Drug: Carboplatin
Sponsor:   Hoffmann-La Roche
Completed

Thu, 11 Nov 2010 12:00:00 EST

Intravitreal Bevacizumab (Avastin®) Versus Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema

Conditions:   Diabetic Retinopathy;   Macular Edema
Interventions:   Drug: bevacizumab;   Drug: dexamethasone
Sponsors:   University of Sydney;   National Health and Medical Research Council, Australia
Completed

Thu, 17 Feb 2011 12:00:00 EST

A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer

Conditions:   Ovarian Cancer;   Platinum-resistant Ovarian Cancer
Intervention:   Drug: Bevacizumab
Sponsor:   British Columbia Cancer Agency
Not yet recruiting

Mon, 08 Mar 2021 12:00:00 EST

ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer

Condition:   Metastatic Breast Cancer
Interventions:   Drug: ABI-007;   Drug: Bevacizumab
Sponsor:   Celgene
Completed

Tue, 31 Oct 2006 12:00:00 EST

Metronomic Vinorelbine and Bevacizumab in Patients With Non Small Cell Lung Cancer

Condition:   Non Small Cell Lung Cancer
Interventions:   Drug: Vinorelbine;   Drug: Bevacizumab
Sponsors:   Hellenic Oncology Research Group;   University Hospital of Crete
Completed

Thu, 18 Sep 2008 12:00:00 EDT

Alectinib in Combination With Bevacizumab in ALK Positive NSCLC

Conditions:   ALK Gene Rearrangement Positive;   Non-Squamous Non-Small Cell Neoplasm of Lung
Interventions:   Drug: Alectinib;   Drug: Bevacizumab
Sponsors:   Instituto Nacional de Cancerologia de Mexico;   Roche Pharma AG
Recruiting

Wed, 19 Dec 2018 12:00:00 EST

A Study of Tarceva (Erlotinib) in Combination With Avastin (Bevacizumab) in Patients With Advanced Non-Small Cell Lung Cancer.

Condition:   Non-Small Cell Lung Cancer
Interventions:   Drug: Erlotinib;   Drug: Bevacizumab;   Drug: Standard platinum-based chemotherapy
Sponsor:   Hoffmann-La Roche
Completed

Wed, 19 Sep 2007 12:00:00 EDT

Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma

Conditions:   Glial Cell Tumors;   Malignant Gliomas;   Glioblastoma Multiforme;   Anaplastic Astrocytoma;   Gliomatosis Cerebri;   Gliosarcoma;   Brainstem Glioma;   Diffuse Intrinsic Pontine Glioma
Interventions:   Drug: Valproic acid;   Drug: Bevacizumab;   Radiation: Radiation therapy
Sponsors:   Baylor College of Medicine;   Cook Children's Medical Center;   University of Oklahoma;   University of Texas, Southwestern Medical Center at Dallas;   The University of Texas Health Science Center at San Antonio;   M.D. Anderson Cancer Center
Completed

Fri, 10 Apr 2009 12:00:00 EDT

Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Biliary Tract and Gallbladder Cancer

Conditions:   Biliary Tract Cancer;   Gallbladder Adenocarcinoma
Interventions:   Drug: Bevacizumab;   Drug: Gemcitabine;   Drug: Oxaliplatin
Sponsors:   Massachusetts General Hospital;   Genentech, Inc.;   Sanofi;   Beth Israel Deaconess Medical Center;   Brigham and Women's Hospital;   Dana-Farber Cancer Institute
Completed

Tue, 08 Aug 2006 12:00:00 EDT

A Study Comparing the Pharmacokinetic Similarity of MB02-SP, MB02-DM and USlicensed Avastin®.

Condition:   Healthy Volunteers
Interventions:   Drug: MB02-SP;   Drug: MB02-DM;   Drug: US licenced Avastin®
Sponsor:   mAbxience S.A
Active, not recruiting

Mon, 01 Jun 2020 12:00:00 EDT

Bevacizumab for Neovascular Age-related Macular Degeneration

Condition:   Exudative Age-related Macular Degeneration
Interventions:   Drug: Bevacizumab 1;   Drug: Bevacizumab
Sponsor:   Peking University People's Hospital
Completed

Wed, 02 Mar 2011 12:00:00 EST

Hypofractionated Intensity-Modulated Radiation Therapy With Temozolomide and Bevacizumab for Glioblastoma Multiforme

Condition:   Glioblastoma Multiforme
Interventions:   Drug: Bevacizumab;   Drug: Temozolomide;   Radiation: RT (Radiation Therapy)
Sponsors:   University of Colorado, Denver;   Genentech, Inc.
Completed

Mon, 27 Sep 2010 12:00:00 EDT

Proton Therapy and Bevacizumab for Primary Liver Tumors

Conditions:   Liver Cancer;   Hepatocellular Carcinoma;   Cholangiocarcinoma
Interventions:   Drug: Bevacizumab;   Radiation: Proton Radiation Therapy
Sponsors:   M.D. Anderson Cancer Center;   Genentech, Inc.
Terminated

Thu, 25 Jan 2007 12:00:00 EST

Neoadjuvant Bevacizumab Plus Docetaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy

Conditions:   Prostate Cancer;   Adenocarcinoma of the Prostate
Interventions:   Drug: Bevacizumab;   Drug: Docetaxel
Sponsors:   Mary-Ellen Taplin, MD;   Beth Israel Deaconess Medical Center;   Duke University;   Genentech, Inc.;   Sanofi
Completed

Thu, 04 May 2006 12:00:00 EDT

Randomized Controlled Trial of Subconjunctival Bevacizumab Injection in Impending Recurrent Pterygium

Condition:   Pterygium of the Conjunctiva and Cornea
Interventions:   Drug: Fluorometholone;   Drug: Bevacizumab
Sponsor:   Ramathibodi Hospital
Completed

Wed, 02 Feb 2011 12:00:00 EST

Irinotecan and Bevacizumab for Recurrent Ovarian Cancer

Conditions:   Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Carcinoma
Interventions:   Drug: Irinotecan;   Drug: Bevacizumab
Sponsors:   NYU Langone Health;   Genentech, Inc.
Completed

Tue, 23 Mar 2010 12:00:00 EDT

Bevacizumab, Autologous Tumor/DC Vaccine, IL-2 and IFNα-2b in Metastatic Renal Cell Carcinoma (RCC) Patients

Condition:   Metastatic Renal Cell Carcinoma
Interventions:   Biological: DC vaccine;   Drug: Bevacizumab;   Biological: IL-2;   Biological: IFN
Sponsors:   Dartmouth-Hitchcock Medical Center;   National Cancer Institute (NCI)
Terminated

Thu, 04 Jun 2009 12:00:00 EDT

A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma

Condition:   Lymphoma, Follicular
Interventions:   Drug: Bevacizumab;   Drug: Rituximab
Sponsors:   SCRI Development Innovations, LLC;   Genentech, Inc.
Completed

Mon, 19 Sep 2005 12:00:00 EDT

PK Bioequivalence Single-dose Safety Tolerability Study in Healthy Male Volunteers to Compare CBT124 & Avastin(EU&US)

Condition:   Healthy
Interventions:   Biological: CBT124;   Biological: EU Sourced Avastin®;   Biological: US Sourced Avastin®
Sponsors:   Cipla BioTec Pvt. Ltd.;   Quintiles, Inc.
Unknown status

Fri, 22 Apr 2016 12:00:00 EDT

Docetaxel Plus Bevacizumab in Metastatic Non Small Cell Lung Cancer

Condition:   Non-small-cell Lung Cancer
Interventions:   Drug: Docetaxel;   Drug: Bevacizumab
Sponsor:   Hellenic Oncology Research Group
Completed

Tue, 26 Aug 2008 12:00:00 EDT

Efficacy of a Bevacizumab Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)

Conditions:   Hereditary Hemorrhagic Telangiectasia;   Epistaxis
Interventions:   Drug: Bevacizumab;   Drug: placebo
Sponsor:   Hospices Civils de Lyon
Terminated

Tue, 08 Apr 2014 12:00:00 EDT

R-CHOP-B Bevacizumab for Diffuse Large B Cell Lymphoma

Conditions:   Non-Hodgkin's Lymphoma;   B-cell Lymphoma
Intervention:   Drug: bevacizumab, Rituximab
Sponsors:   Royal Marsden NHS Foundation Trust;   Hoffmann-La Roche
Terminated

Tue, 11 Nov 2008 12:00:00 EST

Exploratory Study of the Modulation of the Immune System by VEGF Blockade in Patients With Glioblastoma Multiforme (GBM)

Condition:   Glioblastoma Multiforme
Intervention:   Drug: Bevacizumab
Sponsors:   Dartmouth-Hitchcock Medical Center;   Genentech, Inc.
Completed

Wed, 24 Mar 2010 12:00:00 EDT

Pemetrexed Plus Bevacizumab in Non Small Cell Lung Cancer

Condition:   Non-small-cell Lung Cancer
Interventions:   Drug: Pemetrexed;   Drug: Bevacizumab
Sponsor:   Hellenic Oncology Research Group
Completed

Tue, 26 Aug 2008 12:00:00 EDT

The Use of Bevacizumab as a Modulator of Wound Healing Following Trabeculectomy Surgery

Condition:   Glaucoma
Interventions:   Drug: bevacizumab;   Drug: 5-fluorouracil;   Drug: Dexamethasone
Sponsor:   Moorfields Eye Hospital NHS Foundation Trust
Completed

Tue, 10 May 2016 12:00:00 EDT

Phase III Study of Trifluridine/Tipiracil in Combination With Bevacizumab vs Trifluridine/Tipiracil Single Agent in Patients With Refractory Metastatic Colorectal Cancer

Condition:   Refractory Metastatic Colorectal Cancer
Interventions:   Drug: Trifluridine/Tipiracil;   Drug: Bevacizumab
Sponsors:   Taiho Oncology, Inc.;   Institut de Recherches Internationales Servier
Recruiting

Wed, 03 Feb 2021 12:00:00 EST

Randomized Phase 2 Study to Investigate Efficacy of ALECSAT in Patients With GBM Measured Compared to Avastin/Irinotecan

Condition:   Glioblastoma Multiforme
Interventions:   Biological: ALECSAT;   Drug: Bevacizumab/Irinotecan
Sponsor:   CytoVac A/S
Terminated

Wed, 12 Feb 2014 12:00:00 EST

Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases

Conditions:   Metastatic Breast Cancer;   Breast Cancer;   Progressive Breast Cancer
Interventions:   Drug: carboplatin;   Drug: bevacizumab;   Drug: herceptin
Sponsors:   Dana-Farber Cancer Institute;   Brigham and Women's Hospital;   Massachusetts General Hospital;   Beth Israel Deaconess Medical Center;   Genentech, Inc.
Completed

Thu, 29 Oct 2009 12:00:00 EDT

Maintenance Bevacizumab Only or Bevacizumab Plus Metronomic Chemotherapy in Advanced Colorectal Cancer

Condition:   Metastatic Colorectal Cancer
Interventions:   Drug: Maintenance:BEVACIZUMAB;   Drug: Maintenance:BEVACIZUMAB+CAPECITABINE+CYCLOPHOSPHAMIDE
Sponsor:   Azienda Ospedaliero, Universitaria Pisana
Completed

Wed, 22 Oct 2014 12:00:00 EDT

Manta Study: Avastin Versus Lucentis in Age Related Macular Degeneration

Condition:   Age Related Macular Degeneration
Interventions:   Drug: Ranibizumab;   Drug: Bevacizumab
Sponsors:   The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery;   Krankenanstalt Rudolfstiftung;   Medical University of Vienna;   Medical University of Graz;   Medical University Innsbruck;   Krankenhaus der Barmherzigen Brüder Linz;   Universitätsaugenklinik Salzburg;   Hospital Hietzing;   Hanuschkrankenhaus
Unknown status

Fri, 04 Jul 2008 12:00:00 EDT

Bevacizumab Plus mFOLFOXIRI as First-line Treatment for Patients With Unresectable Metastatic Colorectal Cancer

Condition:   Colorectal Cancer
Interventions:   Drug: mFOLFOXIRI plus Bevacizumab;   Drug: mFOLFOX6 Plus Bevacizumab
Sponsor:   Yanhong Deng
Recruiting

Sat, 18 Jan 2020 12:00:00 EST

Angiogenic Factor Expression During Fractionated Irradiation

Condition:   Primary Esophageal Carcinoma
Intervention:   Drug: Bevacizumab
Sponsors:   VU University Medical Center;   Noordwest Ziekenhuisgroep;   Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Unknown status

Wed, 26 Feb 2014 12:00:00 EST

Long-term Results After Intravitreal Bevacizumab Treatment Of Neovascular Age-related Macular Degeneration

Condition:   Neovascular Age-related Macular Degeneration
Intervention:   Drug: Bevacizumab
Sponsor:   Medical University of Vienna
Completed

Tue, 08 Dec 2009 12:00:00 EST

A Study of Bevacizumab (Avastin) in Combination With Temozolomide (TMZ) and Radiotherapy in Paediatric and Adolescent Participants With High-Grade Glioma

Condition:   High Grade Glioma
Interventions:   Drug: Bevacizumab;   Radiation: Radiotherapy;   Drug: Temozolomide (TMZ)
Sponsor:   Hoffmann-La Roche
Completed

Mon, 11 Jul 2011 12:00:00 EDT

Carboplatin and Gemcitabine With Bevacizumab Every 2 Weeks for Stage IIIb/IV Non-small Cell Lung Cancer

Condition:   Carcinoma, Non-Small-Cell Lung
Intervention:   Drug: Gemcitabine, Carboplatin, Bevacizumab
Sponsors:   Masonic Cancer Center, University of Minnesota;   Eli Lilly and Company;   Genentech, Inc.
Completed

Fri, 17 Nov 2006 12:00:00 EST

Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients

Conditions:   Kaposi's Sarcoma;   HIV Infections;   HIV Seronegativity
Intervention:   Biological: Bevacizumab
Sponsor:   National Cancer Institute (NCI)
Completed

Fri, 21 Feb 2003 12:00:00 EST

Abraxane, Avastin, and Gemcitabine as First-Line Therapy for Patients With Metastatic Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Avastin;   Drug: Gemcitabine;   Drug: Abraxane
Sponsor:   University of Miami
Completed

Thu, 19 Jul 2007 12:00:00 EDT

BABH Study: Efficacy and Safety of Bevacizumab on Severe Bleedings Associated With Hemorrhagic Hereditary Telangiectasia (HHT).

Condition:   Hemorrhagic Hereditary Telangiectasia (HHT)
Interventions:   Drug: Bevacizumab;   Drug: sodium chloride 0.9%
Sponsor:   Hospices Civils de Lyon
Completed

Mon, 24 Jul 2017 12:00:00 EDT

Phase II Study of Avastin + Erbitux + Irinotecan as 2nd Line Treatment of Colorectal Cancer

Condition:   Colorectal Cancer
Interventions:   Drug: Irinotecan;   Drug: Avastin;   Drug: Erbitux
Sponsors:   Hellenic Oncology Research Group;   University Hospital of Crete
Terminated

Wed, 21 May 2008 12:00:00 EDT

Irinotecan, Capecitabine and Avastin for Metastatic Colorectal Cancer as Salvage Treatment

Condition:   Metastatic Colorectal Cancer
Interventions:   Drug: Capecitabine;   Drug: Bevacizumab;   Drug: Irinotecan
Sponsor:   University Hospital of Crete
Terminated

Fri, 18 Jul 2008 12:00:00 EDT

Bevacizumab (Avastin®) + Erlotinib as First-line Therapy for Stage IIIB/IV or Recurrent, Non-squamous Cell Lung Cancer

Condition:   Cancer
Intervention:   Drug: Bevacizumab and Erlotinib
Sponsors:   University of Utah;   Genentech, Inc.
Completed

Thu, 03 Jan 2008 12:00:00 EST

Pilot Study of Single Dose Bevacizumab as Treatment for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Patients

Conditions:   ARDS, Human;   Coronavirus Infection
Interventions:   Drug: Bevacizumab;   Drug: BAT
Sponsor:   Maimónides Biomedical Research Institute of Córdoba
Terminated

Thu, 08 Jul 2021 12:00:00 EDT

Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Alone Versus Ozurdex Given Every 3 Months for Treatment of Persistent Diabetic Macular Edema

Condition:   Diabetic Macular Edema
Interventions:   Drug: Ozurdex;   Drug: Bevacizumab
Sponsors:   Raj K. Maturi, MD;   Allergan
Completed

Wed, 15 Jan 2014 12:00:00 EST

Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma

Conditions:   Brain Cancer;   Pediatric Cancers
Interventions:   Drug: Bevacizumab;   Drug: Lapatinib
Sponsors:   M.D. Anderson Cancer Center;   CERN Foundation - Collaborative Ependymoma Research Network
Completed

Mon, 20 Apr 2009 12:00:00 EDT

Bevacizumab and Paclitaxel for Neuroendocrine Tumors of the Cervix

Conditions:   Cervical Cancer;   Uterine Cancer
Interventions:   Drug: Bevacizumab;   Drug: Paclitaxel
Sponsors:   M.D. Anderson Cancer Center;   Genentech, Inc.
Terminated

Fri, 29 Feb 2008 12:00:00 EST

Avastin+ GemAOD As First-Line Treatment in NK/T Cell Lymphoma

Condition:   Extranodal NK/T-cell Lymphoma, Nasal Type
Interventions:   Biological: Avastin;   Drug: Gemcitabine;   Drug: Oxaliplatin;   Drug: Pegaspargase;   Drug: Dexamethasone
Sponsors:   Sun Yat-sen University;   Hoffmann-La Roche;   Eli Lilly and Company
Unknown status

Tue, 13 Aug 2013 12:00:00 EDT

Olaparib and Bevacizumab in Relapsed Small Cell Lung Cancer Subjects

Condition:   Lung Cancer
Intervention:   Drug: Olaparib+Bevacizumab to SCLC patients
Sponsors:   Se-Hoon Lee;   AstraZeneca;   Roche Pharma AG
Recruiting

Fri, 25 Jun 2021 12:00:00 EDT

A Study of Avastin (Bevacizumab) in Combination With Taxane-based Chemotherapy as First Line Treatment in Patients With HER-2 Negative Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Bevacizumab;   Drug: Paclitaxel;   Drug: Gemcitabine
Sponsor:   Hoffmann-La Roche
Completed

Wed, 18 Feb 2009 12:00:00 EST

Perioperative Chemotherapy With Bevacizumab for Colorectal Carcinomatosis French Part of the Main Bev-IP Study

Condition:   Colorectal Carcinomatosis
Interventions:   Procedure: Cytoreductive surgery combined with HIPEC;   Drug: bevacizumab and HIPEC (Oxaliplatin 360 mg/m2).
Sponsor:   Hospices Civils de Lyon
Withdrawn

Fri, 19 May 2017 12:00:00 EDT

Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM)

Condition:   Mesothelioma
Intervention:   Drug: Carboplatin, Bevacizumab and Pemetrexed
Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   Genentech, Inc.
Terminated

Wed, 30 Jan 2008 12:00:00 EST

Paclitaxel + Bevacizumab (Avastin) for the Treatment of Metastatic or Unresectable Angiosarcoma

Conditions:   Angiosarcomas;   Soft Tissue Sarcoma
Interventions:   Drug: Bevacizumab;   Drug: Paclitaxel
Sponsors:   Stanford University;   Genentech, Inc.
Terminated

Mon, 25 Jan 2010 12:00:00 EST

RAD001 Plus Bevacizumab in Metastatic Melanoma

Condition:   Metastatic Melanoma
Interventions:   Drug: Bevacizumab;   Drug: Everolimus
Sponsors:   SCRI Development Innovations, LLC;   Genentech, Inc.;   Novartis
Completed

Fri, 11 Jan 2008 12:00:00 EST

Bevacizumab After Chemoradiotherapy For Locally Advanced Lung Adenocarcinoma

Condition:   Lung Adenocarcinoma
Interventions:   Drug: Bevacizumab;   Radiation: chest radiation;   Drug: concurrent chemotherapy
Sponsor:   Sun Yat-sen University
Recruiting

Fri, 05 Apr 2019 12:00:00 EDT

Bevacizumab for Central Retinal Vein Occlusion Study

Condition:   Central Retinal Vein Occlusion
Interventions:   Drug: bevacizumab;   Drug: Sham bevacizumab injection
Sponsor:   Anders Kvanta
Completed

Thu, 21 May 2009 12:00:00 EDT

Optic Neuropathy in 10 Patients With Glioblastoma Receiving Bevacizumab

Conditions:   Glioblastoma;   Optic Neuropathy
Intervention:   Drug: Bevacizumab (Avastin)
Sponsor:   West Penn Allegheny Health System
Unknown status

Fri, 08 Apr 2011 12:00:00 EDT

Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity

Condition:   Retinopathy of Prematurity
Interventions:   Drug: Bevacizumab;   Procedure: Conventional Laser for ROP
Sponsor:   The University of Texas Health Science Center, Houston
Unknown status

Mon, 25 Feb 2008 12:00:00 EST

Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma

Condition:   Hepatocellular Carcinoma
Interventions:   Drug: Bevacizumab;   Drug: Erlotinib
Sponsors:   University of Arkansas;   Genentech, Inc.
Completed

Mon, 06 Feb 2006 12:00:00 EST

Use of Bevacizumab in Trabeculectomy Surgery

Conditions:   Glaucoma;   Optic Neuropathy;   Fibrosis
Interventions:   Drug: Bevacizumab;   Drug: Control
Sponsors:   Sunnybrook Health Sciences Centre;   Glaucoma Research Society of Canada
Completed

Wed, 21 Jul 2010 12:00:00 EDT

Analysis of Growth Factors in Patients Undergoing Lucentis or Avastin Injections for Diabetic Macular Edema and Exudative Macular Degeneration

Conditions:   Exudative Macular Degeneration;   Diabetic Macular Edema
Interventions:   Drug: Avastin;   Drug: Lucentis
Sponsors:   Vitreo-Retinal Associates, Michigan;   Van Andel Research Institute
Completed

Thu, 17 Nov 2011 12:00:00 EST

Metronomic Therapy in Metastatic Breast Cancer.

Condition:   Breast Cancer
Interventions:   Biological: bevacizumab, Paclitaxel;   Biological: Bevacizumab, Cyclophosphamide, Capecitabine
Sponsor:   Swiss Group for Clinical Cancer Research
Completed

Wed, 26 May 2010 12:00:00 EDT

Safety Evaluation of a Combination of Brain Radiation Therapy and Bevacizumab (Avastin®) for Treatment of Brain Metastasis

Condition:   Metastatic Malignant Neoplasm to Brain
Intervention:   Drug: Bevacizumab
Sponsors:   Centre Francois Baclesse;   National Cancer Institute, France;   Roche Pharma AG;   Institut Curie
Completed

Mon, 11 Apr 2011 12:00:00 EDT

Intraocular Anti-VEGF Compared With Intraocular Triamcinolone in Patients With Diabetic Macular Edema

Condition:   Diabetic Macular Edema
Interventions:   Drug: Bevacizumab (Avastin);   Drug: Triamcinolone;   Drug: Sham;   Procedure: Lucentis
Sponsor:   Medical University of Vienna
Completed

Thu, 22 May 2008 12:00:00 EDT

Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus)

Conditions:   Kidney Neoplasms;   Kidney (Renal Cell) Cancer
Interventions:   Drug: Everolimus;   Drug: Bevacizumab
Sponsors:   Sandy Srinivas;   Genentech, Inc.;   Novartis
Terminated

Wed, 02 Apr 2008 12:00:00 EDT

Bevacizumab and Bortezomib in Patients With Advanced Malignancy

Conditions:   Advanced Malignancy;   Lymphoma;   Myeloma;   Solid Tumors
Interventions:   Drug: Bevacizumab;   Drug: Bortezomib
Sponsor:   M.D. Anderson Cancer Center
Completed

Tue, 30 Jan 2007 12:00:00 EST

Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary Peritoneal Carcinoma

Conditions:   Ovarian Carcinoma;   Primary Peritoneal Carcinoma
Interventions:   Drug: Pemetrexed;   Drug: Bevacizumab
Sponsors:   Washington University School of Medicine;   Columbia University
Completed

Tue, 24 Mar 2009 12:00:00 EDT

FOLFOX With Bevacizumab in Metastatic or Unresectable Gastroesophageal and Gastric Cancer

Conditions:   Gastroesophageal Cancer;   Gastric Cancer
Interventions:   Drug: FOLFOX;   Drug: bevacizumab
Sponsors:   Yale University;   Genentech, Inc.
Completed

Wed, 07 May 2008 12:00:00 EDT

Neoadjuvant Therapy in Advanced Ovarian Cancer With Avastin

Condition:   Cancer, Ovarian
Interventions:   Drug: Bevacizumab;   Drug: Paclitaxel;   Drug: Carboplatin
Sponsors:   Grupo Español de Investigación en Cáncer de Ovario;   Roche Pharma AG
Terminated

Tue, 07 May 2013 12:00:00 EDT

Pilot Study for Locally Advanced Head and Neck Cancer

Condition:   Head and Neck Neoplasms
Intervention:   Drug: bevacizumab
Sponsors:   University of Pittsburgh;   Genentech, Inc.
Withdrawn

Fri, 17 Dec 2010 12:00:00 EST

A Trial of Everolimus and Bevacizumab in Children With Recurrent Solid Tumors

Conditions:   Recurrent or Refractory Solid Tumors;   CNS Malignancies
Interventions:   Drug: Bevacizumab;   Drug: Everolimus
Sponsors:   St. Jude Children's Research Hospital;   Novartis Pharmaceuticals
Completed

Mon, 22 Sep 2008 12:00:00 EDT

Safety Study of Bevacizumab Plus Chemotherapy To Treat Metastatic Colorectal Cancer

Condition:   Metastatic Colorectal Cancer
Intervention:   Drug: bevacizumab
Sponsors:   Sun Yat-sen University;   Proswell Medical Corporation
Unknown status

Wed, 31 Jul 2013 12:00:00 EDT

Evaluation of the Efficacy and the Safety of FOLFIRINOX3 Bevacizumab Treatment in Patients With Colorectal Cancer (FOLFIRINOX 3)

Condition:   Colorectal Cancer
Intervention:   Drug: FOLFIRINOX Bevacizumab
Sponsor:   Centre Georges Francois Leclerc
Recruiting

Mon, 07 Jan 2019 12:00:00 EST

Effect of Ozurdex® 0.7 mg on Improvement of Efficacy of Bevacizumab for Central Retinal Vein Occlusion

Condition:   Non-Ischemic Central Retinal Vein Occlusion
Interventions:   Drug: Active bevacizumab and Sham dexamethasone;   Drug: Active bevacizumab and Active dexamethasone
Sponsor:   Texas Retina Associates
Completed

Mon, 14 Feb 2011 12:00:00 EST

Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin® Plus Chemotherapy in Patients With Lung Cancer

Condition:   Carcinoma, Non-Small-Cell Lung
Interventions:   Drug: BI 695502;   Drug: Avastin
Sponsor:   Boehringer Ingelheim
Completed

Thu, 23 Oct 2014 12:00:00 EDT

Capecitabine Plus Oxaliplatin Plus Bevacizumab as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer

Condition:   Metastatic Colorectal Cancer
Interventions:   Drug: Oxaliplatin;   Drug: Capecitabine;   Drug: Bevacizumab
Sponsors:   Hellenic Oncology Research Group;   University Hospital of Crete
Completed

Wed, 02 Dec 2009 12:00:00 EST

Bevacizumab Treatment and Retinal Vessel Monitoring

Condition:   Cancer
Intervention:   Drug: bevacizumab treatment
Sponsor:   Technische Universität Dresden
Completed

Fri, 22 Aug 2008 12:00:00 EDT

An Observational Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) And Oxaliplatin in Patients With Colorectal Cancer

Condition:   Colorectal Cancer
Interventions:   Biological: Bevacizumab;   Biological: Capecitabine;   Drug: Oxaliplatin
Sponsor:   Hoffmann-La Roche
Completed

Thu, 21 Jul 2011 12:00:00 EDT

Temozolomide Plus Bevacizumab in Supratentorial Glioblastoma in 70 Years and Older Patients With an Impaired Functional Status

Conditions:   Glioblastoma Multiforme;   Primary Brain Tumor
Interventions:   Drug: Temozolomide;   Drug: Bevacizumab
Sponsors:   Assistance Publique - Hôpitaux de Paris;   Roche Pharma AG
Completed

Tue, 13 Sep 2016 12:00:00 EDT

A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma

Condition:   Glioblastoma
Interventions:   Drug: Bevacizumab;   Drug: Lomustine;   Drug: Placebo;   Radiation: Radiotherapy;   Drug: Temozolomide;   Drug: SOC Agent
Sponsor:   Hoffmann-La Roche
Completed

Thu, 23 May 2013 12:00:00 EDT

Metronomic Docetaxel and Bevacizumab in Patients With Small Cell Lung Cancer

Condition:   Small Cell Lung Cancer
Interventions:   Drug: Docetaxel;   Drug: Bevacizumab
Sponsor:   University Hospital of Crete
Withdrawn

Thu, 18 Sep 2008 12:00:00 EDT

Macular Perfusion Changes After Anti-VEGF Versus Targeted Retinal Photocoagulation in Proliferative Diabetic Retinopathy

Conditions:   Proliferative Diabetic Retinopathy;   Vascular Endothelial Growth Factor Overexpression;   Diabetic Retinopathy
Interventions:   Drug: Bevacizumab Injection;   Procedure: Targeted retinal photocoagulation;   Procedure: Standard pan-retinal photocoagulation
Sponsor:   Cairo University
Recruiting

Sat, 19 Dec 2020 12:00:00 EST

Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma

Conditions:   Brain Cancer;   MALIGNANT GLIOMA;   Glioblastoma;   Anaplastic Astrocytoma (AA);   Anaplastic Oligodendroglioma (AO);   Anaplastic Oligo-astrocytoma (AOA);   Anaplastic Mixed Gliomas;   Malignant Glioma NOS
Intervention:   Other: Bevacizumab & Stereotactic Radiotherapy
Sponsors:   Memorial Sloan Kettering Cancer Center;   Genentech, Inc.;   Columbia University;   University of California, San Francisco
Completed

Tue, 12 Jul 2011 12:00:00 EDT

Bevacizumab in Recurrent Grade II and III Glioma

Condition:   Central Nervous System Tumors
Interventions:   Biological: Bevacizumab;   Drug: Temozolomide
Sponsors:   European Organisation for Research and Treatment of Cancer - EORTC;   Hoffmann-La Roche
Completed

Fri, 16 Jul 2010 12:00:00 EDT

Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer

Condition:   Carcinoma, Non-Small-Cell Lung
Interventions:   Drug: bevacizumab;   Drug: Erlotinib
Sponsors:   Fox Chase Cancer Center;   Genentech, Inc.;   OSI Pharmaceuticals
Unknown status

Tue, 06 Nov 2007 12:00:00 EST

An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE)

Conditions:   Hepatocellular Carcinoma;   Non-small Cell Lung Cancer Metastatic;   Liver Metastases
Interventions:   Drug: Atezolizumab;   Drug: Bevacizumab
Sponsors:   University Health Network, Toronto;   Hoffmann-La Roche
Recruiting

Thu, 24 Sep 2020 12:00:00 EDT

Study of Bevacizumab(BAT1706) and Comparators in Healthy Subjects

Condition:   NSCLC
Interventions:   Biological: BAT1706 injection;   Biological: EU-sourced Avastin;   Biological: US-sourced Avastin
Sponsor:   Bio-Thera Solutions
Completed

Wed, 25 Jan 2017 12:00:00 EST

Hypertension Monitoring in Glioma Patients Treated With Bevacizumab

Condition:   Glioma Patients
Intervention:   Drug: Bevacizumab
Sponsor:   University of Zurich
Terminated

Mon, 11 Jan 2010 12:00:00 EST

Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment

Condition:   Hepatocellular Carcinoma
Interventions:   Drug: Durvalumab;   Drug: Bevacizumab;   Other: Placebo
Sponsor:   AstraZeneca
Recruiting

Wed, 20 Feb 2019 12:00:00 EST

Trial of Vascular Endothelial Growth Factor (VEGF), Bevacizumab, in Combination With Cytotoxic Chemotherapy for Endometrial Cancer

Condition:   Endometrial Carcinoma
Intervention:   Drug: carboplatin, paclitaxel, and bevacizumab
Sponsors:   The Cleveland Clinic;   Genentech, Inc.
Completed

Fri, 10 Apr 2009 12:00:00 EDT

Pembrolizumab +/- Bevacizumab for Recurrent GBM

Condition:   Glioblastoma
Interventions:   Drug: Pembrolizumab;   Drug: Bevacizumab
Sponsor:   Dana-Farber Cancer Institute
Completed

Tue, 13 Jan 2015 12:00:00 EST

Bevacizumab, Pemetrexed Disodium, and Cisplatin or Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial).

Condition:   Lung Cancer
Interventions:   Biological: bevacizumab, erlotinib;   Drug: bevacizumab, pemetrexed, cisplatin
Sponsor:   Swiss Group for Clinical Cancer Research
Completed

Tue, 04 May 2010 12:00:00 EDT

A Study of Tarceva (Erlotinib) and Avastin (Bevacizumab) in Patients With Advanced or Metastatic Liver Cancer.

Condition:   Liver Cancer
Interventions:   Drug: bevacizumab (Avastin);   Drug: erlotinib (Tarceva)
Sponsor:   Hoffmann-La Roche
Completed

Thu, 31 Jan 2008 12:00:00 EST

Efficacy Study of Triamcinolone and Bevacizumab Intravitreal for Treatment of Diabetic Macular Edema

Condition:   Diabetic Macular Edema
Interventions:   Drug: Bevacizumab intravitreal;   Drug: Triamcinolone;   Drug: Triamcinolone + Bevacizumab
Sponsor:   Rubens Belfort Jr.
Completed

Wed, 20 Aug 2008 12:00:00 EDT

Salvage Therapy With Bevacizumab Plus Docetaxel and Cisplatin for Taiwanese Metastatic Breast Cancer

Condition:   Metastatic Breast Cancer
Intervention:   Drug: Bevacizumab, docetaxel, cisplatin
Sponsor:   Taipei Medical University Hospital
Completed

Thu, 03 Dec 2009 12:00:00 EST

Intrapleural Administration of Bevacizumab Versus Endostar for Pleural Effusions in NSCLC

Condition:   Non Small Cell Lung Cancer
Interventions:   Drug: Bevacizumab;   Drug: recombinant human endostatin
Sponsor:   Zhejiang University
Unknown status

Mon, 09 Dec 2013 12:00:00 EST

Temozolomide and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery

Condition:   Melanoma (Skin)
Interventions:   Biological: bevacizumab;   Drug: temozolomide
Sponsor:   Swiss Group for Clinical Cancer Research
Completed

Wed, 05 Dec 2007 12:00:00 EST

Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas

Conditions:   Glioblastoma;   Gliosarcoma;   Brain Tumor
Interventions:   Drug: Avastin;   Drug: Temozolomide;   Radiation: Radiation Therapy (XRT);   Drug: Irinotecan
Sponsors:   Duke University;   Genentech, Inc.;   Schering-Plough
Completed

Fri, 18 Jan 2008 12:00:00 EST

Upfront Treatment With Chemotherapy and Bevacizumab in Advanced Ovarian Cancer

Condition:   Advanced Ovarian Cancer
Intervention:   Drug: Bevacizumab
Sponsors:   Nada Hassan Salah;   Assiut University
Not yet recruiting

Thu, 02 Aug 2018 12:00:00 EDT

Phase I-II for Patients With Recurrent or Refractory Non-small Cell Lung Cancer (NSCLC)

Condition:   Lung Cancer
Interventions:   Drug: Bevacizumab;   Drug: Bortezomib
Sponsors:   M.D. Anderson Cancer Center;   Millennium Pharmaceuticals, Inc.;   Genentech, Inc.
Withdrawn

Thu, 14 Dec 2006 12:00:00 EST

First-line Irinotecan, Lederfolin and 5FU (FOLFIRI) and Bevacizumab in Patients With Advanced Colorectal Cancer

Condition:   Colorectal Cancer Stage II
Intervention:   Drug: Bevacizumab and FOLFIRI
Sponsors:   Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente;   Azienda Ospedaliero, Universitaria Ospedali Riuniti
Completed

Wed, 15 May 2013 12:00:00 EDT

Imaging HSP90 Inhibitor AUY922 on VEGF-89ZR-bevacizumab Positron Emission Tomography (PET)

Condition:   Breast Cancer
Intervention:   Other: 89Zr-bevacizumab PET imaging
Sponsor:   University Medical Center Groningen
Completed

Fri, 05 Mar 2010 12:00:00 EST

Pharmacokinetic Study Comparing MB02 And US And EU Avastin® In Healthy Male Volunteers

Condition:   Healthy Volunteers
Interventions:   Drug: MB02 (Bevacizumab Biosimilar);   Drug: EU approved Avastin®;   Drug: US licenced Avastin®
Sponsor:   mAbxience S.A
Completed

Thu, 23 Jan 2020 12:00:00 EST

A Study of Bevacizumab Versus Placebo in Combination With Carboplatin/Paclitaxel in Participants With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Previous Chemotherapy

Condition:   Non-Small Cell Lung Cancer
Interventions:   Drug: Bevacizumab;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed

Thu, 02 Jun 2011 12:00:00 EDT

Phase II Pilot Study of Visudyne® Photodynamic Therapy (PDT) (Low and Very Low Fluence) Combined With Bevacizumab.

Condition:   Macular Degeneration
Interventions:   Drug: Verteporfin Photodynamic Therapy (Low Fluence) and bevacizumab;   Drug: Verteporfin Photodynamic Therapy (Very Low Fluence) and bevacizumab;   Drug: Verteporfin Photodynamic Therapy (SHAM) and bevacizumab
Sponsor:   University of British Columbia
Completed

Tue, 01 Aug 2006 12:00:00 EDT

ProspectiveTrial of Proton Beam Combined With Anti-VEGF Therapy for Exudative Age-related Macular Degeneration (AMD)

Condition:   Exudative Age-related Macular Degeneration
Interventions:   Drug: 24GyE proton and Anti-VEGF;   Drug: 16GyE and anti-VEGF;   Drug: Sham Irradiation and anti-VEGF
Sponsors:   University of California, Davis;   University of California, San Francisco
Completed

Fri, 01 Oct 2010 12:00:00 EDT

A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.

Condition:   Non-Squamous Non-Small Cell Lung Cancer
Interventions:   Drug: Platinum-based chemotherapy;   Drug: Bevacizumab [Avastin]
Sponsor:   Hoffmann-La Roche
Completed

Mon, 26 Mar 2007 12:00:00 EDT

A Study to Compare the Pharmacokinetics of JHL1149 and Bevacizumab (Avastin) in Healthy Male Volunteers

Condition:   Healthy Male Subjects
Interventions:   Biological: JHL1149;   Biological: Bevacizumab
Sponsor:   JHL Biotech, Inc.
Completed

Tue, 03 Jul 2018 12:00:00 EDT

Pilot Study of Docetaxel & Bevacizumab +/- Trastuzumab in First-Line Treatment of Patients With Metastatic Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Bevacizumab;   Drug: Docetaxel;   Drug: Trastuzumab
Sponsor:   Sanofi
Completed

Tue, 15 Aug 2006 12:00:00 EDT

A Pharmacokinetic Study Comparing PF-06439535 And Bevacizumab In Healthy Male Volunteers (REFLECTIONS B739-01)

Condition:   Healthy
Interventions:   Biological: PF-06439535;   Biological: Avastin
Sponsor:   Pfizer
Completed

Thu, 09 Jan 2014 12:00:00 EST

A Phase II Study of Eloxatin and Alimta in Combination With Bevacizumab in Advanced Non-Squamous NSCLC

Condition:   Non-Small Cell Lung Cancer
Intervention:   Drug: Bevacizumab, Oxaliplatin, Pemetrexed
Sponsors:   Veeda Oncology;   Sanofi;   Eli Lilly and Company;   Genentech, Inc.
Completed

Thu, 10 Nov 2005 12:00:00 EST

A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma

Condition:   Glioblastoma
Interventions:   Drug: Bevacizumab;   Drug: Temozolomide;   Radiation: Radiation therapy;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed

Wed, 22 Jul 2009 12:00:00 EDT

A Phase I Study Comparing Pharmacokinetics and Safety of Bevacizumab

Conditions:   Pharmacokinetics;   Safety Issues
Intervention:   Biological: Bevacizumab
Sponsors:   Laboratorios Richmond S.A.C.I.F.;   FP Clinical Pharma S.R.L.;   Syngene International Limited
Completed

Thu, 18 Apr 2019 12:00:00 EDT

Osimertinib Plus Bevacizumab in Untreated EGFR Exon21 L858R Mutated NSCLC

Condition:   Lung Cancer
Interventions:   Drug: Osimertinib;   Drug: Bevacizumab
Sponsor:   Guangdong Association of Clinical Trials
Not yet recruiting

Tue, 03 Aug 2021 12:00:00 EDT

Valproic Acid and Bevacizumab in Patients With Advanced Cancer

Condition:   Advanced Cancer
Interventions:   Drug: Valproic Acid;   Drug: Bevacizumab
Sponsor:   M.D. Anderson Cancer Center
Completed

Tue, 18 Sep 2007 12:00:00 EDT

Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLC

Condition:   Non-Small Cell Lung Cancer
Interventions:   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Bevacizumab
Sponsors:   SCRI Development Innovations, LLC;   Genentech, Inc.
Terminated

Mon, 17 Aug 2009 12:00:00 EDT

Bevacizumab, Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma

Condition:   Neuroblastoma
Intervention:   Drug: Bevacizumab, Irinotecan and Temozolomide
Sponsors:   Memorial Sloan Kettering Cancer Center;   Genentech, Inc.
Completed

Mon, 03 May 2010 12:00:00 EDT

Nab-paclitaxel Combined With Bevacizumab in the Treatment of Metastatic Neuroendocrine Carcinoma

Condition:   Neuroendocrine Carcinoma
Intervention:   Drug: Nab-paclitaxel Combined With Bevacizumab
Sponsors:   Peking University;   Qilu Pharmaceutical Co., Ltd.
Recruiting

Tue, 12 Jan 2021 12:00:00 EST

Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer

Conditions:   Breast Cancer;   Cancer of the Breast;   Breast Neoplasm
Interventions:   Other: Letrozole (Femara);   Drug: Letrozole; Avastin
Sponsors:   University of Alabama at Birmingham;   Genentech, Inc.;   Breast Cancer Research Foundation
Completed

Tue, 18 Sep 2007 12:00:00 EDT

A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

Condition:   Colorectal Cancer
Interventions:   Drug: Tivozanib;   Drug: Bevacizumab;   Drug: mFOLFOX6
Sponsor:   AVEO Pharmaceuticals, Inc.
Completed

Wed, 23 Nov 2011 12:00:00 EST

Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung Cancer

Conditions:   Leptomeningeal Metastasis;   Non-small Cell Lung Cancer;   EGFR Activating Mutation
Interventions:   Drug: Osimertinib;   Drug: Bevacizumab
Sponsors:   Second Affiliated Hospital of Nanchang University;   Nanchang University
Recruiting

Thu, 11 Jun 2020 12:00:00 EDT

Paclitaxel Plus Bevacizumab for Older Patients With Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Bevacizumab;   Drug: Paclitaxel
Sponsors:   Hellenic Oncology Research Group;   University Hospital of Crete
Terminated

Mon, 10 May 2010 12:00:00 EDT

Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

Condition:   Breast Cancer
Interventions:   Biological: bevacizumab;   Drug: Carboplatin;   Drug: ABI-007
Sponsors:   Loyola University;   Genentech, Inc.;   Celgene Corporation
Completed

Wed, 09 Apr 2008 12:00:00 EDT

Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab

Conditions:   Fallopian Tubes Cancer;   Ovarian Cancer;   Peritoneal Cancer
Intervention:   Biological: bevacizumab and the polyvalent vaccine-KLH conjugate + OPT-821
Sponsors:   Memorial Sloan Kettering Cancer Center;   Genentech, Inc.
Completed

Mon, 18 Oct 2010 12:00:00 EDT

Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma

Conditions:   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Recurrent Adult Brain Tumor
Interventions:   Biological: bevacizumab;   Radiation: radiation therapy
Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Active, not recruiting

Wed, 21 Nov 2012 12:00:00 EST

A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib

Conditions:   Peritoneal Cancer;   Ovarian Cancer;   Fallopian Tube Cancer
Interventions:   Drug: Bevacizumab;   Drug: Nivolumab;   Drug: Rucaparib
Sponsors:   Dana-Farber Cancer Institute;   Bristol-Myers Squibb
Recruiting

Mon, 22 Aug 2016 12:00:00 EDT

A Study to Compare Pharmacokinetic and Safety of TRS003 to China-approved Bevacizumab and US-licensed Avastin®

Condition:   Healthy
Interventions:   Biological: TRS003;   Biological: China-approved Bevacizumab;   Biological: US-licensed Avastin
Sponsor:   Zhejiang Teruisi Pharmaceutical Inc.
Completed

Wed, 20 Mar 2019 12:00:00 EDT

A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

Condition:   Ovarian Cancer
Interventions:   Drug: Bevacizumab;   Drug: Paclitaxel;   Drug: Carboplatin
Sponsor:   Hoffmann-La Roche
Completed

Mon, 13 Jul 2009 12:00:00 EDT

A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Conditions:   Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Cancer
Interventions:   Drug: Paclitaxel;   Drug: Bevacizumab;   Drug: Carboplatin;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Active, not recruiting

Fri, 17 Aug 2018 12:00:00 EDT

Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG)

Condition:   Low Grade Glioma
Interventions:   Drug: Vinblastine;   Drug: Bevacizumab
Sponsors:   The Hospital for Sick Children;   Hoffmann-La Roche
Recruiting

Thu, 21 Jul 2016 12:00:00 EDT

PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors

Conditions:   Colon Cancer;   Colorectal Cancer;   Rectal Cancer;   Metastatic Colorectal Cancer
Interventions:   Drug: Panitumumab;   Drug: Bevacizumab;   Drug: mFOLFOX6
Sponsor:   Amgen
Completed

Fri, 09 Jan 2009 12:00:00 EST

Intraperitoneal Chemotherapy Alone or in Combination With Bevacizumab for Ovarian Cancer With Peritoneal Adhesion

Condition:   Peritoneal Adhesion
Interventions:   Drug: Bevacizumab;   Drug: Carboplatin;   Drug: paclitaxel
Sponsor:   Chinese PLA General Hospital
Unknown status

Wed, 29 Mar 2017 12:00:00 EDT

Effects of Anti-VEGF Targeted Drugs on Patients' Blood Pressure and Endothelial Function

Conditions:   Cardiac Toxicity;   VEGF;   Endothelial Dysfunction
Intervention:   Drug: Anti-VEGF
Sponsor:   Peking University Third Hospital
Recruiting

Thu, 15 Jul 2021 12:00:00 EDT

A Study Evaluating S 95005 Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Colorectal Cancer Who Are Non-eligible for Intensive Therapy

Condition:   Metastatic Colorectal Cancer
Interventions:   Drug: Trifluridine/tipiracil + bevacizumab;   Drug: Capecitabine + bevacizumab
Sponsors:   Institut de Recherches Internationales Servier;   ADIR, a Servier Group company
Completed

Tue, 19 Apr 2016 12:00:00 EDT

Efficacy and Safety of Bevacizumab in the Neodjuvant Treatment of Inflammatory Breast Cancer

Condition:   Inflammatory Breast Cancer
Interventions:   Biological: Bevacizumab;   Drug: Cyclophosphamide;   Drug: epirubicin hydrochloride;   Drug: fluorouracil;   Drug: Docetaxel;   Biological: Trastuzumab
Sponsors:   Association Tunisienne de lutte Contre le Cancer;   Hoffmann-La Roche;   Sanofi
Unknown status

Wed, 19 Jun 2013 12:00:00 EDT

Bevacizumab With or Without Sunitinib in Sunitinib-Refractory Renal Cell Carcinoma

Condition:   Renal Cell Carcinoma
Interventions:   Drug: Sunitinib;   Drug: Bevacizumab
Sponsors:   Massachusetts General Hospital;   Beth Israel Deaconess Medical Center;   Pfizer
Withdrawn

Fri, 09 Nov 2007 12:00:00 EST

Comparison of Therapeutic Effects Between Intravitreal Injection of Bevacizumab With Intravitreal Injection of Bevacizumab and Targeted Laser Photocoagulation of Non Perfused Areas of Retina in Patients With Acute Retinal Vein Occlusion

Condition:   Retinal Vein Occlusion With Macular Edema
Interventions:   Drug: intravitreal injection of bevacizumab;   Radiation: intravitreal injection of bevacizumab+ targeted laser
Sponsor:   Shahid Beheshti University of Medical Sciences
Unknown status

Mon, 27 Nov 2017 12:00:00 EST

Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal Neovascularization

Condition:   Corneal Neovascularization
Intervention:   Drug: Bevacizumab (Avastin)
Sponsors:   Walter Reed Army Medical Center;   Massachusetts Eye and Ear Infirmary
Completed

Wed, 08 Aug 2007 12:00:00 EDT

A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) in Patients With Advanced or Metastatic Liver Cancer

Condition:   Liver Cancer
Interventions:   Drug: bevacizumab [Avastin];   Drug: capecitabine [Xeloda]
Sponsor:   Hoffmann-La Roche
Completed

Tue, 17 Dec 2013 12:00:00 EST

A Phase I Trial Evaluating mFOLFOX6 and Avastin With Nexavar as First-Line Treatment for Metastatic Colorectal Cancer

Condition:   Metastatic Colorectal Cancer
Interventions:   Drug: sorafenib;   Drug: bevacizumab;   Drug: mFOLFOX6 regimen
Sponsors:   Accelerated Community Oncology Research Network;   Bayer
Terminated

Fri, 24 Oct 2008 12:00:00 EDT

Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer

Condition:   Metastatic Breast Cancer
Interventions:   Drug: Doxil;   Drug: Carboplatin;   Drug: Bevacizumab
Sponsors:   Rutgers, The State University of New Jersey;   Rutgers Cancer Institute of New Jersey;   National Cancer Institute (NCI)
Completed

Wed, 06 Feb 2008 12:00:00 EST

A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab in Patients With Glioblastoma

Conditions:   Glioblastoma;   Glioblastoma Multiforme
Interventions:   Drug: TRC105;   Drug: Bevacizumab
Sponsors:   Tracon Pharmaceuticals Inc.;   The Cleveland Clinic;   Case Comprehensive Cancer Center
Completed

Wed, 28 Mar 2012 12:00:00 EDT

Bevacizumab and Radiotherapy for Oligometastasis of Lung Adenocarcinoma With Negative Driver Gene

Condition:   Lung Adenocarcinoma
Interventions:   Drug: Bevacizumab Injection;   Radiation: chest radiation;   Drug: concurrent chemotherapy
Sponsor:   Sun Yat-sen University
Recruiting

Fri, 05 Apr 2019 12:00:00 EDT

Bevacizumab in Treating Patients With Recurrent or Progressive Glioma

Condition:   Brain and Central Nervous System Tumors
Intervention:   Biological: bevacizumab
Sponsors:   Northwestern University;   National Cancer Institute (NCI)
Completed

Thu, 15 Jun 2006 12:00:00 EDT

Efficacy of FOLFOX+Bevacizumab in Combination With Irinotecan in the Treatment of Metastatic Colorectal Cancer

Condition:   Metastatic Colorectal Cancer
Interventions:   Drug: Oxaliplatin, 5FU/LV, Bevacizumab;   Drug: 5FU/LV, Oxaliplatin, Bevacizumab, Irinotecan
Sponsors:   Martin-Luther-Universität Halle-Wittenberg;   Roche Pharma AG
Completed

Thu, 24 Mar 2011 12:00:00 EDT

A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) as Maintenance Treatment in Patients With Metastatic Colorectal Cancer

Condition:   Colorectal Cancer
Interventions:   Drug: Bevacizumab;   Drug: Capecitabine;   Drug: Oxaliplatin
Sponsor:   Hoffmann-La Roche
Completed

Tue, 26 Feb 2008 12:00:00 EST

Study of Oral Topotecan With Bevacizumab for Recurrent Small Cell Lung Cancer

Conditions:   Recurrent Small-cell Lung Cancer (SCLC);   Lung Cancer, Small Cell
Intervention:   Drug: Oral Hycamtin (topotecan) Capsules + IV Avastin (bevacizumab)
Sponsor:   GlaxoSmithKline
Completed

Tue, 17 Jun 2008 12:00:00 EDT

Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma

Condition:   Glioblastoma
Interventions:   Drug: Pembrolizumab;   Drug: Bevacizumab;   Radiation: Re-irradiation
Sponsors:   Dana-Farber Cancer Institute;   Merck Sharp & Dohme Corp.
Active, not recruiting

Fri, 07 Sep 2018 12:00:00 EDT

A Randomized Study to Determine the Efficacy of a Taxane and Bevacizumab With or Without Capecitabine as First Line Chemotherapy in Patients With Metastatic Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Taxane, Avastin;   Drug: Taxane, Avastin, Xeloda
Sponsor:   German Breast Group
Terminated

Mon, 13 Sep 2010 12:00:00 EDT

Bevacizumab With Etoposide and Cisplatin in Breast Cancer Patients With Brain and/or Leptomeningeal Metastasis

Conditions:   Breast Neoplasms;   Leptomeningeal Metastasis;   Brain Metastases
Interventions:   Drug: Bevacizumab, etoposide, cisplatin;   Drug: Intrathecal methotrexate
Sponsors:   National Taiwan University Hospital;   Taipei Veterans General Hospital, Taiwan;   Taichung Veterans General Hospital;   Chang Gung Memorial Hospital
Completed

Mon, 24 Jan 2011 12:00:00 EST

A Study of Avastin (Bevacizumab) in Patients With Inflammatory or Locally Advanced Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: 5-fluorouracil;   Drug: Epidoxorubicin;   Drug: Cyclophosphamide;   Drug: Paclitaxel;   Biological: Bevacizumab
Sponsor:   Hoffmann-La Roche
Completed

Fri, 16 Nov 2007 12:00:00 EST

Bevacizumab and Abraxane as Second-line Therapy in Triple Negative Metastatic Breast Cancer

Condition:   Breast Cancer
Intervention:   Drug: Bevacizumab, Abraxane
Sponsors:   Abramson Cancer Center of the University of Pennsylvania;   Genentech, Inc.
Completed

Mon, 14 May 2007 12:00:00 EDT

Bevacizumab Given With Either Anastrozole or Fulvestrant With Trastuzumab for Postmenopausal Metastatic Breast Cancer

Conditions:   Breast Cancer;   Breast Neoplasms
Interventions:   Drug: Bevacizumab;   Drug: Anastrozole;   Drug: Fulvestrant
Sponsors:   SCRI Development Innovations, LLC;   Genentech, Inc.;   AstraZeneca
Completed

Thu, 30 Nov 2006 12:00:00 EST

Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer (mCRC)

Condition:   Colorectal Cancer
Interventions:   Drug: 5-Fluorouracil;   Drug: Bevacizumab;   Drug: Irinotecan;   Drug: Leucovorin;   Drug: Oxaliplatin;   Drug: Capecitabine
Sponsor:   Genentech, Inc.
Completed

Thu, 16 Jun 2011 12:00:00 EDT

Antiangiogenic Treatment of Hepatocellular Cancer With Bevacizumab and RAD001

Condition:   Hepatocellular Carcinoma
Intervention:   Drug: Everolimus, Bevacizumab
Sponsors:   Gerhard Treiber;   Crolll Gmbh;   Estimate, GmbH;   Janssen Diagnostics, LLC
Completed

Fri, 17 Oct 2008 12:00:00 EDT

LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma

Condition:   Malignant Glioma
Interventions:   Drug: LBH589;   Drug: bevacizumab
Sponsors:   Patrick Y. Wen, MD;   Brigham and Women's Hospital;   Massachusetts General Hospital;   Beth Israel Deaconess Medical Center;   Northwestern University;   University of Virginia;   Genentech, Inc.;   Novartis
Completed

Tue, 10 Mar 2009 12:00:00 EDT

Repeat Radiation, Minocycline and Bevacizumab in Patients With Recurrent Glioma

Condition:   Recurrent Glioma
Interventions:   Drug: Bevacizumab;   Drug: Minocycline;   Radiation: Radiation
Sponsor:   University of Utah
Completed

Thu, 19 Apr 2012 12:00:00 EDT

A Study of Bevacizumab (Avastin) Versus Placebo in Combination With Capecitabine (Xeloda) and Cisplatin as First-Line Therapy for Advanced Gastric Cancer

Condition:   Gastric Cancer
Interventions:   Drug: Bevacizumab;   Drug: Placebo;   Drug: Capecitabine;   Drug: Cisplatin
Sponsor:   Hoffmann-La Roche
Completed

Fri, 24 Apr 2009 12:00:00 EDT

A Study of Bevacizumab and Modified FOLFOX-6 (mFOLFOX-6) in Participants With Metastatic Colorectal Cancer

Condition:   Colorectal Cancer
Interventions:   Drug: 5-Fluorouracil (5-FU);   Drug: Bevacizumab;   Drug: Levofolinic acid;   Drug: Oxaliplatin
Sponsor:   Hoffmann-La Roche
Completed

Tue, 28 Jun 2011 12:00:00 EDT

Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC)

Condition:   Renal Cell Carcinoma
Intervention:   Drug: everolimus and bevacizumab
Sponsors:   Memorial Sloan Kettering Cancer Center;   Novartis Pharmaceuticals
Completed

Fri, 22 Jul 2011 12:00:00 EDT

Interest of Intravitreal Injections of Anti-VEGF as Initial and Adjuvant Treatment in Coats Disease

Conditions:   Retinal Telangiectasis;   Coats Disease
Interventions:   Drug: Anti-VEGF injections of bevacizumab;   Device: Laser
Sponsor:   Fondation Ophtalmologique Adolphe de Rothschild
Recruiting

Tue, 07 May 2019 12:00:00 EDT

A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma

Condition:   Ovarian Cancer
Interventions:   Drug: Carboplatin;   Drug: Gemcitabine;   Drug: Bevacizumab;   Drug: Placebo
Sponsor:   Genentech, Inc.
Completed

Tue, 13 Feb 2007 12:00:00 EST

Bevacizumab in Severe or Critically Severe Patients With COVID-19 Pneumonia-RCT

Condition:   COVID-19 Pneumonia
Intervention:   Drug: Bevacizumab
Sponsors:   Qilu Hospital of Shandong University;   Renmin Hospital of Wuhan University;   Ialy Moriggia Pelascini Gravedona Hospital S.p.A;   Wuhan University;   Jiangbei Union Hospital of Huazhong University of science and technology;   Shandong Provincial Chest Hospital
Recruiting

Thu, 12 Mar 2020 12:00:00 EDT

The Effect of Bevacizumab on Corneal Neovascularization

Condition:   Corneal Neovascularization
Intervention:   Drug: Bevacizumab
Sponsor:   Instituto de Olhos de Goiania
Completed

Tue, 25 Nov 2008 12:00:00 EST

Sintilimab Combined With Bevacizumab for Brain Metastases From Non-small Cell Lung Cancer

Conditions:   Brain Metastases;   Non Small Cell Lung Cancer;   Sintilimab;   Bevacizumab
Intervention:   Drug: sintilimab
Sponsor:   Sun Yat-sen University
Recruiting

Mon, 30 Dec 2019 12:00:00 EST

Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)

Condition:   Hepatocellular Carcinoma
Interventions:   Drug: HX008;   Drug: Bevacizumab;   Drug: Lenvatinib
Sponsor:   Taizhou Hanzhong biomedical co. LTD
Recruiting

Fri, 05 Feb 2021 12:00:00 EST

Vinorelbine Metronomic Plus Bevacizumab as Salvage Therapy for Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Vinorelbine;   Drug: Bevacizumab
Sponsors:   Hellenic Oncology Research Group;   University Hospital of Crete
Terminated

Tue, 10 Jun 2008 12:00:00 EDT

A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma

Condition:   B-cell Lymphoma
Interventions:   Drug: Bevacizumab;   Drug: Rituximab;   Drug: CHOP;   Drug: Placebo
Sponsors:   Hoffmann-La Roche;   Genentech, Inc.
Terminated

Fri, 15 Jun 2007 12:00:00 EDT

Effect of Intravitreal Bevacizumab on Focal Edema With Hard Exudates Secondary to Diabetic Retinopathy

Condition:   Diabetes Complications
Intervention:   Drug: Avastin (bevacizumab)
Sponsor:   Seoul St. Mary's Hospital
Unknown status

Tue, 23 Aug 2011 12:00:00 EDT

Comparison of Treatment Response to Intravitreal Injection of Combined Propranolol and Bevacizumab Versus Bevacizumab Monotherapy in Patients With Wet Age Related Macular Degeneration :A Clinical Trial

Condition:   Age Related Macular Degeneration
Interventions:   Drug: Combined Intravitreal bevacizumab and propranolol;   Drug: Intravitreal bevacizumab
Sponsor:   Shahid Beheshti University of Medical Sciences
Unknown status

Wed, 01 Aug 2018 12:00:00 EDT

Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic Melanoma

Condition:   Metastatic Melanoma
Intervention:   Drug: Biochemo + bevacizumab then ipilimumab
Sponsor:   California Pacific Medical Center Research Institute
Completed

Thu, 06 Dec 2012 12:00:00 EST

BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab)

Condition:   Solid Tumors
Intervention:   Drug: bevacizumab, everolimus, panitumumab
Sponsors:   Herbert Hurwitz, MD;   Novartis;   Genentech, Inc.;   Amgen
Completed

Fri, 04 Jan 2008 12:00:00 EST

Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer

Condition:   Ovarian Neoplasms
Interventions:   Drug: Bevacizumab;   Drug: atezolizumab;   Drug: acetylsalicylic acid;   Drug: placebo
Sponsor:   European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting

Wed, 20 Jan 2016 12:00:00 EST

SBRT + Atezolizumab + Bevacizumab in Resectable HCC

Conditions:   Hepatocellular Carcinoma;   Resectable Hepatocellular Carcinoma
Interventions:   Drug: Atezolizumab;   Drug: Bevacizumab;   Radiation: Stereotactic Beam Radiation Therapy (SBRT)
Sponsors:   Massachusetts General Hospital;   Genentech, Inc.
Not yet recruiting

Fri, 23 Apr 2021 12:00:00 EDT

Bevacizumab as Adjunctive Treatment to Laser Panretinal Photocoagulation for Proliferative Diabetic Retinopathy

Condition:   Proliferative Diabetic Retinopathy
Interventions:   Procedure: Panretinal photocoagulation;   Procedure: Procedure: Panretinal Photocoagulation (PRP) Drug: Intravitreous injection of Bevacizumab
Sponsors:   Instituto do Coracao;   Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.
Unknown status

Fri, 08 Jul 2011 12:00:00 EDT

NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma

Conditions:   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Recurrent Adult Brain Tumor
Interventions:   Biological: Bevacizumab;   Device: NovoTTF-l00A;   Other: Quality of Life Assessment
Sponsors:   Case Comprehensive Cancer Center;   NovoCure Ltd.;   National Cancer Institute (NCI)
Completed

Tue, 09 Jul 2013 12:00:00 EDT

Randomized Study Of Sunitinib Plus FOLFOX Versus Bevacizumab Plus FOLFOX In Metastatic Colorectal Cancer

Condition:   Colorectal Neoplasms
Interventions:   Drug: sunitinib;   Drug: mFOLFOX6;   Drug: bevacizumab
Sponsor:   Pfizer
Terminated

Thu, 07 Feb 2008 12:00:00 EST

Preoperative Combined Induction Chemotherapy With Capecitabine, Oxaliplatin, Bevacizumab and Radiotherapy

Condition:   Rectal Cancer
Intervention:   Drug: preoperative induction chemotherapy in combination with bevacizumab followed by combined radiochemotherapy with capecitabine
Sponsors:   Austrian Breast & Colorectal Cancer Study Group;   Hoffmann-La Roche
Completed

Wed, 14 Sep 2011 12:00:00 EDT

Phase II Study of Bevacizumab, Capecitabine and Oxaliplatin in Colon Cancer

Condition:   Metastatic Colorectal Cancer
Intervention:   Drug: Bevacizumab
Sponsor:   Asan Medical Center
Completed

Tue, 19 Sep 2006 12:00:00 EDT

Topical Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)

Condition:   Hereditary Hemorrhagic Telangiectasia (HHT)
Intervention:   Drug: Bevacizumab
Sponsor:   University of California, San Diego
Completed

Tue, 19 Jul 2011 12:00:00 EDT

Efficacy and Safety Study of Avastin to Treat Neovascularisation of the Cornea

Condition:   Corneal Newvessels
Interventions:   Drug: bevacizumab;   Drug: NaCl
Sponsor:   University Hospital, Limoges
Completed

Thu, 29 Dec 2011 12:00:00 EST

Bevacizumab and Irinotecan to Treat Brain Tumors

Condition:   High-Grade Gliomas
Interventions:   Biological: Bevacizumab;   Drug: Irinotecan hydrochloride
Sponsor:   National Cancer Institute (NCI)
Terminated

Thu, 26 Oct 2006 12:00:00 EDT

Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant Glioma

Conditions:   Brain Cancer;   Malignant Glioma
Intervention:   Other: radiotherapy (RT) in combination with temozolomide and bevacizumab
Sponsors:   Memorial Sloan Kettering Cancer Center;   Genentech, Inc.;   National Institutes of Health (NIH)
Completed

Fri, 31 Oct 2008 12:00:00 EDT

Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma

Condition:   Mesothelioma
Interventions:   Drug: Erlotinib;   Drug: Bevacizumab
Sponsors:   Dana-Farber Cancer Institute;   Massachusetts General Hospital;   University of Chicago
Completed

Tue, 30 Aug 2005 12:00:00 EDT

TRC105 Combined With Standard-dose Bevacizumab for Two Patients With Metastatic And Refractory Choriocarcinoma

Condition:   Choriocarcinoma
Interventions:   Biological: TRC105;   Biological: Bevacizumab
Sponsor:   Tracon Pharmaceuticals Inc.
Completed

Tue, 24 Mar 2015 12:00:00 EDT

Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant Glioma

Condition:   Brain and Central Nervous System Tumors
Interventions:   Drug: bevacizumab;   Drug: irinotecan;   Procedure: dynamic contrast-enhanced magnetic resonance imaging
Sponsors:   Duke University;   National Cancer Institute (NCI)
Completed

Fri, 14 Jul 2006 12:00:00 EDT

A Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma

Condition:   Unresectable Hepatocellular Carcinoma
Interventions:   Drug: Atezolizumab;   Drug: Bevacizumab
Sponsors:   Kristen Spencer;   Genentech, Inc.;   Rutgers Cancer Institute of New Jersey
Recruiting

Fri, 02 Apr 2021 12:00:00 EDT

Intravitreal Bevacizumab and Triamcinolone Associated to Laser Photocoagulation for Diabetic Macular Edema(IBeTA)

Condition:   Diabetic Macular Edema
Interventions:   Procedure: Laser photocoagulation;   Drug: Intravitreal triamcinolone;   Drug: Intravitreal bevacizumab
Sponsors:   University of Sao Paulo;   Fundação de Amparo à Pesquisa do Estado de São Paulo
Completed

Mon, 19 Oct 2009 12:00:00 EDT

Abraxane/Bevacizumab

Conditions:   Ovarian Cancer;   Peritoneal Cancer
Interventions:   Drug: Abraxane;   Drug: Bevacizumab
Sponsor:   OHSU Knight Cancer Institute
Terminated

Mon, 01 Apr 2013 12:00:00 EDT

Carboplatin, Abraxane, Avastin as Neoadjuvant Therapy for Her2-Negative Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Abraxane;   Drug: Carboplatin;   Drug: Avastin
Sponsors:   William Sikov MD;   Yale University
Completed

Mon, 28 Jul 2008 12:00:00 EDT

Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Patients With Hepatocellular Carcinoma

Condition:   Hepatocellular Carcinoma
Interventions:   Drug: Gemcitabine;   Drug: Oxaliplatin;   Drug: Bevacizumab
Sponsors:   Massachusetts General Hospital;   Dana-Farber Cancer Institute;   Beth Israel Deaconess Medical Center;   Brigham and Women's Hospital;   Genentech, Inc.;   Sanofi-Synthelabo;   Eli Lilly and Company
Completed

Fri, 02 Sep 2005 12:00:00 EDT

Phase Ib/II Single-arm Study of mFOLFOX6, Bevacizumab and Atezolizumab in Advanced Biliary Tract Cancer

Condition:   Biliary Tract Cancer
Intervention:   Drug: mFOLFOX6, Atezolizumab and Bevacizumab
Sponsor:   University Hospital, Essen
Not yet recruiting

Wed, 22 Sep 2021 12:00:00 EDT

Preoperative Radiotherapy With Capecitabine and Bevacizumab in Locally Advanced Rectal Cancer: CRAB Phase II Study

Condition:   Locally Advanced Rectal Cancer
Intervention:   Drug: bevacizumab, capecitabine
Sponsor:   Institute of Oncology Ljubljana
Unknown status

Thu, 12 Feb 2009 12:00:00 EST

Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers

Conditions:   Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer
Interventions:   Drug: Topotecan;   Drug: Bevacizumab
Sponsors:   Benaroya Research Institute;   GlaxoSmithKline;   Genentech, Inc.
Completed

Thu, 22 Jun 2006 12:00:00 EDT

Almonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal Metastasis

Conditions:   NSCLC;   Leptomeningeal Metastasis;   EGFR Activating Mutation
Interventions:   Drug: Almonertinib;   Drug: Bevacizumab
Sponsors:   Second Affiliated Hospital of Nanchang University;   Jiangsu Hansoh Pharmaceutical Co., Ltd.
Not yet recruiting

Tue, 29 Jun 2021 12:00:00 EDT

Pharmacokinetic, Safety and Immunogenicity Phase I Study of HLX04 Versus Avastin® in Healthy Male Subjects

Condition:   Healthy Male Subjects
Interventions:   Drug: HLX04;   Drug: US-Avastin®;   Drug: EU-Avastin®;   Drug: CN-Avastin®
Sponsor:   Shanghai Henlius Biotech
Completed

Fri, 30 Mar 2018 12:00:00 EDT

Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer

Conditions:   Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Cancer;   No Prior Chemotherapy
Interventions:   Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Bevacizumab
Sponsors:   David O'Malley;   Genentech, Inc.
Unknown status

Wed, 13 Oct 2010 12:00:00 EDT

Folfoxiri Plus Bevacizumab Followed by Chemoradiotherapy Plus Bevacizumab in Patients With Resectable Rectal Cancer

Condition:   Rectal Cancer
Interventions:   Drug: FOLFOXIRI plus Bevacizumab;   Other: Chemoradiotherapy plus Bevacizumab
Sponsor:   Azienda Ospedaliero, Universitaria Pisana
Completed

Wed, 22 Mar 2017 12:00:00 EDT

A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic Syndromes

Conditions:   Myelodysplastic Syndromes;   Chronic Myelomonocytic Leukemia
Interventions:   Drug: abaloparatide;   Drug: bevacizumab
Sponsor:   University of Rochester
Recruiting

Mon, 19 Nov 2018 12:00:00 EST

Paclitaxel With or Without Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: bevacizumab;   Drug: Paclitaxel
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI);   North Central Cancer Treatment Group;   NCIC Clinical Trials Group;   NSABP Foundation Inc
Completed

Mon, 27 Jan 2003 12:00:00 EST

Pan-VEGF Blockade for the Treatment of Retinopathy of Prematurity (BLOCK-ROP)

Condition:   Retinopathy of Prematurity
Intervention:   Drug: Bevacizumab
Sponsor:   Vision Research Foundation
Withdrawn

Tue, 02 Nov 2010 12:00:00 EDT

A Genotype-guided Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer Patients

Condition:   Metastatic Colorectal Cancer
Intervention:   Drug: FOLFIRI, Avastin, Irinotecan
Sponsors:   University of Chicago;   IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Completed

Tue, 17 Aug 2010 12:00:00 EDT

Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma

Conditions:   Glioblastoma;   Brain Tumor
Interventions:   Drug: Bevacizumab;   Behavioral: Modified Atkins Diet
Sponsors:   Case Comprehensive Cancer Center;   University of Cincinnati;   OhioHealth Research Institute
Completed

Wed, 11 May 2016 12:00:00 EDT

Anti-VEGF Instead of Intraoperative PRP in Proliferative Diabetic Retinopathy

Conditions:   Anti-VEGF;   Proliferative Diabetic Retinopathy;   PRP;   Vitrectomy
Interventions:   Procedure: anti-VEGF;   Procedure: PRP
Sponsor:   Wenzhou Medical University
Not yet recruiting

Thu, 16 Aug 2018 12:00:00 EDT

SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors

Conditions:   Malignant Peripheral Nerve Sheath Tumors;   MPNST;   Sarcoma
Interventions:   Drug: everolimus;   Drug: bevacizumab
Sponsors:   Sarcoma Alliance for Research through Collaboration;   Novartis Pharmaceuticals;   Genentech, Inc.;   United States Department of Defense
Completed

Thu, 09 Aug 2012 12:00:00 EDT

BELOVA Data Collection: Safety and Efficacy of Frontline Bevacizumab Treatment in Participants With Ovarian Cancer 70 Years and Older

Condition:   Ovarian Cancer
Interventions:   Drug: Bevacizumab;   Drug: Carboplatin;   Drug: Paclitaxel
Sponsor:   Hoffmann-La Roche
Completed

Fri, 20 Mar 2015 12:00:00 EDT

Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer

Condition:   Carcinoma, Non-Small-Cell Lung
Interventions:   Drug: FKB238 (bevacizumab);   Drug: Avastin (bevacizumab);   Drug: Paclitaxel;   Drug: Carboplatin
Sponsor:   Centus Biotherapeutics Limited
Active, not recruiting

Thu, 23 Jun 2016 12:00:00 EDT

Chemotherapy Plus Bevacizumab in Elderly Non-small Cell Lung Cancer Patients

Condition:   Non-small Cell Lung Cancer (NSCLC)
Intervention:   Biological: bevacizumab, carboplatin and paclitaxel
Sponsor:   Grupo de Investigación y Divulgación Oncológica
Unknown status

Mon, 11 Nov 2013 12:00:00 EST

Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma

Condition:   Intracranial Meningioma
Interventions:   Drug: Everolimus;   Drug: Bevacizumab
Sponsors:   SCRI Development Innovations, LLC;   Genentech, Inc.;   Novartis
Terminated

Fri, 04 Sep 2009 12:00:00 EDT

Sintilimab and Bevacizumab Combined With Radiotherapy for Advanced Recurrent Hepatocellular Carcinoma

Condition:   Recurrent Hepatocellular Carcinoma
Intervention:   Drug: Sintilimab and Bevacizumab Combined with Radiotherapy
Sponsors:   Sun Yat-sen University;   Innovent Biologics (Suzhou) Co. Ltd.
Recruiting

Wed, 18 Aug 2021 12:00:00 EDT

Phase II Trial of Combination Therapy With Bevacizumab and S-1 in Elderly Patients With Unresectable or Recurrent Colorectal Cancer (BASIC)

Condition:   Colorectal Cancer
Intervention:   Drug: S-1, Bevacizumab
Sponsor:   Taiho Pharmaceutical Co., Ltd.
Completed

Fri, 07 Dec 2007 12:00:00 EST

Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer

Conditions:   Adult Primary Hepatocellular Carcinoma;   Localized Unresectable Adult Primary Liver Cancer;   Recurrent Adult Primary Liver Cancer
Intervention:   Biological: bevacizumab
Sponsor:   National Cancer Institute (NCI)
Completed

Fri, 07 Mar 2003 12:00:00 EST

Radiomics Assess of Bevacizumab Plus Chemo in Colorectal Cancer Liver Metastases

Conditions:   Colon Cancer;   Rectal Cancer;   Liver Metastases
Intervention:   Drug: Bevacizumab
Sponsor:   Peking University People's Hospital
Not yet recruiting

Mon, 30 Dec 2019 12:00:00 EST

A Study of Bevacizumab Plus XELOX/XELIRI for First-line Treatment in Unresectable Advanced Colorectal Cancer

Condition:   Advanced Colorectal Cancer
Intervention:   Drug: Bevacizumab、Oxaliplatin、Irinotecan、Capecitabine
Sponsor:   Jiangsu Cancer Institute & Hospital
Recruiting

Fri, 27 Mar 2020 12:00:00 EDT

Anti-VEGF Instead of Intraoperative Fan-shaped Photocoagulation in BRVO Combined With Vitreous Hemorrhage

Conditions:   Anti-VEGF;   Branch Retinal Vein Occlusion;   Vitrectomy
Interventions:   Procedure: anti-VEGF;   Procedure: fan-shaped photocoagulation
Sponsor:   Wenzhou Medical University
Not yet recruiting

Fri, 17 Aug 2018 12:00:00 EDT

Intravitreal Injection of Bevacizumab and Gas for Diabetic Premacular Hemorrhage With Active Fibrovascular Proliferation

Condition:   Diabetic Retinopathy With Premacular Hemorrhage
Intervention:   Drug: Intravitreal Bevacizumab
Sponsor:   National Taiwan University Hospital
Unknown status

Wed, 07 May 2008 12:00:00 EDT

Combined Intravitreal Fasudil and Bevacizumab for Diabetic Macular Edema

Condition:   Diabetic Macular Edema
Interventions:   Drug: Intravitreal injection of bevacizumab (Avastin);   Drug: Intravitreal injection of fasudil and bevacizumab (Avastin)
Sponsor:   Shahid Beheshti University of Medical Sciences
Completed

Thu, 04 Apr 2013 12:00:00 EDT

Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer

Conditions:   Endometrial Cancer;   Endometrial Adenocarcinoma;   Endometrial Serous Adenocarcinoma;   Endometrial Clear Cell Adenocarcinoma
Interventions:   Drug: Mirvetuximab Soravtansine;   Drug: Bevacizumab
Sponsors:   University of Oklahoma;   ImmunoGen, Inc.
Withdrawn

Mon, 11 Feb 2019 12:00:00 EST

Comparison of the Effects of Bevacizumab Before vs After Pattern Panretinal Photocoagulation

Condition:   Macular Edema
Intervention:   Drug: bevacizumab
Sponsor:   Asociación para Evitar la Ceguera en México
Unknown status

Mon, 08 Dec 2008 12:00:00 EST

Image Guided Surgery in Sinonasal Inverted Papilloma

Conditions:   Inverted Papilloma;   Molecular Fluorescence Imaging
Intervention:   Drug: Bevacizumab-800CW
Sponsor:   University Medical Center Groningen
Active, not recruiting

Wed, 24 Apr 2019 12:00:00 EDT

Single Site, Masked, Randomized, Controlled Study to Assess Efficacy of Osurdex as Adjunct to Avastin Compared With Avastin Alone in the Treatment of Patients With Macular Edema Due to Central or Branch Retinal Vein Occlusion

Condition:   Retinal Vein Occlusions
Interventions:   Drug: Avastin;   Drug: Osurdex
Sponsor:   Maturi, Raj K., M.D., P.C.
Completed

Fri, 12 Mar 2010 12:00:00 EST

Intravitreal Bevacizumab vs.Combination Therapy for CNV Due to Other Than AMD

Conditions:   Choroidal Neovascularization;   Myopia;   Punctate Inner Choroidopathy (PIC);   Multifocal Choroiditis;   Ocular Histoplasmosis Syndrome;   Central Serous Chorioretinopathy (CSC);   Angioid Streaks;   Trauma, or Hereditary Eye Diseases
Interventions:   Drug: Bevacizumab (Avastin; Genentech, Inc.);   Drug: Bevacizumab, Dexamethasone, Verteporfin Photodynamic Therapy
Sponsor:   Massachusetts Eye and Ear Infirmary
Withdrawn

Wed, 08 Dec 2010 12:00:00 EST

Strategies for Management of Recurrent Pterygium

Condition:   Recurrent Pterygium
Interventions:   Drug: Bevacizumab;   Drug: 5 fluorouracil
Sponsor:   University of Nottingham
Unknown status

Fri, 21 Aug 2015 12:00:00 EDT

Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, Leucovorin, and Avastin

Conditions:   Liver Cancer;   Advanced Solid Tumors
Interventions:   Drug: Fluorouracil;   Drug: Avastin;   Drug: Leucovorin;   Drug: Oxaliplatin
Sponsor:   M.D. Anderson Cancer Center
Completed

Thu, 26 Jul 2007 12:00:00 EDT

Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer

Condition:   Neuroendocrine Carcinomas
Interventions:   Drug: Folfiri-bevacizumab;   Drug: Folfiri
Sponsor:   Hospices Civils de Lyon
Recruiting

Fri, 01 Jul 2016 12:00:00 EDT

Optimization of Bevacizumab Scheduling With Chemotherapy for Metastatic Colorectal Cancer

Condition:   Colorectal Cancer
Interventions:   Drug: Bevacizumab;   Drug: Oxaliplatin;   Drug: levo-folinic acid;   Drug: 5-fluorouracil;   Drug: Capecitabine
Sponsor:   National Cancer Institute, Naples
Unknown status

Wed, 31 Oct 2012 12:00:00 EDT

Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma

Conditions:   Neuroblastoma;   Sarcoma
Intervention:   Drug: Cyclophosphamide, Topotecan, and Bevacizumab
Sponsors:   Memorial Sloan Kettering Cancer Center;   Genentech, Inc.;   Children's Mercy Hospital Kansas City;   Penn State University;   University of Colorado, Denver;   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   Phoenix Children's Hospital Center for Cancer & Blood Disorders;   Alberta Children's Hospital;   MD Anderson Cancer Center Orlando;   M.D. Anderson Cancer Center
Completed

Thu, 15 Dec 2011 12:00:00 EST

Abrogation of Chronic Monoclonal Antibody Treatment-induced T-cell Exhaustion With DURVALUMAB in Advanced HER-2 Negative Breast Cancer

Conditions:   Metastatic Breast Cancer;   Bevacizumab-alone Maintenance Treatment Progression
Interventions:   Drug: Durvalumab;   Drug: Bevacizumab
Sponsors:   Centro Nacional de Investigaciones Oncologicas CARLOS III;   Fundacion CRIS de Investigación para Vencer el Cáncer
Completed

Thu, 16 Jun 2016 12:00:00 EDT

Bevacizumab for Recurrent Malignant Glioma

Conditions:   Recurrent High-Grade Gliomas;   Malignant Gliomas
Intervention:   Drug: Bevacizumab
Sponsor:   National Cancer Institute (NCI)
Completed

Mon, 02 Jan 2006 12:00:00 EST

Bevacizumab in the Radiation Treatment of Recurrent Malignant Glioma

Conditions:   Brain Cancer;   Recurrent Malignant Gliomas;   Primary Brain Tumor
Intervention:   Other: bevacizumab and radiation (IMRT)
Sponsors:   Memorial Sloan Kettering Cancer Center;   Weill Medical College of Cornell University;   Genentech, Inc.
Completed

Wed, 16 Jan 2008 12:00:00 EST

Preoperative Combined RadioChemo-Molecular Target Therapy With Capecitabine, Bevacizumab, and Radiotherapy

Condition:   Rectal Cancer
Intervention:   Drug: capecitabine, bevacizumab
Sponsors:   Austrian Breast & Colorectal Cancer Study Group;   Hoffmann-La Roche
Terminated

Mon, 05 May 2008 12:00:00 EDT

Translational Study of Nivolumab in Combination With Bevacizumab for Recurrent Glioblastoma

Condition:   Recurrent Adult Brain Tumor
Interventions:   Drug: Nivolumab;   Drug: Bevacizumab
Sponsors:   Ulrik Lassen;   Herlev Hospital;   University of Copenhagen
Recruiting

Tue, 26 Mar 2019 12:00:00 EDT

A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)

Condition:   Non-Squamous Non-Small Cell Lung Cancer
Interventions:   Drug: Bevacizumab;   Drug: Docetaxel;   Drug: Erlotinib;   Drug: Pemetrexed
Sponsor:   Hoffmann-La Roche
Completed

Tue, 10 May 2011 12:00:00 EDT

Ahmed Valve Glaucoma Implant With Adjunctive Subconjunctival Bevacizumab in Refractory Glaucoma

Condition:   Refractory Glaucoma
Interventions:   Drug: Subconjunctival Avastin;   Device: Ahmed Valve implant
Sponsor:   Vanak Eye Surgery Center
Unknown status

Mon, 24 May 2010 12:00:00 EDT

Combination Therapy for Age-Related Macular Degeneration.

Condition:   Age Related Macular Degeneration
Interventions:   Drug: Avastin (Bevacizumab);   Drug: Bevacizumab
Sponsors:   Lawson Health Research Institute;   QLT Inc.;   Canadian Retinal Trials Group
Completed

Fri, 15 Sep 2006 12:00:00 EDT

Vitreous Levels of Cysteine-rich 61 in Patients With Proliferative Diabetic Retinopathy

Condition:   Proliferative Diabetic Retinopathy
Intervention:   Drug: intravitreal injection of 1.25 mg of bevacizumab
Sponsor:   National Taiwan University Hospital
Completed

Tue, 13 Aug 2013 12:00:00 EDT

Pharmacokinetic, Safety, Tolerability, and Immunogenicity Study of SB8 in Healthy Male Subjects

Condition:   Healthy
Interventions:   Biological: SB8;   Biological: EU sourced Avastin®;   Biological: US Sourced Avastin®
Sponsor:   Samsung Bioepis Co., Ltd.
Completed

Mon, 25 May 2015 12:00:00 EDT

Comparison of Intravitreal Bevacizumab and Triamcinolone With Placebo

Condition:   Acute Nonarteritic Anterior Ischemic Optic Neuropathy
Interventions:   Drug: Avastin and Triamcinolone;   Other: placebo
Sponsor:   Shahid Beheshti University of Medical Sciences
Unknown status

Thu, 07 Apr 2011 12:00:00 EDT

Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian Cancer

Condition:   Ovarian Cancer
Interventions:   Drug: Niraparib;   Drug: Bevacizumab
Sponsors:   Nordic Society of Gynaecological Oncology - Clinical Trials Unit;   European Network of Gynaecological Oncological Trial Groups (ENGOT);   Gynecologic Cancer Intergroup (GCIG);   University of Utah;   Massachusetts General Hospital;   Myriad Genetics, Inc.
Active, not recruiting

Tue, 03 Feb 2015 12:00:00 EST

A Study of Bevacizumab (Avastin) in Participants With Newly Diagnosed Locally Advanced Rectal Cancer

Condition:   Rectal Cancer
Interventions:   Drug: Bevacizumab;   Drug: Oxaliplatin;   Drug: Folinic Acid;   Drug: 5-fluorouracil;   Radiation: Preoperative Radiotherapy;   Procedure: Surgery
Sponsor:   Hoffmann-La Roche
Completed

Thu, 19 Mar 2009 12:00:00 EDT

Bevacizumab Plus Irinotecan Plus Carboplatin for Recurrent Malignant Glioma (MG)

Condition:   Malignant Glioma
Intervention:   Drug: bevacizumab and CPT-11 and Carboplatin
Sponsor:   Annick Desjardins
Completed

Thu, 06 Aug 2009 12:00:00 EDT

Trastuzumab (Herceptin), Bevacizumab, and Docetaxel (Taxotere) Trial in Stage IV Metastatic Breast Cancer (MBC) Patients

Condition:   Breast Cancer
Interventions:   Drug: Trastuzumab;   Drug: Bevacizumab;   Drug: Docetaxel
Sponsors:   Bhuvaneswari Ramaswamy;   Genentech, Inc.;   Case Comprehensive Cancer Center;   University of Pittsburgh
Completed

Tue, 30 Jan 2007 12:00:00 EST

Temozolomide Plus Bevacizumab in Patients With Metastatic Melanoma Involving the Central Nervous System

Condition:   Melanoma
Interventions:   Drug: Temozolomide;   Drug: Bevacizumab
Sponsors:   Mt. Sinai Medical Center, Miami;   Northern California Melanoma Center
Completed

Wed, 13 Jan 2010 12:00:00 EST

Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma

Condition:   Head and Neck Cancer
Intervention:   Other: bevacizumab, cisplatin, cetuximab, radiation therapy
Sponsors:   Memorial Sloan Kettering Cancer Center;   Genentech, Inc.
Completed

Mon, 31 Aug 2009 12:00:00 EDT

Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib

Condition:   Prostate Cancer
Intervention:   Drug: Erlotinib + Bevacizumab
Sponsors:   Translational Oncology Research International;   Genentech, Inc.
Completed

Tue, 20 Sep 2005 12:00:00 EDT

A Dose- and Efficacy-Finding Study of RO5323441 in Combination With Avastin (Bevacizumab) in Patients With Recurrent Glioblastoma

Condition:   Glioblastoma Multiforme
Interventions:   Drug: RO5323441 + bevacizumab [Avastin];   Drug: bevacizumab [Avastin]
Sponsor:   Hoffmann-La Roche
Completed

Fri, 04 Mar 2011 12:00:00 EST

A Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy in Patients With Advanced Non-Small Cell Lung Carcinoma (NSCLC)

Condition:   Non-Small Cell Lung Cancer
Intervention:   Drug: Pemetrexed, Cisplatin, Bevacizumab
Sponsor:   Columbia University
Terminated

Tue, 20 Oct 2009 12:00:00 EDT

Efficacy and Safety of QL1101 and Avastin® Respectively Combined With Paclitaxel and Carboplatin in the First-line Treatment of Non-squamous Non-small Cell Lung Cancer

Condition:   Non-squamous Non-small Cell Lung Cancer
Interventions:   Drug: QL1101;   Drug: Avastin®;   Drug: Paclitaxel;   Drug: Carboplatin
Sponsor:   Qilu Pharmaceutical Co., Ltd.
Completed

Tue, 30 May 2017 12:00:00 EDT

Bevacizumab Versus Mitomycin C as Trabeculectomy Adjuvant in Uncontrolled Glaucoma

Condition:   Glaucoma
Interventions:   Procedure: Standard Guarded Trabeculectomy;   Drug: Mitomycin C;   Drug: Bevacizumab
Sponsor:   Athens Vision Eye Institute
Completed

Thu, 15 Sep 2016 12:00:00 EDT

Safety and Clinical Effectiveness of Intravitreal Bevacizumab (Lumiere®) in Patients With Wet Age-related Macular Degeneration (Wet AMD)

Condition:   Age-Related Macular Degeneration
Intervention:   Drug: Bevacizumab (Lumiere®)
Sponsor:   Laboratorio Elea Phoenix S.A.
Completed

Wed, 12 Sep 2018 12:00:00 EDT

Safety Study of Bevacizumab, Everolimus and LBH589 (BEL) for Advanced Solid Tumors

Condition:   Advanced Solid Tumors
Intervention:   Drug: Bevacizumab, Everolimus and LBH589
Sponsors:   Herbert Hurwitz;   Novartis;   Genentech, Inc.
Completed

Tue, 26 Jan 2010 12:00:00 EST

Ranibizumab and Bevacizumab for Diabetic Macular Edema

Condition:   Diabetic Macular Edema
Interventions:   Drug: Ranibizumab;   Drug: Bevacizumab
Sponsors:   National Eye Institute (NEI);   The Emmes Company, LLC
Completed

Mon, 04 Jun 2012 12:00:00 EDT

A Combination Study to Determine the Safety and Efficacy of Panzem NCD With Avastin in Metastatic Carcinoid Tumors

Condition:   Carcinoid Tumor
Intervention:   Drug: Panzem (2-methoxyestradiol) NCD, Avastin (Bevacizumab)
Sponsor:   CASI Pharmaceuticals, Inc.
Completed

Mon, 22 May 2006 12:00:00 EDT

Neoadjuvant Chemotherapy With Methotrexate, Vinblastine, Adriamycin and Cisplatin (M-VAC) Plus Avastin in Patients With Urothelial Cancer

Condition:   Bladder Cancer
Interventions:   Drug: Avastin;   Drug: Cisplatin;   Drug: Doxorubicin;   Drug: Methotrexate;   Drug: Vinblastine Sulfate
Sponsors:   M.D. Anderson Cancer Center;   Genentech, Inc.
Completed

Wed, 25 Jul 2007 12:00:00 EDT

Efficacy-Safety-Immunogenicity Study of CBT124&EU-sourced Avastin® in Stage 4 NSCLC

Condition:   Non-Small Cell Lung Carcinoma
Interventions:   Biological: CBT124;   Biological: EU-sourced Avastin®;   Drug: Carboplatin;   Drug: Paclitaxel
Sponsor:   Cipla BioTec Pvt. Ltd.
Unknown status

Thu, 25 Aug 2016 12:00:00 EDT

Fluorescence Guided Surgery in Breast Cancer

Condition:   Breast Cancer
Intervention:   Drug: Bevacizumab-800CW
Sponsors:   University Medical Center Groningen;   Martini Hospital Groningen
Completed

Thu, 22 Oct 2015 12:00:00 EDT

The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma

Condition:   Hepatocellular Carcinoma
Interventions:   Drug: Atezolizumab;   Drug: Bevacizumab;   Procedure: TACE
Sponsor:   Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Recruiting

Thu, 18 Mar 2021 12:00:00 EDT

Carboplatin, Bevacizumab and Pemetrexed in Advanced Non Small Cell Lung Cancer

Condition:   Non Small Cell Lung Cancer
Intervention:   Drug: Carboplatin, Pemetrexed and Bevacizumab
Sponsors:   Christiana Care Health Services;   Eli Lilly and Company
Completed

Wed, 13 Feb 2008 12:00:00 EST

Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema

Conditions:   Diabetic Macular Edema;   Non-proliferative Diabetic Retinopathy;   Proliferative Diabetic Retinopathy
Interventions:   Drug: dexamethasone intravitreal implant;   Drug: intravitreal bevacizumab
Sponsors:   Retina Macula Institute;   Allergan
Completed

Thu, 05 Apr 2012 12:00:00 EDT

Bevacizumab and Capecitabine in Treatment of Elderly Patients With Metastatic Breast Cancer

Conditions:   Breast Cancer;   Metastasis
Intervention:   Drug: Capecitabine and Bevacizumab
Sponsors:   South Eastern European Research Oncology Group;   Roche Pharma AG
Unknown status

Mon, 06 Sep 2010 12:00:00 EDT

Sirolimus Versus Anti-Vascular Endothelial Growth Factor (antiVEGF) for Wet AMD

Condition:   Age-Related Macular Degeneration
Interventions:   Drug: Sirolimus;   Drug: Standard of Care intravitreal injections of anti-VEGF
Sponsor:   Maturi, Raj K., M.D., P.C.
Completed

Fri, 06 Feb 2015 12:00:00 EST

Bevacizumab for Treatment of Recurrent Respiratory Papillomatosis (RRP)

Condition:   Recurrent Respiratory Papillomatosis
Interventions:   Drug: Avastin® (bevacizumab);   Drug: Saline
Sponsor:   Massachusetts General Hospital
Completed

Wed, 25 Nov 2009 12:00:00 EST

Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)

Condition:   Hepatocellular Carcinoma
Interventions:   Other: Y-90 TARE;   Drug: Atezolizumab;   Drug: Bevacizumab
Sponsors:   Aiwu Ruth He, MD;   Georgetown University;   Genentech, Inc.
Recruiting

Wed, 09 Sep 2020 12:00:00 EDT

Paclitaxel, Carboplatin Plus Bevacizumab in Pretreated, Advanced or Metastatic Non Small Cell Lung Cancer

Condition:   Non Small Cell Lung Cancer
Interventions:   Drug: Carboplatin;   Drug: Bevacizumab;   Drug: Paclitaxel
Sponsor:   Hellenic Oncology Research Group
Completed

Wed, 17 Sep 2008 12:00:00 EDT

A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE)

Condition:   Glioblastoma
Interventions:   Drug: VB-111 + bevacizumab;   Drug: Bevacizumab
Sponsor:   Vascular Biogenics Ltd. operating as VBL Therapeutics
Completed

Thu, 30 Jul 2015 12:00:00 EDT

Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s Sarcoma

Condition:   Sarcoma, Kaposi
Interventions:   Drug: Liposomal Doxorubicin;   Drug: Bevacizumab
Sponsor:   National Cancer Institute (NCI)
Completed

Thu, 18 Jun 2009 12:00:00 EDT

Avastin and Tarceva for Upper Gastrointestinal Cancers

Conditions:   Cholangiocarcinoma;   Gallbladder Cancer
Intervention:   Drug: Erlotinib and bevacizumab
Sponsors:   Rigshospitalet, Denmark;   Aarhus University Hospital
Completed

Tue, 11 Jul 2006 12:00:00 EDT

PRP vs Bevacizumab for PDR Treatment

Condition:   Proliferative Diabetic Retinopathy
Interventions:   Drug: Bevacizumab;   Procedure: Panretinal photocoagulation
Sponsor:   Marashi Eye Clinic
Completed

Thu, 10 Mar 2016 12:00:00 EST

Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer

Conditions:   Colorectal Cancer;   Metastatic Cancer
Intervention:   Drug: Pembrolizumab, Bevacizumab, and Binimetinib
Sponsor:   University of Colorado, Denver
Recruiting

Fri, 23 Mar 2018 12:00:00 EDT

Bevacizumab, Oxaliplatin, and Docetaxel in Treating Patients With Locally Advanced Unresectable or Metastatic Stomach or Gastroesophageal Junction Cancer

Conditions:   Esophageal Cancer;   Gastric Cancer
Interventions:   Biological: Bevacizumab;   Drug: Docetaxel;   Drug: Oxaliplatin
Sponsors:   Barbara Ann Karmanos Cancer Institute;   National Cancer Institute (NCI)
Completed

Thu, 22 Sep 2005 12:00:00 EDT

Refractive Error and Biometry in Retinopathy of Prematurity

Condition:   Retinopathy of Prematurity
Interventions:   Drug: Bevacizumab;   Drug: Ranibizumab
Sponsor:   San Ni Chen
Completed

Tue, 07 Nov 2017 12:00:00 EST

Pentostatin, Cyclophosphamide, and Rituximab With or Without Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Conditions:   Leukemia;   Lymphoma
Interventions:   Biological: bevacizumab;   Biological: pegfilgrastim;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: pentostatin
Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
Completed

Thu, 01 Jan 2009 12:00:00 EST

The Effect of a Single Intravitreal Anti-VEGF Therapy on Optic Nerve Head Perfusion

Conditions:   Macular Degeneration;   Regional Blood Flow;   Vascular Endothelial Growth Factor
Intervention:   Drug: ranibizumab, bevacizumab or pegaptanib
Sponsor:   Medical University of Vienna
Terminated

Thu, 03 Jul 2008 12:00:00 EDT

Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO

Conditions:   Macular Edema;   Retinal Vein Occlusion
Interventions:   Drug: suprachoroidal CLS-TA;   Drug: suprachoroidal sham;   Drug: Lucentis or Avastin
Sponsor:   Clearside Biomedical, Inc.
Terminated

Thu, 29 Jun 2017 12:00:00 EDT

Exploration of Circulating VE-cadherin in Metastatic Colorectal Adenocarcinoma Patients Treated With Bevacizumab

Conditions:   Colorectal Cancer;   Metastasis
Intervention:   Biological: Bevacizumab + blood samples
Sponsors:   Centre Leon Berard;   UMR-S Inserm 1036
Completed

Fri, 29 Jul 2011 12:00:00 EDT

Bevacizumab in Combination With Visudyne Photodynamic Therapy (PDT)

Conditions:   Age Related Macular Degeneration;   Choroidal Neovascularization;   Macular Edema
Interventions:   Drug: Bevacizumab;   Device: verteporfin photodynamic therapy reduced fluence;   Device: verteporfin photodynamic therapy standardfluence
Sponsors:   California Retina Consultants;   Novartis
Completed

Fri, 08 Aug 2008 12:00:00 EDT

Amgen 386 for Recurrent Glioblastoma

Condition:   Glioblastoma Multiforme
Interventions:   Drug: Amgen 386;   Drug: Bevacizumab
Sponsors:   Dana-Farber Cancer Institute;   Amgen
Completed

Fri, 04 Feb 2011 12:00:00 EST

Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA

Conditions:   Glioblastoma Multiforme;   Anaplastic Astrocytoma
Intervention:   Drug: Bevacizumab
Sponsors:   Northwell Health;   Feinstein Institute for Medical Research
Recruiting

Tue, 04 Jan 2011 12:00:00 EST

Carboplatin-Paclitaxel ± Bevacizumab in Advanced (Stage III-IV) or Recurrent Endometrial Cancer

Condition:   Stage III-IV or Recurrent Endometrial Cancer
Interventions:   Drug: Bevacizumab;   Drug: Carboplatin AUC 5+Paclitaxel 175 mg/mq q 21 for 6-8 cycles
Sponsor:   Catholic University of the Sacred Heart
Unknown status

Thu, 17 Jan 2013 12:00:00 EST

A Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin)

Condition:   Diabetic Retinopathy
Interventions:   Procedure: Laser Photocoagulation;   Drug: Bevacizumab
Sponsors:   Jaeb Center for Health Research;   National Eye Institute (NEI)
Completed

Tue, 13 Jun 2006 12:00:00 EDT

Suberoylanilide Hydroxamic Acid (SAHA), Bevacizumab, Daily Temozolomide for Recurrent Malignant Gliomas

Conditions:   Brain Tumor;   Glioblastoma
Intervention:   Drug: Vorinostst/Bevacizumab/Temozolomide
Sponsors:   Katy Peters;   Genentech, Inc.;   Merck Sharp & Dohme Corp.
Completed

Wed, 15 Jul 2009 12:00:00 EDT

Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors

Condition:   Solid Tumors
Interventions:   Drug: CRLX101;   Drug: Bevacizumab;   Drug: mFOLFOX6
Sponsor:   NewLink Genetics Corporation
Terminated

Thu, 07 Jan 2016 12:00:00 EST

Study to Assess Safety & Tolerability of AZD2281 in Combination With Bevacizumab in Patients With Advanced Solid Tumours

Condition:   Neoplasm Metastasis
Interventions:   Drug: AZD2281;   Drug: Bevacizumab
Sponsor:   AstraZeneca
Completed

Fri, 04 Jul 2008 12:00:00 EDT

Comparison of Single Intravitreal Injection of Triamcinolone or Bevacizumab for the Treatment of Diabetic Macular Edema

Condition:   Diabetic Macular Edema
Interventions:   Drug: Bevacizumab;   Drug: Triamcinolone acetonide
Sponsor:   Universidade Federal de Goias
Completed

Thu, 02 Apr 2009 12:00:00 EDT

A Study of Avastin (Bevacizumab) in Combination With Standard Chemotherapy in Children and Adolescents With Sarcoma.

Condition:   Sarcoma
Interventions:   Drug: Standard chemotherapy;   Drug: bevacizumab [Avastin]
Sponsor:   Hoffmann-La Roche
Completed

Wed, 26 Mar 2008 12:00:00 EDT

Phase 1/2 CTO + Bevacizumab for Recurrent Glioma Post-Bevacizumab Failure

Condition:   Malignant Glioma (WHO Grade III or IV)
Interventions:   Drug: CTO and Bevacizumab;   Drug: CTO alone
Sponsors:   Annick Desjardins;   Tactical Therapeutics, Inc.
Terminated

Tue, 01 Oct 2013 12:00:00 EDT

Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma

Condition:   Brain and Central Nervous System Tumors
Interventions:   Drug: bevacizumab;   Drug: erlotinib hydrochloride
Sponsors:   Northwestern University;   M.D. Anderson Cancer Center
Completed

Tue, 22 Jul 2008 12:00:00 EDT

PTK787/ZK222584 With Bevacizumab in Patients With Refractory and/or Advanced Malignancies

Conditions:   Refractory Malignancy;   Advanced Malignancies
Intervention:   Drug: PTK787/ZK222584 and Bevacizumab
Sponsors:   SCRI Development Innovations, LLC;   Novartis
Completed

Mon, 11 Feb 2008 12:00:00 EST

Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM)

Condition:   Glioblastoma
Interventions:   Drug: Cilengitide;   Drug: Bevacizumab;   Behavioral: Questionnaire
Sponsors:   M.D. Anderson Cancer Center;   Brain Tumor Trials Collaborative;   EMD Serono
Withdrawn

Mon, 04 Feb 2013 12:00:00 EST

Pemetrexed Disodium, Gemcitabine, and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Condition:   Lung Cancer
Interventions:   Biological: bevacizumab;   Drug: gemcitabine hydrochloride;   Drug: pemetrexed disodium
Sponsors:   Barbara Ann Karmanos Cancer Institute;   National Cancer Institute (NCI)
Terminated

Thu, 22 Feb 2007 12:00:00 EST

Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM)

Conditions:   Brain Cancer;   Glioblastoma
Interventions:   Drug: Standard Dose Bevacizumab;   Drug: Low Dose Bevacizumab;   Drug: Lomustine
Sponsor:   M.D. Anderson Cancer Center
Completed

Thu, 11 Feb 2010 12:00:00 EST

HAIC With Oxaliplatin, 5-FU and Bevacizumab Plus Intravenous Toripalimab for Advanced BTC

Condition:   Advanced Biliary Tract Cancer
Intervention:   Drug: OXA, 5-FU and bevacizumab plus Toripalimab
Sponsor:   Peking University
Recruiting

Mon, 06 Jan 2020 12:00:00 EST

POSTERIOR SUB-TENON'S Avastin

Condition:   Diffuse Diabetic Macular Edema
Intervention:   Drug: bevacizumab (Sub-tenon´s injection)
Sponsor:   Asociación para Evitar la Ceguera en México
Unknown status

Tue, 04 Dec 2007 12:00:00 EST

Evaluate the Efficacy and Safety of IBI305 in Patients With Advanced or Recurrent Non-squamous NSCLC

Condition:   NSCLC
Interventions:   Drug: Bevacizumab in Combination With Paclitaxel/Carboplatin;   Drug: IBI305 in Combination with Paclitaxel/Carboplatin
Sponsors:   Innovent Biologics (Suzhou) Co. Ltd.;   WuXi CDS Clinical Research (Shanghai) Co.Ltd.
Completed

Thu, 03 Nov 2016 12:00:00 EDT

Phase II Trial of Combination Therapy With S-1, Irinotecan, and Bevacizumab (SIRB) in Patients With Unresectable or Recurrent Colorectal Cancer

Condition:   Colorectal, Cancer
Intervention:   Drug: S-1, Irinotecan, Bevacizumab
Sponsor:   Taiho Pharmaceutical Co., Ltd.
Completed

Fri, 07 Dec 2007 12:00:00 EST

Role of Sub-Conjunctival Bevacizumab in Post Pterygium Excision Management

Condition:   Pterygium
Intervention:   Drug: Bevacizumab
Sponsor:   Arrowhead Regional Medical Center
Completed

Thu, 29 Nov 2012 12:00:00 EST

A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer

Condition:   Colorectal Neoplasms
Interventions:   Drug: Oxaliplatin;   Drug: Capecitabine;   Drug: Bevacizumab;   Drug: Leucovorin;   Drug: 5-Fluouracil;   Drug: Irinotecan
Sponsor:   Hoffmann-La Roche
Completed

Tue, 01 May 2012 12:00:00 EDT

Perioperative vs Postoperative Chemotherapy + Bevacizumab in Colorectal Cancer, Liver Mets

Conditions:   Colorectal Cancer;   Liver Metastasis
Intervention:   Drug: Bevacizumab, mFOLFOX, FOLFIRI
Sponsor:   Yonsei University
Completed

Tue, 03 Jul 2012 12:00:00 EDT

Bevacizumab Therapy Untreated Unresectable Liver Metastases From Colorectal Cancer

Conditions:   Liver Metastases;   Colorectal Cancer
Intervention:   Drug: bevacizumab plus chemotherapy
Sponsor:   Liaoning Tumor Hospital & Institute
Unknown status

Tue, 08 Jan 2013 12:00:00 EST

A Study of LY01008 and Bevacizumab Combined With Paclitaxel and Carboplatin for Treatment of Naïve Subjects With Metastatic or Recurrent Nonsquamous Non-small Cell Lung Cancer

Conditions:   Non Small Cell Lung Cancer;   Non Small Cell Lung Cancer Metastatic;   Non Small Cell Lung Cancer Recurrent
Interventions:   Drug: LY01008;   Drug: Bevacizumab
Sponsor:   Luye Pharma Group Ltd.
Unknown status

Tue, 22 May 2018 12:00:00 EDT

Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers

Conditions:   Non-small Cell Lung Cancer;   EGFR-mutant Lung Cancers
Interventions:   Drug: osimertinib;   Drug: Bevacizumab
Sponsors:   Memorial Sloan Kettering Cancer Center;   AstraZeneca;   Genentech, Inc.
Active, not recruiting

Thu, 16 Jun 2016 12:00:00 EDT

Randomized Ph 2 Trial Of Paclitaxel/Carboplatin /Bevacizumab + PF-3512676 And P/C/B Alone In Advanced Nonsquamous NSCLC

Condition:   Carcinoma, Non-Small-Cell Lung
Interventions:   Drug: paclitaxel + carboplatin + bevacizumab;   Drug: carboplatin + paclitaxel + bevacizumab + PF-3512676
Sponsor:   Pfizer
Terminated

Wed, 12 Apr 2006 12:00:00 EDT

A Study of Avastin (Bevacizumab) Combined With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum

Condition:   Colorectal Cancer
Intervention:   Drug: bevacizumab [Avastin]
Sponsor:   Hoffmann-La Roche
Completed

Fri, 13 Aug 2010 12:00:00 EDT

Atezolizumab and Bevacizumab in Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer in Patients With Progressive Disease After Receiving Osimertinib

Condition:   Non Small Cell Lung Cancer
Interventions:   Drug: Atezolizumab;   Drug: Bevacizumab
Sponsor:   Duke University
Recruiting

Mon, 23 Sep 2019 12:00:00 EDT

CCI-779 and Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney Cancer

Conditions:   Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions:   Drug: CCI-779;   Drug: Bevacizumab
Sponsor:   National Cancer Institute (NCI)
Completed

Fri, 03 Jun 2005 12:00:00 EDT

Study of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFOX) + Bevacizumab Versus 5-Fluorouracil/Leucovorin/Oxaliplatin/Irinotecan (FOLFOXIRI) + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral Cells

Condition:   Metastatic Colorectal Cancer
Interventions:   Drug: modified FOLFOX6 + bevacizumab;   Drug: FOLFOXIRI + Bevacizumab
Sponsors:   Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD);   Roche Pharma AG
Completed

Fri, 13 Jul 2012 12:00:00 EDT

Detection of PitNET Tissue During TSS Using Bevacizumab-800CW

Conditions:   Pituitary Tumor;   Pituitary Adenoma;   Pituitary Macroadenoma
Interventions:   Drug: Bevacizumab-IRDye800CW;   Device: Molecular Fluorescence Endoscopy platform
Sponsor:   University Medical Center Groningen
Recruiting

Mon, 30 Dec 2019 12:00:00 EST

XELOX+Bevacizumab and XELIRI + Bevacizumab Alternative Regimen as First-line Treatment for Advanced Colorectal Cancer

Conditions:   Colorectal Neoplasms;   Chemotherapy
Interventions:   Drug: XELIRI + bevacizumab;   Drug: XELOX + bevacizumab
Sponsors:   Harbin Medical University;   Cancer Institute and Hospital, Chinese Academy of Medical Sciences;   Fudan University;   Sun Yat-sen University;   First Affiliated Hospital of Harbin Medical University;   The Second Affiliated Hospital of Harbin Medical University;   Liaoning Tumor Hospital & Institute;   Shengjing Hospital;   The First Hospital of Jilin University;   The First Affiliated Hospital of Dalian Medical University;   Jilin Provincial Tumor Hospital;   The First People's Hospital of Jingzhou
Unknown status

Fri, 27 Apr 2018 12:00:00 EDT

TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma

Conditions:   Glioblastoma Multiforme;   Glioblastoma;   Malignant Glioma;   GBM
Interventions:   Drug: Bevacizumab;   Device: Optune;   Other: Brain MRI;   Other: Quality of Life Questionnaires
Sponsors:   University of Florida;   NovoCure Ltd.
Terminated

Tue, 26 Jan 2016 12:00:00 EST

A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer

Condition:   Pancreatic Cancer
Intervention:   Drug: bevacizumab [Avastin]
Sponsor:   Hoffmann-La Roche
Completed

Tue, 05 Oct 2010 12:00:00 EDT

Intranasal Submucosal Bevacizumab for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)

Conditions:   HHT;   Morbus Osler;   Epistaxis
Interventions:   Drug: Bevacizumab;   Drug: NaCl
Sponsor:   Medical University of Vienna
Completed

Mon, 14 Mar 2011 12:00:00 EDT

Efficacy and Safety of Bevacizumab/Temsirolimus Combination to Treat Advanced Renal Cell Carcinoma

Condition:   Kidney Cancer
Interventions:   Drug: Bevacizumab;   Drug: Temsirolimus
Sponsor:   Hellenic Cooperative Oncology Group
Terminated

Tue, 21 Dec 2010 12:00:00 EST

A Trial of Bevacizumab in Myelodysplastic Syndromes (Int-1, Int-2 and High Risk According to International Prognostic Scoring System (IPSS)) With Excess of Marrow Blasts

Condition:   Myelodysplastic Syndromes
Intervention:   Drug: BEVACIZUMAB
Sponsor:   Centre Hospitalier Universitaire de Nice
Terminated

Fri, 30 Nov 2007 12:00:00 EST

Safety Study of the Combination of Tandutinib With Temozolomide and Bevacizumab After Radiation and Temozolomide in Patients With Newly Diagnosed With Glioblastoma Multiforme

Condition:   Glioblastoma Multiforme
Intervention:   Drug: Tandutinib, bevacizumab, and temozolomide
Sponsor:   Millennium Pharmaceuticals, Inc.
Withdrawn

Wed, 20 May 2009 12:00:00 EDT

Effect of the Adjunctive IVB Before PRP

Condition:   Diabetic Retinopathy
Intervention:   Drug: bevacizumab
Sponsor:   Kyungpook National University Hospital
Completed

Thu, 05 Jan 2012 12:00:00 EST

Observational Study of Bevacizumab [Avastin] in Patients With Metastatic Colorectal Cancer (AVASTART)

Condition:   Colorectal Cancer
Intervention:   Drug: bevacizumab [Avastin]
Sponsor:   Hoffmann-La Roche
Completed

Thu, 18 Mar 2010 12:00:00 EDT

Gemcitabine Plus Bevacizumab in Locally Recurrent or Metastatic Breast Cancer

Conditions:   Metastatic Breast Cancer;   Locally Advanced Breast Cancer
Interventions:   Drug: Gemcitabine;   Drug: Bevacizumab
Sponsors:   Eli Lilly and Company;   Genentech, Inc.
Completed

Mon, 25 Feb 2008 12:00:00 EST

VEGF Early Imaging for Breast Cancer

Condition:   Breast Cancer
Intervention:   Other: 89Zr-bevacizumab PET
Sponsor:   University Medical Center Groningen
Completed

Thu, 08 Oct 2009 12:00:00 EDT

Combined Intravitreal Injection of Bevacizumab and Fasudil Versus Bevacizumab Alone for Macular Edema Secondary to Retinal Vein Occlusion in Previously Treated Patients

Condition:   Retinal Vein Occlusion
Interventions:   Drug: injection bevacizumab;   Drug: injection Combined Bevacizumab and Fasudil
Sponsor:   Shahid Beheshti University of Medical Sciences
Unknown status

Fri, 05 Jan 2018 12:00:00 EST

Capecitabine, Cetuximab, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer That Cannot Be Removed By Surgery

Condition:   Colorectal Cancer
Interventions:   Biological: bevacizumab;   Biological: cetuximab;   Drug: capecitabine;   Drug: oxaliplatin
Sponsors:   Herbert Hurwitz;   National Cancer Institute (NCI)
Completed

Mon, 13 Feb 2006 12:00:00 EST

Pilot Study of Zirconium-89 Bevacizumab Positron Emission Tomography for Imaging Angiogenesis in Patients With Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy

Condition:   Inflammatory Breast Carcinoma
Interventions:   Drug: 89Zr-bevacizumab;   Procedure: FDG-PET/CT;   Procedure: MRI scan;   Procedure: Tumor biopsies
Sponsors:   Dana-Farber Cancer Institute;   National Cancer Institute (NCI)
Completed

Wed, 10 Jul 2013 12:00:00 EDT

Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a Kras Mutation

Conditions:   Metastatic Colorectal Cancer;   KRAS Gene Mutation
Interventions:   Drug: Onvansertib;   Biological: Bevacizumab;   Drug: FOLFIRI
Sponsor:   Cardiff Oncology
Recruiting

Mon, 04 Feb 2019 12:00:00 EST

Adjuvant Intravitreal Bevacizumab in Pars Plana Vitrectomy for Diabetic Vitreous Hemorrhage

Conditions:   Recurrent;   Hemorrhage
Intervention:   Procedure: bevacizumab injection
Sponsor:   University of Sao Paulo
Unknown status

Mon, 28 Jun 2010 12:00:00 EDT

A Biomarker Study in Patients With HER2-negative Metastatic Breast Cancer Treated With Bevacizumab and Paclitaxel

Condition:   Breast Cancer
Interventions:   Drug: Bevacizumab;   Drug: Paclitaxel
Sponsor:   Theodoros Foukakis
Completed

Wed, 07 Nov 2012 12:00:00 EST

Levocetirizine + Capecitabine + Bevacizumab for Patients With Refractory Colorectal Cancer

Condition:   Colorectal Neoplasms
Interventions:   Drug: Bevacizumab;   Drug: Capecitabine;   Drug: Levocetirizine
Sponsor:   Washington University School of Medicine
Completed

Tue, 06 Nov 2012 12:00:00 EST

Neoadjuvant Chemoradiation With Bevacizumab for Chinese Rectal Cancer Patients

Condition:   Rectal Adenocarcinoma
Interventions:   Drug: Bevacizumab;   Drug: Oxaliplatin;   Drug: 5-FU;   Radiation: Radiotherapy
Sponsor:   Sixth Affiliated Hospital, Sun Yat-sen University
Completed

Wed, 14 Mar 2012 12:00:00 EDT

A+C in Metastatic Lung Adenocarcinoma Cancer

Condition:   Lung Adenocarcinoma Metastatic
Intervention:   Drug: Crizotinib, bevacizumab
Sponsor:   Chinese PLA General Hospital
Unknown status

Thu, 27 Oct 2016 12:00:00 EDT

TACE Combined With Sintilimab and Bevacizumab for Unresectable HCC

Condition:   Hepatocellular Carcinoma Non-resectable
Intervention:   Drug: TACE combined with sintilimab and bevacizumab
Sponsor:   Second Affiliated Hospital of Guangzhou Medical University
Active, not recruiting

Mon, 19 Oct 2020 12:00:00 EDT

Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Abraxane;   Drug: Bevacizumab;   Drug: Carboplatin
Sponsors:   Duke University;   Genentech, Inc.;   Celgene Corporation
Completed

Mon, 28 May 2007 12:00:00 EDT

Lapatinib and Bevacizumab for Metastatic Breast Cancer

Condition:   Neoplasms, Breast
Interventions:   Drug: lapatinib;   Drug: bevacizumab
Sponsor:   Novartis Pharmaceuticals
Completed

Thu, 08 Mar 2007 12:00:00 EST

A Study of Avastin (Bevacizumab) + Xeloda (Capecitabine)as Maintenance Therapy in Patients With HER2-Negative Metastatic Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: bevacizumab [Avastin];   Drug: capecitabine [Xeloda]
Sponsor:   Hoffmann-La Roche
Completed

Fri, 26 Jun 2009 12:00:00 EDT

Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma

Conditions:   Adult Grade III Lymphomatoid Granulomatosis;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Childhood Burkitt Lymphoma;   Childhood Diffuse Large Cell Lymphoma;   Childhood Grade III Lymphomatoid Granulomatosis;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Progressive Hairy Cell Leukemia, Initial Treatment;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Hairy Cell Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Adult T-cell Leukemia/Lymphoma;   Stage IV Childhood Anaplastic Large Cell Lymphoma;   Stage IV Childhood Hodgkin Lymphoma;   Stage IV Childhood Large Cell Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Stage IV Childhood Small Noncleaved Cell Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IVA Mycosis Fungoides/Sezary Syndrome;   Stage IVB Mycosis Fungoides/Sezary Syndrome;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Unspecified Adult Solid Tumor, Protocol Specific;   Unspecified Childhood Solid Tumor, Protocol Specific;   Waldenström Macroglobulinemia
Interventions:   Biological: bevacizumab;   Drug: cediranib maleate
Sponsor:   National Cancer Institute (NCI)
Completed

Wed, 11 Apr 2007 12:00:00 EDT

Bevacizumab in Pats w/ Recurrent ST Brain Metas Who Have Failed Whole Brain Radiation Therapy

Conditions:   Metastatic Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Biological: bevacizumab;   Procedure: quality-of-life assessment
Sponsors:   Northwestern University;   Genentech, Inc.
Completed

Fri, 12 Jul 2013 12:00:00 EDT

Bevacizumab and Vasoconstriction

Conditions:   Hypertension;   Cancer
Intervention:   Drug: Bevacizumab
Sponsor:   Radboud University
Completed

Fri, 26 Jun 2009 12:00:00 EDT

Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma

Conditions:   Melanoma;   Metastatic Melanoma
Interventions:   Drug: Vemurafenib;   Drug: Bevacizumab;   Drug: Cobimetinib
Sponsors:   Melanoma Research Foundation Breakthrough Consortium;   Genentech, Inc.
Terminated

Wed, 21 Dec 2011 12:00:00 EST

A New Agent GM-CT-01 in Combination With 5-FU, Avastin and Leucovorin in Subjects With Colorectal Cancer

Condition:   Colorectal Cancer
Interventions:   Drug: GM-CT-01;   Drug: 5-Fluorouracil, Leukovorin, bevacizumab
Sponsor:   Galectin Therapeutics Inc.
Withdrawn

Tue, 17 Oct 2006 12:00:00 EDT

Intraocular Bevacizumab (Avastin) for Rubeosis Iridis

Conditions:   Glaucoma;   Rubeosis Iridis
Intervention:   Drug: bevacizumab
Sponsor:   Instituto de Olhos de Goiania
Completed

Mon, 12 Nov 2007 12:00:00 EST

Evaluation the Pharmacokinetics, Safety, Tolerability of BCD-021 in Patients With Neovascular Age-related Macular Degeneration

Condition:   Neovascular Age-related Macular Degeneration
Intervention:   Drug: Bevacizumab (BCD-021)
Sponsor:   Biocad
Withdrawn

Thu, 21 May 2015 12:00:00 EDT

Combination of Cisplatin, Docetaxel and Bevacizumab in Patients With Non-small Cell Lung Carcinoma (NSCLC)

Condition:   NSCLC
Interventions:   Drug: Bevacizumab;   Drug: Cisplatin;   Drug: Docetaxel
Sponsors:   Arbeitsgemeinschaft medikamentoese Tumortherapie;   Sanofi;   Roche Pharma AG
Completed

Wed, 08 Jun 2011 12:00:00 EDT

A Study to Evaluate the Effectiveness of 5-Azacitidine and Bevacizumab in Advanced Renal Cell Carcinoma

Condition:   Renal Cell Carcinoma
Interventions:   Drug: Bevacizumab;   Drug: Azacitidine
Sponsors:   University of Kansas Medical Center;   Celgene
Terminated

Wed, 08 Jul 2009 12:00:00 EDT

Recurrent GBM Treated With Neurosurgical Resection and IORT Using the Xoft Axxent eBx System and Bevacizumab

Conditions:   Glioblastoma;   Recurrent Glioblastoma;   GBM;   Recurrent GBM
Interventions:   Radiation: Radiation: Intra-operative Radiation Therapy - IORT;   Drug: Bevacizumab;   Drug: Avastin
Sponsors:   Xoft, Inc.;   Icad, Inc.
Not yet recruiting

Wed, 23 Dec 2020 12:00:00 EST

Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

Conditions:   Recurrent Colon Cancer;   Recurrent Rectal Cancer;   Stage IV Colon Cancer;   Stage IV Rectal Cancer
Interventions:   Drug: sorafenib tosylate;   Biological: bevacizumab
Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
Completed

Thu, 22 Jan 2009 12:00:00 EST

A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma

Condition:   Renal Cell Carcinoma
Interventions:   Drug: Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody;   Drug: Bevacizumab;   Drug: Sunitinib
Sponsor:   Hoffmann-La Roche
Completed

Thu, 14 Nov 2013 12:00:00 EST

The Safety and Efficacy of Pemetrexed Rechallenge With Bevacizumab

Condition:   Advanced Non-small Cell Lung Cancer
Intervention:   Drug: pemetrexed with bevacizumab
Sponsor:   Kobe City General Hospital
Terminated

Fri, 25 Jul 2014 12:00:00 EDT

Bevacizumab in Treating Patients With Recurrent or Persistent Endometrial Cancer

Condition:   Recurrent Endometrial Carcinoma
Interventions:   Biological: bevacizumab;   Other: laboratory biomarker analysis
Sponsors:   National Cancer Institute (NCI);   Gynecologic Oncology Group
Completed

Mon, 13 Mar 2006 12:00:00 EST

Study of Pemetrexed and Bevacizumab in Patients With Head and Neck Cancer

Condition:   Cancer
Interventions:   Drug: Pemetrexed;   Drug: Bevacizumab
Sponsors:   University of Pittsburgh;   Eli Lilly and Company;   Genentech, Inc.
Completed

Thu, 22 Sep 2005 12:00:00 EDT

Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women

Condition:   Breast Cancer
Interventions:   Drug: Letrozole;   Drug: Bevacizumab;   Drug: Fulvestrant
Sponsors:   Spanish Breast Cancer Research Group;   Hoffmann-La Roche;   German Breast Group
Completed

Wed, 17 Oct 2007 12:00:00 EDT

Intravitreal Dexamethasone Implant (Ozurdex) Versus Bevacizumab in Patients With Diabetic Macular Edema Undergoing Cataract Surgery

Conditions:   Diabetic Macular Edema;   Cataract
Intervention:   Drug: Bevacizumab Injection
Sponsors:   Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center;   Allergan;   Doheny Image Reading Center
Withdrawn

Wed, 28 Aug 2019 12:00:00 EDT

FOLFOXIRI With or Without Bevacizumab as First-line Treatment for Unresectable Liver-only Metastatic Colorectal Cancer Patients With RAS Mutation-type

Condition:   Metastatic Colorectal Cancer
Interventions:   Drug: FOLFOXIRI + Bevacizumab;   Drug: FOLFOXIRI
Sponsor:   Sun Yat-sen University
Unknown status

Thu, 29 Jan 2015 12:00:00 EST

Bevacizumab Versus Ranibizumab in Age Related Macular Degeneration

Condition:   Age Related Macular Degeneration
Interventions:   Drug: Ranibizumab (Intravitreal injection);   Drug: Bevacizumab (Intravitreal injection)
Sponsor:   Instituto de Olhos de Goiania
Unknown status

Tue, 17 Nov 2009 12:00:00 EST

Intravitreal Bevacizumab for Neovascular Glaucoma

Conditions:   Neovascular;   Glaucoma
Interventions:   Other: subconjunctival normal saline;   Drug: Avastin
Sponsor:   Shahid Beheshti University of Medical Sciences
Completed

Fri, 06 Oct 2006 12:00:00 EDT

A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma

Condition:   Hepatocellular Carcinoma
Interventions:   Drug: Durvalumab;   Drug: Bevacizumab;   Other: Placebo;   Procedure: Transarterial Chemoembolization (TACE)
Sponsor:   AstraZeneca
Recruiting

Wed, 19 Dec 2018 12:00:00 EST

Atezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients (BEAT)

Condition:   Non-small-cell Lung Cancer Patients
Interventions:   Drug: Atezolizumab;   Drug: Bevacizumab
Sponsor:   Fondazione Ricerca Traslazionale
Not yet recruiting

Fri, 29 Mar 2019 12:00:00 EDT

Bevacizumab and Erlotinib Study in Advanced Ovarian Cancer

Condition:   Ovarian Neoplasms
Interventions:   Drug: bevacizumab;   Drug: erlotinib
Sponsors:   University of Arizona;   Genentech, Inc.
Completed

Mon, 15 Aug 2005 12:00:00 EDT

A Study of Bevacizumab in Combination With Gemcitabine and Carboplatin in Participants With Triple Negative Metastatic Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Bevacizumab;   Drug: Carboplatin;   Drug: Gemcitabine
Sponsor:   Hoffmann-La Roche
Completed

Tue, 14 Sep 2010 12:00:00 EDT

The Effects of RFA in Combination With Second-line Chemotherapy and Bevacizumab on Unresectable CRLM

Condition:   Colorectal Neoplasms Malignant
Interventions:   Combination Product: RFA, bevacizumab and second-line chemotherapy;   Drug: Bevacizumab and second-line chemotherapy
Sponsor:   Nanfang Hospital of Southern Medical University
Recruiting

Wed, 26 Sep 2018 12:00:00 EDT

Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer

Conditions:   Melanoma;   Non-small Cell Lung Cancer;   Brain Metastasis
Intervention:   Drug: Pembrolizumab plus Bevacizumab
Sponsor:   Yale University
Recruiting

Fri, 12 Feb 2016 12:00:00 EST

Bevacizumab, Docetaxel, and Carboplatin in Treating Women With Stage II or Stage III Breast Cancer

Condition:   Breast Cancer
Intervention:   Drug: Avastin, docetaxel, carboplatin
Sponsor:   Severance Hospital
Completed

Fri, 24 Sep 2010 12:00:00 EDT

Intravitreal Bevasizumab VS Sham Treatment in Acute BRVO: A Randomized Clinical Trial

Condition:   Retinal Disease
Intervention:   Drug: Avastin (Bevacizumab)
Sponsor:   Shahid Beheshti University of Medical Sciences
Completed

Fri, 01 Sep 2006 12:00:00 EDT

Sintilimab Combined With Bevacizumab Biosimilar for Potentially Resectable Intermediate HCC

Condition:   Hepatocellular Carcinoma
Interventions:   Drug: Sintilimab;   Drug: Bevacizumab Biosimilar
Sponsor:   Fudan University
Not yet recruiting

Wed, 14 Apr 2021 12:00:00 EDT

Trial of Deforolimus in Combination With Bevacizumab for Patients With Advanced Cancers (8669-010)(COMPLETED)

Condition:   Solid Tumor
Interventions:   Drug: ridaforolimus;   Drug: bevacizumab
Sponsors:   Merck Sharp & Dohme Corp.;   Ariad Pharmaceuticals
Completed

Wed, 29 Oct 2008 12:00:00 EDT

A Study to Evaluate the Efficacy of Bevacizumab Plus Irinotecan in Recurrent Gliomas

Conditions:   Glioblastoma;   Astrocytoma
Intervention:   Drug: Bevacizumab/Irinotecan
Sponsors:   Clinical Research Center for Solid Tumor, Korea;   Seoul National University Hospital
Completed

Tue, 16 Jun 2009 12:00:00 EDT

Preoperative Chemotherapy With Bevacizumab For Potentially Resectable Gastric Cancer With Liver Metastasis

Conditions:   Gastric Cancer;   Liver Metastasis
Interventions:   Drug: Oxaliplatin;Capecitabine;   Drug: Oxaliplatin;Capecitabine;Bevacizumab
Sponsor:   Hebei Medical University
Unknown status

Mon, 14 Oct 2013 12:00:00 EDT

Optimized Chemotherapy Followed by Maintenance With Bevacizumab With or Without Erlotinib in Treating Patients With Metastatic Colorectal Cancer That Cannot be Removed by Surgery (DREAM)

Condition:   Colorectal Cancer
Interventions:   Drug: bevacizumab;   Drug: bevacizumab, erlotinib
Sponsor:   GERCOR - Multidisciplinary Oncology Cooperative Group
Completed

Thu, 15 Dec 2005 12:00:00 EST

S0108 Bevacizumab in Treating Patients With Non-Hodgkin's Lymphoma

Conditions:   Anaplastic Large Cell Lymphoma;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Mantle Cell Lymphoma
Interventions:   Biological: bevacizumab;   Other: laboratory biomarker analysis
Sponsor:   National Cancer Institute (NCI)
Completed

Mon, 27 Jan 2003 12:00:00 EST

Docetaxel, Gemcitabine and Bevacizumab for Metastatic Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Bevacizumab;   Drug: Docetaxel;   Drug: Gemcitabine
Sponsor:   University Hospital of Crete
Completed

Thu, 18 Sep 2008 12:00:00 EDT

Elaboration of a Model for Predicting Efficacy of Monoclonal Antibodies (Cetuximab and Bevacizumab) in Patients With Colorectal Cancer and Liver Metastases

Conditions:   Colorectal Cancer;   Neoplasm Metastasis
Interventions:   Drug: cetuximab;   Drug: bevacizumab
Sponsor:   Hospices Civils de Lyon
Terminated

Thu, 18 May 2006 12:00:00 EDT

Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD

Condition:   Exudative Age-related Macular Degeneration
Interventions:   Drug: 4.0 mg iSONEP;   Drug: 0.5 mg iSONEP;   Drug: 0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea;   Drug: sham injection
Sponsor:   Lpath, Inc.
Completed

Thu, 11 Aug 2011 12:00:00 EDT

Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies

Condition:   Advanced Cancer
Interventions:   Drug: Dasatinib;   Drug: Bevacizumab;   Drug: Paclitaxel
Sponsor:   M.D. Anderson Cancer Center
Active, not recruiting

Wed, 18 Nov 2009 12:00:00 EST

Single or Combined Protocols for NV-AMD

Condition:   Age-Related Macular Degeneration
Intervention:   Drug: Bevacizumab
Sponsors:   University Hospital of Ferrara;   Regione Emilia-Romagna
Completed

Tue, 12 Jun 2018 12:00:00 EDT

Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer

Condition:   Progression Free Survival
Interventions:   Drug: Osimertinib;   Drug: docetaxel, bevacizumab
Sponsor:   Qingdao Central Hospital
Completed

Wed, 09 Nov 2016 12:00:00 EST

Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in pMMR/MSS CRLM Patients

Condition:   Colorectal Cancer Metastatic
Interventions:   Drug: Sintilimab;   Drug: Oxaliplatin;   Drug: Capecitabine;   Drug: Bevacizumab
Sponsor:   Sun Yat-sen University
Recruiting

Fri, 25 Jun 2021 12:00:00 EDT

Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix

Conditions:   Cervical Squamous Cell Carcinoma;   Recurrent Cervical Cancer
Interventions:   Biological: bevacizumab;   Other: laboratory biomarker analysis
Sponsors:   National Cancer Institute (NCI);   Gynecologic Oncology Group
Completed

Mon, 27 Jan 2003 12:00:00 EST

Bevacizumab And Combination Chemotherapy in Rectal Cancer Until Surgery

Condition:   Rectal Cancer
Interventions:   Biological: Bevacizumab;   Drug: Irinotecan;   Drug: Oxaliplatin;   Drug: 5-Fluorouracil
Sponsors:   University College, London;   Cancer Research UK;   Hoffmann-La Roche
Completed

Thu, 26 Jul 2012 12:00:00 EDT

Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma

Conditions:   Stomach Cancer;   Gastric (Stomach) Cancer;   Neoplasm of Cardioesophageal Junction;   Gastrointestinal Stromal Tumor (GIST)
Interventions:   Drug: bevacizumab;   Drug: carboplatin;   Drug: capecitabine
Sponsors:   Pamela L. Kunz;   Genentech, Inc.
Completed

Mon, 27 Oct 2008 12:00:00 EDT

A Comparative Study of BAT1706 and EU Avastin® in Patients With Advanced Non Squamous Non Small Cell Lung Cancer

Condition:   Non-squamous Non-small Cell Lung Cancer
Interventions:   Drug: EU Avastin®;   Drug: BAT1706;   Drug: Paclitaxel;   Drug: carboplatin
Sponsor:   Bio-Thera Solutions
Completed

Mon, 06 Nov 2017 12:00:00 EST

CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)

Condition:   Metastatic Renal Cell Carcinoma
Interventions:   Drug: CRLX101;   Drug: Bevacizumab;   Drug: Standard of Care (Investigator Choice)
Sponsor:   NewLink Genetics Corporation
Completed

Fri, 11 Jul 2014 12:00:00 EDT

Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies

Condition:   Advanced Cancer
Interventions:   Drug: Nab-paclitaxel;   Drug: Bevacizumab;   Drug: Gemcitabine
Sponsor:   M.D. Anderson Cancer Center
Unknown status

Fri, 30 Apr 2010 12:00:00 EDT

Use of Pan-Vascular Endothelial Growth Factor Receptor (Pan-VEGF) Blockade for the Treatment of Retinopathy of Prematurity (ROP) (Compassionate Use BLOCK-ROP)

Condition:   Retinopathy of Prematurity
Intervention:   Drug: Bevacizumab (Avastin)
Sponsor:   Children's Hospital Los Angeles
Temporarily not available

Fri, 27 Mar 2009 12:00:00 EDT

FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer

Condition:   Colorectal Cancer
Interventions:   Drug: FOLIRI;   Drug: FOLIRI plus E7820;   Drug: FOLFIRI plus Bevacizumab
Sponsors:   Eisai Inc.;   PharmaBio Development Inc.
Completed

Mon, 31 May 2010 12:00:00 EDT

Study of Docetaxel, Cisplatin, and Fluorouracil (Modified DCF) With Bevacizumab in Patients With Unresectable or Metastatic Gastroesophageal Adenocarcinoma

Conditions:   Stomach Neoplasms;   Esophageal Neoplasms
Intervention:   Drug: Docetaxel, Cisplatin, Fluorouracil, Bevacizumab, Leucovorin
Sponsors:   Memorial Sloan Kettering Cancer Center;   Sanofi;   Genentech, Inc.
Completed

Thu, 19 Oct 2006 12:00:00 EDT

Bevacizumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Conditions:   Primary Peritoneal Cavity Cancer;   Recurrent Ovarian Epithelial Cancer;   Stage IV Ovarian Epithelial Cancer
Interventions:   Biological: bevacizumab;   Other: laboratory biomarker analysis
Sponsors:   National Cancer Institute (NCI);   Gynecologic Oncology Group
Completed

Mon, 27 Jan 2003 12:00:00 EST

A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)

Condition:   Renal Cell Carcinoma
Interventions:   Drug: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody;   Drug: Bevacizumab;   Drug: Sunitinib
Sponsor:   Hoffmann-La Roche
Active, not recruiting

Mon, 20 Apr 2015 12:00:00 EDT

Xeloda and Bevacizumab to Treat Rectal Cancer

Condition:   Rectal Cancer
Interventions:   Biological: Bevacizumab;   Drug: capecitabine (Xeloda);   Radiation: Rectal Radiotherapy
Sponsors:   Institut Català d'Oncologia;   Hoffmann-La Roche
Completed

Thu, 19 Feb 2009 12:00:00 EST

Real World Study on Erlotinib/Gefitinib Combined With Bevacizumab in Advanced Non-aquamous Non-small Cell Lung Cancer

Condition:   Non Small Cell Lung Cancer
Intervention:   Drug: Erlotinib/Gefitinib combined with Bevacizumab
Sponsor:   Hunan Province Tumor Hospital
Recruiting

Mon, 27 Aug 2018 12:00:00 EDT

Oxaliplatin and Paclitaxel Plus Bevacizumab in Advanced Peritoneal Carcinomatosis

Condition:   Peritoneal Cancer
Interventions:   Drug: Bevacizumab;   Drug: Oxaliplatin;   Drug: Paclitaxel
Sponsor:   M.D. Anderson Cancer Center
Completed

Tue, 26 Jun 2007 12:00:00 EDT

Chemotherapy and Avastin Followed by Maintenance Treatment With Avastin +/- Tarceva

Condition:   Metastatic Colorectal Cancer
Interventions:   Drug: erlotinib (Tarceva);   Drug: bevacizumab (Avastin)
Sponsors:   Lund University Hospital;   Hoffmann-La Roche
Completed

Fri, 18 Jan 2008 12:00:00 EST

VEGF Concentrations After Intravitreal Bevacizumab vs Ranibizumab as a Treatment for Type 1 ROP

Conditions:   Retinopathy of Prematurity Both Eyes;   Retinal Disease;   Premature Birth;   Eye Diseases
Interventions:   Drug: Bevacizumab Injection;   Drug: Ranibizumab Ophthalmic
Sponsors:   Universidad Autonoma de San Luis Potosí;   Hospital Central "Dr. Ignacio Morones Prieto"
Completed

Wed, 10 May 2017 12:00:00 EDT

Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer

Condition:   Recurrent Ovarian Carcinoma
Interventions:   Drug: Bevacizumab;   Drug: Atezolizumab;   Drug: Chemotherapy;   Drug: Placebos
Sponsors:   AGO Research GmbH;   Hoffmann-La Roche
Recruiting

Mon, 27 Nov 2017 12:00:00 EST

Study of Oxaliplatin Plus Bevacizumab in Germ Cell Tumor Patients

Condition:   Neoplasms, Germ Cell and Embryonal
Intervention:   Drug: Bevacizumab and Oxaliplatin
Sponsors:   Indiana University;   Genentech, Inc.
Completed

Sun, 29 Oct 2006 12:00:00 EDT

Intravitreal Bevacizumab for Non-Arteritic Anterior Ischemic Optic Neuropathy

Condition:   Non-arteritic Anterior Ischemic Optic Neuropathy
Intervention:   Drug: Intra-vitreal injection of bevacizumab (1.25mg/0.05ml)
Sponsor:   Mount Sinai Hospital, Canada
Unknown status

Mon, 22 Dec 2008 12:00:00 EST

A Study to Establish the Safety and Tolerability of Zimura® (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)

Condition:   Idiopathic Polypoidal Choroidal Vasculopathy
Intervention:   Drug: Zimura
Sponsor:   Ophthotech Corporation
Completed

Wed, 25 Mar 2015 12:00:00 EDT

Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)

Condition:   Central Retinal Vein Occlusion
Interventions:   Drug: aflibercept;   Drug: bevacizumab
Sponsors:   The Emmes Company, LLC;   National Eye Institute (NEI);   Milton S. Hershey Medical Center;   University of Wisconsin, Madison
Completed

Fri, 25 Oct 2013 12:00:00 EDT

Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer

Condition:   Locally Recurrent or Metastatic Breast Cancer
Interventions:   Drug: Imetelstat sodium;   Drug: Bevacizumab;   Drug: Paclitaxel
Sponsor:   Geron Corporation
Completed

Thu, 09 Dec 2010 12:00:00 EST

A Study on the Efficacy and Safety of Bevacizumab in Untreated Patients With Locally Advanced Cervical Cancer

Condition:   Disease Free Survival
Interventions:   Drug: bevacizumab;   Drug: DDP;   Drug: Docetaxel;   Radiation: radiotherapy
Sponsor:   Air Force Military Medical University, China
Recruiting

Fri, 25 Oct 2019 12:00:00 EDT

Efficacy and Safety of Bevacizumab Plus Sorafenib for the Third-line Treatment in Metastatic Renal Cancer Patients

Condition:   Metastatic Renal Cell Carcinoma
Interventions:   Drug: Bevacizumab;   Drug: Sorafenib
Sponsor:   Beijing Cancer Hospital
Unknown status

Mon, 05 Jan 2015 12:00:00 EST

Phase II Study Alimta and Gemzar + Avastin as First Line Chemotherapy for Elderly Patients With Stage IIIB/IV NSCLC

Condition:   Non-Small Cell Lung Cancer
Intervention:   Drug: Pemetrexed and Gemcitabine plus Bevacizumab
Sponsors:   Accelerated Community Oncology Research Network;   Eli Lilly and Company;   Genentech, Inc.
Completed

Fri, 17 Aug 2007 12:00:00 EDT

Phase II Trial of Combination Therapy With Irinotecan, S-1, and Bevacizumab (IRIS/Bev) in Patients With Unresectable or Recurrent Colorectal Cancer

Condition:   Colorectal Cancer
Intervention:   Drug: S-1, Irinotecan, Bevacizumab
Sponsor:   Taiho Pharmaceutical Co., Ltd.
Completed

Fri, 07 Dec 2007 12:00:00 EST

Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma

Conditions:   Glioblastoma Multiforme;   Anaplastic Astrocytoma
Intervention:   Drug: Bevacizumab and Carboplatin
Sponsor:   Northwell Health
Suspended

Fri, 01 Jul 2011 12:00:00 EDT

NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse

Conditions:   Adult Brain Glioblastoma;   Recurrent Adult Brain Neoplasm
Interventions:   Procedure: Electric Field Therapy;   Biological: Bevacizumab;   Drug: Carmustine;   Other: Quality-of-Life Assessment
Sponsors:   University of California, Davis;   National Cancer Institute (NCI);   NovoCure Ltd.
Withdrawn

Wed, 28 Jan 2015 12:00:00 EST

A Pilot Trial of GI-4000 Plus Bevacizumab and Either FOLFOX or FOLFIRI

Condition:   Colon Cancer
Interventions:   Drug: chemotherapy and GI-4000;   Drug: GI-4000
Sponsors:   Georgetown University;   GlobeImmune
Terminated

Fri, 25 Mar 2011 12:00:00 EDT

Safety and Efficacy Study of Gemcitabine Plus Bevacizumab in Patients With Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Conditions:   Fallopian Tube Neoplasms;   Ovarian Cancer;   Primary Peritoneal
Intervention:   Drug: Gemcitabine/Bevacizumab
Sponsors:   Emory University;   Genentech, Inc.
Withdrawn

Wed, 26 May 2010 12:00:00 EDT

Doxil, Bevacizumab and Temsirolimus Trial

Condition:   Advanced Cancer
Interventions:   Drug: Doxil;   Drug: Bevacizumab;   Drug: Temsirolimus
Sponsor:   M.D. Anderson Cancer Center
Completed

Mon, 29 Sep 2008 12:00:00 EDT

Intravenous and Intraperitoneal Paclitaxel, Intraperitoneal Cisplatin, and Intravenous Bevacizumab for the Initial Treatment of Optimal Stage II or III Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

Conditions:   Ovarian Cancer;   Primary PERITONEUM;   Fallopian Tube Cancer
Intervention:   Drug: Paclitaxel,Cisplatin, Bevacizumab
Sponsors:   Memorial Sloan Kettering Cancer Center;   Genentech, Inc.
Completed

Tue, 08 Jan 2008 12:00:00 EST

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)

Condition:   Colorectal Cancer
Interventions:   Drug: Bevacizumab;   Drug: Capecitabine/Oxaliplatin;   Drug: Fluorouracil/Folinic Acid/Oxaliplatin;   Drug: Capecitabine;   Drug: Fluorouracil/Folinic Acid/Irinotecan;   Drug: Fluorouracil +/- Folinic Acid
Sponsor:   Hoffmann-La Roche
Completed

Mon, 09 Jan 2012 12:00:00 EST

Avastin for Post-Photocoagulation Macular Edema

Condition:   Macular Edema
Interventions:   Drug: Bevacizumab;   Procedure: Panretinal Photocoagulation
Sponsor:   Asociación para Evitar la Ceguera en México
Completed

Thu, 04 Dec 2008 12:00:00 EST

Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer

Conditions:   Epithelial Ovarian Cancer;   Primary Peritoneal Carcinoma
Interventions:   Drug: Bevacizumab;   Drug: Abraxane
Sponsors:   Accelerated Community Oncology Research Network;   Genentech, Inc.;   Celgene Corporation
Completed

Tue, 05 Dec 2006 12:00:00 EST

Strategies for Management of Corneal Neovascularisation

Condition:   Corneal Neovascularisation
Interventions:   Device: Fine Needle Diathermy;   Drug: Bevacizumab
Sponsor:   University of Nottingham
Unknown status

Tue, 03 Nov 2015 12:00:00 EST

Preop Chemoradiation Resectable Pancreas

Condition:   Pancreatic Neoplasms
Interventions:   Drug: Avastin (Bevacizumab);   Drug: Gemcitabine;   Procedure: Radiation Therapy
Sponsors:   M.D. Anderson Cancer Center;   Genentech, Inc.
Completed

Wed, 14 Jun 2006 12:00:00 EDT

Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium

Conditions:   Cervical Cancer;   Endometrial Cancer
Interventions:   Drug: Rucaparib;   Drug: Bevacizumab
Sponsors:   University of Oklahoma;   Clovis Oncology, Inc.
Active, not recruiting

Mon, 26 Mar 2018 12:00:00 EDT

Phase IB Study of Gemcitabine, Docetaxel and Bevacizumab in Patients With Soft Tissue Sarcoma

Condition:   Sarcoma
Intervention:   Drug: Gemcitabine, Docetaxel and Bevacizumab
Sponsor:   New Mexico Cancer Care Alliance
Completed

Thu, 12 Jan 2006 12:00:00 EST

Efficacy and Safety of Olaparib, Olaparib + Bevacizumab Compared to Bevacizumab + 5-Fluorouracil (FU)

Condition:   Metastatic Colorectal Cancer
Interventions:   Drug: Olaparib;   Drug: 5-FU;   Drug: Bevacizumab
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting

Thu, 02 Jul 2020 12:00:00 EDT

A BRIDGING STUDY OF PF-06439535 (CN) PLUS PACLITAXEL-CARBOPLATIN VERSUS BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN IN NSCLC

Condition:   Advanced Non-squamous NSCLC
Interventions:   Drug: PF-06439535 (CN);   Drug: Bevacizumab-EU;   Drug: Paclitaxel;   Drug: Carboplatin
Sponsor:   Pfizer
Terminated

Fri, 27 Mar 2020 12:00:00 EDT

Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma

Condition:   Melanoma
Interventions:   Drug: Bevacizumab Plus Ipilimumab Cohort 1;   Drug: Bevacizumab Plus Ipilimumab Cohort 2;   Drug: Bevacizumab Plus Ipilimumab Cohort 3;   Drug: Bevacizumab Plus Ipilimumab Cohort 4
Sponsors:   Dana-Farber Cancer Institute;   Genentech, Inc.;   Bristol-Myers Squibb
Active, not recruiting

Thu, 13 Nov 2008 12:00:00 EST

Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme

Conditions:   Adult Brain Glioblastoma;   Glioblastoma Multiforme
Interventions:   Biological: SL-701; poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl cellulose);   Drug: Bevacizumab
Sponsor:   Stemline Therapeutics, Inc.
Completed

Wed, 05 Mar 2014 12:00:00 EST

A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Aromatase Inhibitor;   Drug: Bevacizumab;   Drug: Epirubicine;   Drug: 5-Fluorouracil (5FU);   Drug: Cyclophosphamide;   Drug: Paclitaxel;   Drug: Docetaxel
Sponsors:   Hoffmann-La Roche;   Norwegian Radium Hospital
Active, not recruiting

Thu, 16 Oct 2008 12:00:00 EDT

Weekly Paclitaxel/Carboplatin/Bevacizumab as First Line Therapy for Triple Negative Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Carboplatin;   Drug: Bevacizumab;   Drug: Paclitaxel
Sponsors:   Hellenic Oncology Research Group;   University Hospital of Crete
Completed

Thu, 05 Jun 2008 12:00:00 EDT

Trial Evaluating Efficacy and Safety of Bevacizumab (Avastin®/Zeribev®) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort

Condition:   COVID19 Pneumonia
Intervention:   Drug: Bevacizumab Injection
Sponsor:   Assistance Publique - Hôpitaux de Paris
Not yet recruiting

Tue, 14 Apr 2020 12:00:00 EDT

Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma

Condition:   Clear Cell Renal Cell Carcinoma
Interventions:   Drug: Bevacizumab;   Drug: Erlotinib;   Drug: Imatinib
Sponsors:   SCRI Development Innovations, LLC;   Genentech, Inc.;   Novartis
Completed

Mon, 19 Sep 2005 12:00:00 EDT

Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer

Condition:   Recurrent Endometrial Carcinoma
Interventions:   Biological: bevacizumab;   Drug: temsirolimus
Sponsors:   National Cancer Institute (NCI);   NRG Oncology
Completed

Mon, 28 Jul 2008 12:00:00 EDT

Study of Combined RHUMAB VEGF and Capecitabine-based Chemoradiation for Patients With Locally Advanced Pancreatic Cancer

Condition:   Pancreatic Cancer
Interventions:   Drug: Bevacizumab;   Drug: Capecitabine;   Radiation: Radiotherapy
Sponsors:   M.D. Anderson Cancer Center;   Genentech, Inc.
Completed

Wed, 16 Oct 2002 12:00:00 EDT

OXC401-PO1s/WVU 1309 - A Pilot Study of Fosbretabulin With Bevacizumab in Recurrent High-Grade Gliomas

Condition:   Central Nervous System Tumors
Intervention:   Drug: Bevacizumab, CA4P
Sponsor:   West Virginia University
Withdrawn

Wed, 20 Jan 2010 12:00:00 EST

Docetaxel Plus Bevacizumab for Elderly Patients With Stage IV NSCLC

Condition:   NSCLC
Interventions:   Drug: Docetaxel;   Drug: Bevacizumab
Sponsor:   Hellenic Oncology Research Group
Terminated

Wed, 02 Jul 2014 12:00:00 EDT

Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma

Condition:   Endometrial Cancer
Interventions:   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: bevacizumab
Sponsors:   David O'Malley;   Genentech, Inc.
Completed

Thu, 09 Aug 2007 12:00:00 EDT

BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma

Condition:   Pleural Mesothelioma Malignant Advanced
Interventions:   Drug: Carboplatin;   Drug: Pemetrexed;   Drug: Bevacizumab;   Drug: Atezolizumab
Sponsors:   European Thoracic Oncology Platform;   Hoffmann-La Roche
Recruiting

Mon, 03 Dec 2018 12:00:00 EST

Dose-escalation, Safety, Pharmacokinetics Study of AVE8062 Combined With Bevacizumab in Patients With Advanced Solid Tumors

Condition:   Neoplasms, Malignant
Interventions:   Drug: Ombrabulin (AVE8062);   Drug: bevacizumab
Sponsor:   Sanofi
Completed

Thu, 02 Sep 2010 12:00:00 EDT

Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer

Condition:   Endometrial Cancer
Interventions:   Drug: Bevacizumab;   Drug: Atezolizumab
Sponsors:   University of Oklahoma;   Genentech, Inc.
Recruiting

Wed, 16 May 2018 12:00:00 EDT

Phase I/II Study of Weekly Docetaxel and Cisplatin Together With Capecitabine and Bevacizumab in Advanced Gastric Cancer

Condition:   Advanced Gastric Cancer
Intervention:   Drug: Docetaxel, Cisplatin, Capecitabine, Bevacizumab
Sponsor:   Rabin Medical Center
Unknown status

Wed, 18 Feb 2009 12:00:00 EST

Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma

Conditions:   Renal Cell Carcinoma;   Kidney Cancer
Interventions:   Drug: Capecitabine;   Drug: Gemcitabine;   Drug: Bevacizumab
Sponsors:   M.D. Anderson Cancer Center;   Eli Lilly and Company
Completed

Wed, 04 Jul 2007 12:00:00 EDT

A Randomized Phase III Study Comparing Maintenance Treatment With Fluoropyrimidine + Bevacizumab Versus Fluoropyrimidine After Induction Chemotherapy for a Metastatic Colorectal Cancer

Condition:   Patients With Metastatic Colorectal Cancer
Interventions:   Drug: Fluoropyrimidine;   Drug: Bevacizumab
Sponsor:   Centre Hospitalier Universitaire Dijon
Not yet recruiting

Thu, 05 Dec 2019 12:00:00 EST

Salvage Chemotherapy for Poor Prognosis Germ Cell Tumors

Condition:   Germ Cell Tumor
Interventions:   Drug: Bevacizumab;   Drug: ICE chemotherapy regimen
Sponsor:   Assistance Publique - Hôpitaux de Paris
Unknown status

Tue, 22 Oct 2013 12:00:00 EDT

Study of Bevacizumab With Different Manufacturing Process in Healthy Male Subjects

Condition:   Healthy Male Subjects
Interventions:   Drug: bevacizumab with new manufacturing process.;   Drug: bevacizumab with old manufacturing process.
Sponsor:   Innovent Biologics (Suzhou) Co. Ltd.
Recruiting

Fri, 13 Aug 2021 12:00:00 EDT

Multi-Centre, Observational Study on Safety of Bevacizumab Biosimilars in Clinical Practice Among Chinese Patients

Condition:   Biosimilar
Intervention:   Drug: Bevacizumab
Sponsor:   Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Recruiting

Tue, 17 Aug 2021 12:00:00 EDT

Docetaxel (Taxotere), Vinorelbine, and Bevacizumab, as Adjuvant Chemotherapy for Patients With Resected Stage I-III Non-small Cell Lung Cancer

Condition:   Lung Cancer
Intervention:   Drug: Bevacizumab (Avastin), Taxotere (Docetaxel), Vinorelbine Tartrate (Navelbine)
Sponsors:   Memorial Sloan Kettering Cancer Center;   Sanofi
Completed

Fri, 09 May 2008 12:00:00 EDT

A Trial of Paclitaxel and Bevacizumab vs. Gemcitabine, Paclitaxel, and Bevacizumab in Advanced Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: gemcitabine;   Drug: paclitaxel;   Drug: bevacizumab
Sponsors:   Eli Lilly and Company;   Genentech, Inc.
Completed

Wed, 03 May 2006 12:00:00 EDT

Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer

Condition:   Prostate Cancer
Intervention:   Drug: RAD001, Docetaxel, Bevacizumab
Sponsors:   University of Southern California;   Novartis;   Genentech, Inc.
Completed

Mon, 17 Dec 2007 12:00:00 EST

Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors

Condition:   Advanced/Metastatic Solid Tumors
Interventions:   Drug: Selicrelumab;   Drug: Vanucizumab;   Drug: Bevacizumab
Sponsor:   Hoffmann-La Roche
Completed

Wed, 27 Jan 2016 12:00:00 EST

A SINGLE-DOSE, 2-ARM, PHARMACOKINETIC STUDY OF PF-06439535 (CN) AND EUROPEAN UNION SOURCED BEVACIZUMAB IN CHINESE HEALTHY MALE VOLUNTEERS

Condition:   Pharmacokinetics
Interventions:   Drug: PF-06439535 (CN);   Drug: bevacizumab - EU
Sponsor:   Pfizer
Withdrawn

Mon, 14 Oct 2019 12:00:00 EDT

Study of Interleukin-2, Interferon-alpha and Bevacizumab in Metastatic Kidney Cancer

Condition:   Metastatic Renal Cell Carcinoma
Interventions:   Drug: Interleukin-2;   Drug: Interferon Alfa-2b;   Drug: Bevacizumab
Sponsors:   University of Aarhus;   Danish Renal Cancer Study Group
Unknown status

Tue, 11 Jan 2011 12:00:00 EST

Simultaneous Therapy With Intravitreal Dexamethasone Implant and Bevacizumab for the Treatment of Macular Edema

Condition:   Macular Edema
Intervention:   Drug: simultaneous treatment with intravitreal injection of bevacizumab 1.25mg and intravitreal implant of dexamethasone 0.7mg.
Sponsor:   Retina Clinic, Sao Paulo, Brazil
Completed

Tue, 08 Dec 2015 12:00:00 EST

The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)

Conditions:   Endometrial Cancer;   Uterine Carcinosarcoma
Interventions:   Drug: Rucaparib;   Drug: Bevacizumab;   Drug: Atezolizumab
Sponsors:   Medical College of Wisconsin;   Genentech, Inc.;   Clovis Oncology, Inc.
Active, not recruiting

Wed, 03 Oct 2018 12:00:00 EDT

Study of PD-1 Antibody and Bevacizumab in the Treatment of High-risk GTN After Combined Chemotherapy

Condition:   Gestational Trophoblastic Neoplasia
Intervention:   Drug: PD-1 inhibitor, bevacizumab
Sponsor:   Women's Hospital School Of Medicine Zhejiang University
Not yet recruiting

Tue, 23 Mar 2021 12:00:00 EDT

A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Participants With Recurrent Glioblastoma

Condition:   Glioblastoma
Interventions:   Drug: Bevacizumab;   Drug: Onartuzumab;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed

Mon, 02 Jul 2012 12:00:00 EDT

Study of Oxaliplatin, Capecitabine and Bevacizumab as First Line Treatment for Patients With Advanced Colorectal Cancer

Condition:   Colorectal Cancer
Interventions:   Drug: Oxaliplatin;   Drug: Bevacizumab;   Drug: Capecitabine
Sponsors:   University of Southern California;   Hoffmann-La Roche;   Genentech, Inc.
Completed

Mon, 12 Sep 2005 12:00:00 EDT

A Phase II Study of Bevacizumab, Irinotecan and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer

Condition:   Colorectal Cancer
Interventions:   Drug: Bevacizumab;   Drug: Irinotecan;   Drug: Capecitabine
Sponsors:   University Health Network, Toronto;   Hoffmann-La Roche
Completed

Thu, 07 Jun 2007 12:00:00 EDT

Efficacy and Safety of Bevacizumab (Avastin®) Combined to Weekly Paclitaxel Followed by Bevacizumab (Avastin®) Alone in Patients With Relapsed Ovarian Sex-cord Stromal Tumours (ALIENOR)

Condition:   Ovarian Sex-cord Stromal Tumor
Interventions:   Drug: Paclitaxel;   Drug: Bevacizumab
Sponsors:   ARCAGY/ GINECO GROUP;   Roche Pharma AG
Completed

Thu, 17 Jan 2013 12:00:00 EST

Carboplatin Taxol Avastin in Ovarian Cancer (OVCA)

Condition:   Ovarian Cancer
Interventions:   Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Bevacizumab
Sponsors:   Massachusetts General Hospital;   Women and Infants Hospital of Rhode Island
Completed

Fri, 12 Aug 2005 12:00:00 EDT

Intravitreal Bevacizumab in Agioid Streaks

Conditions:   Angioid Streaks;   Choroidal Neovascularization
Intervention:   Drug: intravitreal injection
Sponsor:   University of Campania "Luigi Vanvitelli"
Completed

Mon, 04 Dec 2006 12:00:00 EST

To Compare Anti-VEGF Monotherapy With Anti-VEGF and EPM Grid Laser Combination Therapy for Diabetic Macular Edema

Condition:   Diabetic Macula Edema
Interventions:   Procedure: End-Point-Management grid laser;   Drug: ranibizumab;   Drug: Bevacizumab
Sponsors:   The University of Hong Kong;   Nagoya City University;   Asahikawa Medical College;   University of Fukui;   Eguchi Eye Clinic;   Kyoto University;   Nagasaki University;   Osaka Medical College;   Kyushu University;   Tokyo Medical University Hachioji Medical Centre;   Hokkaido University;   Kyorin University;   Inje University;   Pusan National University;   Kyungpook National University Hospital;   Chungnam National University Hospital;   Sun Cheon Hyang University;   Kyunghee University;   Yeungnam University Hospital;   Korea University;   National University Hospital, Singapore;   Yamagata University
Unknown status

Thu, 04 Jun 2015 12:00:00 EDT

Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma

Conditions:   Esophageal Neoplasms;   Stomach Neoplasms;   Neoplasm Metastasis
Intervention:   Drug: capecitabine (Xeloda), oxaliplatin and bevacizumab (Avastin)
Sponsors:   Duke University;   Hoffmann-La Roche;   Sanofi;   Genentech, Inc.
Completed

Wed, 14 Mar 2007 12:00:00 EDT

Phase 2 Study of Gemzar, Taxol & Avastin Combination as 1st Line Treatment for Metastatic Breast Cancer

Conditions:   Breast Cancer;   Metastatic Breast Cancer
Interventions:   Drug: Gemcitabine;   Drug: Paclitaxel;   Drug: Bevacizumab
Sponsors:   George Albert Fisher;   Genentech, Inc.;   Eli Lilly and Company
Completed

Thu, 23 Nov 2006 12:00:00 EST

Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers

Condition:   Neuroendocrine Carcinoma
Interventions:   Drug: Bevacizumab;   Drug: Pertuzumab;   Drug: Sandostatin LAR® Depot
Sponsors:   SCRI Development Innovations, LLC;   Genentech, Inc.
Completed

Wed, 12 May 2010 12:00:00 EDT

Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non-Small Cell Lung Cancer

Condition:   Lung Neoplasm Malignant
Interventions:   Drug: sintilimab;   Drug: bevacizumab
Sponsor:   Ruijin Hospital
Not yet recruiting

Thu, 22 Jul 2021 12:00:00 EDT

Paclitaxel, Bevacizumab and Pemetrexed in Patients With Untreated, Advanced Non-Small Cell Lung Cancer Using Web-Based Data Collection, Patient Self-Reporting of Adverse Effects and Automated Response Assessment

Condition:   Lung Cancer
Interventions:   Drug: Paclitaxel;   Drug: Pemetrexed;   Drug: Bevacizumab
Sponsor:   Memorial Sloan Kettering Cancer Center
Completed

Fri, 12 Dec 2008 12:00:00 EST

Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer

Condition:   Prostate Cancer
Interventions:   Drug: Docetaxel;   Drug: Bevacizumab;   Drug: ADT;   Drug: Bicalutamide
Sponsors:   Dana-Farber Cancer Institute;   Brigham and Women's Hospital;   Beth Israel Deaconess Medical Center;   Genentech, Inc.
Completed

Tue, 15 Apr 2008 12:00:00 EDT

Cohort Study to Assess Impact of Chemotherapy Plus Bevacizumab on Health Related Quality of Life in First Line Metastatic Colorectal Cancer

Conditions:   Metastatic Colorectal Cancer;   Quality of Life
Intervention:   Drug: Bevacizumab
Sponsor:   Centre Hospitalier Universitaire de Besancon
Unknown status

Fri, 22 Jul 2016 12:00:00 EDT

Topical Bevacizumab for Preventing Recurrent Pterygium

Conditions:   Pterygium;   Bevacizumab;   VEGF;   Anti-VEGF
Interventions:   Drug: bevacizumab eye drop 0.05%;   Drug: normal saline 0.9%
Sponsor:   Chulalongkorn University
Completed

Thu, 10 Mar 2011 12:00:00 EST

Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer

Condition:   Recurrent Ovarian Cancer
Interventions:   Drug: Bevacizumab;   Drug: Paclitaxel;   Drug: Carboplatin;   Drug: pegylated liposomal doxorubicin;   Drug: Gemcitabine
Sponsors:   National Cancer Institute, Naples;   Mario Negri Institute for Pharmacological Research
Active, not recruiting

Fri, 01 Mar 2013 12:00:00 EST

A Study to Evaluate Avastin in Patients Treated in a Previous Genentech-Sponsored Cancer Study

Conditions:   Breast Cancer;   Colorectal Cancer;   Metastases
Intervention:   Drug: Avastin (bevacizumab)
Sponsor:   Genentech, Inc.
Completed

Thu, 18 Nov 2004 12:00:00 EST

Multimodality Treatment for Patients With Resectable Non-Small Cell Lung Cancer (NSCLC) - BEACON Study: Bevacizumab and Chemotherapy for Operable NSCLC

Condition:   Carcinoma, Non-Small-Cell Lung
Interventions:   Drug: Pre-surgical Treatment with Bevacizumab plus Chemotherapy;   Drug: Pre-Surgical Docetaxel and Cisplatin and Adjuvant Bevacizumab
Sponsor:   Memorial Sloan Kettering Cancer Center
Completed

Tue, 16 Aug 2005 12:00:00 EDT

Atezolizumab Monotherapy and Consequent Therapy With Atezolizumab Plus Bevacizumab for NSCLC

Condition:   Non Small Cell Lung Cancer
Interventions:   Drug: Atezolizumab;   Drug: Bevacizumab
Sponsor:   Samsung Medical Center
Unknown status

Mon, 06 Aug 2018 12:00:00 EDT

Intravitreal Bevacizumab for Nonproliferative Diabetic Retinopathy

Condition:   Non-proliferative Diabetic Retinopathy
Interventions:   Drug: Intravitreal Bevacizumab IVB;   Other: Follow-up with regular examination for determination of DR progression
Sponsor:   Shahid Beheshti University of Medical Sciences
Not yet recruiting

Thu, 13 Aug 2020 12:00:00 EDT

Evaluation of the Irinotecan/Bevacizumab Association for Naive Unresectable Glioblastoma

Condition:   Naive Unresectable Glioblastoma
Interventions:   Drug: Avastin + Campto / radiotherapy + Temodal + Avastin (4 cures);   Drug: Temodal/radiotherapy
Sponsors:   Centre Georges Francois Leclerc;   National Cancer Institute, France;   Association de Neuro-Oncologues d'Expression Francaise;   UNICANCER;   Hoffmann-La Roche;   Pfizer
Completed

Tue, 01 Dec 2009 12:00:00 EST

Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer

Conditions:   Chromophobe Renal Cell Carcinoma;   Clear Cell Renal Cell Carcinoma;   Papillary Renal Cell Carcinoma;   Recurrent Renal Cell Carcinoma;   Sarcomatoid Renal Cell Carcinoma;   Stage IV Renal Cell Cancer
Interventions:   Biological: Bevacizumab;   Drug: Sorafenib Tosylate;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis
Sponsor:   National Cancer Institute (NCI)
Completed

Thu, 04 Aug 2005 12:00:00 EDT

A Study to Evaluate Avastin in Combination With Standard Chemotherapy to Treat Colorectal Cancer

Condition:   Colorectal Cancer
Intervention:   Drug: Avastin (bevacizumab)
Sponsor:   Genentech, Inc.
Completed

Mon, 25 Apr 2005 12:00:00 EDT

Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer

Conditions:   Breast Neoplasms;   Neoplasm Metastasis
Interventions:   Drug: ABI-007 (Abraxane);   Drug: bevacizumab
Sponsor:   Celgene
Terminated

Wed, 25 Jan 2006 12:00:00 EST

Bevacizumab and Temsirolimus in Patients With Advanced Malignancy

Condition:   Advanced Cancer
Interventions:   Drug: Bevacizumab;   Drug: Temsirolimus;   Procedure: Additional Blood Drawn;   Procedure: Biopsy;   Procedure: DCE-MRI Scan
Sponsor:   M.D. Anderson Cancer Center
Completed

Fri, 08 Feb 2008 12:00:00 EST

Metronomic Low-Dose Cyclophosphamide and Methotrexate With or Without Bevacizumab in Treating Women With Metastatic Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: bevacizumab;   Drug: cyclophosphamide;   Drug: methotrexate
Sponsors:   Dana-Farber Cancer Institute;   National Cancer Institute (NCI);   Genentech, Inc.
Completed

Mon, 17 May 2004 12:00:00 EDT

TEACO: Taxotere, Eloxatin, Avastin in Cancer of the Ovary

Condition:   Ovarian Cancer
Interventions:   Drug: Bevacizumab (Avastin®);   Drug: Docetaxel (Taxotere®);   Drug: Oxaliplatin (Eloxatin®)
Sponsor:   Sanofi
Completed

Mon, 27 Feb 2006 12:00:00 EST

Photodynamic Therapy Combined With Bevacizumab vs Bevacizumab Alone for Neovascular Age-Related Macular Degeneration

Condition:   Neovascular Age-Related Macular Degeneration
Intervention:   Drug: Bevacizumab (Avastin), Verteporfin (Visudyne)
Sponsors:   University of Padova;   Department of Ophthalmology, Conegliano Hospital, Treviso, Italy
Unknown status

Thu, 12 Jun 2008 12:00:00 EDT

Perioperative Chemotherapy With Bevacizumab for Colorectal Carcinomatosis

Condition:   Colorectal Neoplasms
Interventions:   Drug: perioperative chemotherapy plus bevacizumab;   Procedure: cytoreductive surgery;   Drug: Intraperitoneal Oxaliplatin
Sponsor:   University Hospital, Ghent
Unknown status

Thu, 26 Mar 2015 12:00:00 EDT

An Extension Study to Evaluate Avastin in Patients Treated in a Previous Genentech-Sponsored Cancer Study

Condition:   Cancer
Intervention:   Drug: Avastin (bevacizumab)
Sponsor:   Genentech, Inc.
Completed

Mon, 25 Apr 2005 12:00:00 EDT

Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer

Condition:   Colorectal Cancer
Interventions:   Drug: Folfox plus Bevacizumab and reolysin;   Drug: Folfox plus Bevacizumab
Sponsors:   Canadian Cancer Trials Group;   Oncolytics Biotech
Completed

Tue, 19 Jun 2012 12:00:00 EDT

Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary Tumors

Conditions:   Cholangiocarcinoma of the Extrahepatic Bile Duct;   Cholangiocarcinoma of the Gallbladder;   Gastrointestinal Cancer;   Recurrent Extrahepatic Bile Duct Cancer;   Recurrent Gallbladder Cancer;   Unresectable Extrahepatic Bile Duct Cancer;   Unresectable Gallbladder Cancer
Interventions:   Drug: erlotinib hydrochloride;   Biological: bevacizumab
Sponsor:   National Cancer Institute (NCI)
Completed

Thu, 27 Jul 2006 12:00:00 EDT

Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma

Condition:   Mesothelioma
Intervention:   Drug: Bevacizumab, Pemetrexed, Carboplatin
Sponsor:   Armando Santoro, MD
Completed

Tue, 05 Dec 2006 12:00:00 EST

Adjuvant Xeloda Plus Eloxatin +/- Avastin After Radical Resection of Liver Metastasis of Colorectal Cancer

Conditions:   Colorectal Cancer;   Liver Metastases
Interventions:   Drug: oxaliplatin+capecitabine;   Drug: Oxaliplatin+capecitabine+bevacizumab
Sponsors:   Dutch Colorectal Cancer Group;   Sanofi;   Roche Pharma AG
Terminated

Thu, 02 Nov 2006 12:00:00 EST

An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of mFOLFOX6 + Bevacizumab Versus mFOLFOX6 + Panitumumab Therapy in Patients With Chemotherapy-naïve Unresectable Advanced or Recurrent Colorectal Cancer

Condition:   Colorectal Cancer
Interventions:   Drug: oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab;   Drug: oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab
Sponsor:   Takeda
Active, not recruiting

Fri, 20 Mar 2015 12:00:00 EDT

A Study to Evaluate Avastin in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer

Condition:   Colorectal Cancer
Intervention:   Drug: Avastin (Bevacizumab)
Sponsor:   Genentech, Inc.
Completed

Tue, 26 Apr 2005 12:00:00 EDT

Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma

Condition:   Glioblastoma
Interventions:   Drug: Capecitabine;   Drug: Bevacizumab
Sponsor:   Case Comprehensive Cancer Center
Active, not recruiting

Mon, 01 Feb 2016 12:00:00 EST

Bevacizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Conditions:   B-cell Chronic Lymphocytic Leukemia;   Refractory Chronic Lymphocytic Leukemia
Intervention:   Biological: bevacizumab
Sponsor:   National Cancer Institute (NCI)
Completed

Mon, 13 Feb 2006 12:00:00 EST

Prevention of Vision Loss in Patients With Age-Related Macular Degeneration (AMD) by Intravitreal Injection of Bevacizumab and Ranibizumab

Condition:   Age-Related Neovascular Macular Degeneration
Interventions:   Drug: bevacizumab;   Drug: ranibizumab
Sponsors:   Klinikum Bremen-Mitte, gGmbH;   Kompetenzzentrum für Klinische Studien, Bremen
Unknown status

Fri, 16 Nov 2007 12:00:00 EST

Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors

Conditions:   Glioblastoma;   Gliosarcoma;   Anaplastic Astrocytoma;   Anaplastic Oligodendroglioma;   Anaplastic Mixed Oligoastrocytoma
Interventions:   Biological: Bevacizumab;   Drug: MLN-518 (Tandutinib);   Procedure: Quality-of-life assessment
Sponsor:   National Cancer Institute (NCI)
Completed

Mon, 28 Apr 2008 12:00:00 EDT

Bevacizumab in Treating Young Patients With Refractory Solid Tumors

Condition:   Unspecified Childhood Solid Tumor, Protocol Specific
Intervention:   Biological: bevacizumab
Sponsor:   National Cancer Institute (NCI)
Completed

Fri, 11 Jun 2004 12:00:00 EDT

Ixabepilone and Carboplatin +/- Bevacizumab in Advanced Non-Small-Cell Lung Cancer

Condition:   Non-Small Cell Lung Cancer
Interventions:   Drug: Ixabepilone;   Drug: Carboplatin;   Drug: Bevacizumab
Sponsors:   SCRI Development Innovations, LLC;   Bristol-Myers Squibb;   Genentech, Inc.
Completed

Wed, 27 Aug 2008 12:00:00 EDT

VEGF-targeted Fluorescence Near-Infrared (NIR) Endoscopy in (Pre)Malignant Esophageal Lesions

Conditions:   Esophageal Cancer;   Dysplasia
Interventions:   Drug: Bevacizumab-IRDye800CW;   Device: Near infrared fluorescence endoscopy platform
Sponsor:   University Medical Center Groningen
Completed

Fri, 02 May 2014 12:00:00 EDT

Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian Malignancies

Conditions:   Ovarian Cancer;   Peritoneal Cancer;   Fallopian Tube Cancer
Interventions:   Drug: Bevacizumab;   Drug: Cyclophosphamide
Sponsors:   Dana-Farber Cancer Institute;   Massachusetts General Hospital;   Brigham and Women's Hospital;   Genentech, Inc.
Completed

Thu, 05 Mar 2009 12:00:00 EST

Phase II Bevacizumab, Gemcitabine and Carboplatin in Newly Diagnosed Non-Small Cell Lung Cancer

Conditions:   Lung Cancer;   Non-small Cell Lung Cancer (NSCLC)
Interventions:   Drug: Bevacizumab;   Drug: Gemcitabine;   Drug: Carboplatin
Sponsors:   Stanford University;   Eli Lilly and Company;   Genentech, Inc.
Completed

Wed, 10 May 2006 12:00:00 EDT

A Study of Biweekly Gemcitabine, Paclitaxel, and Avastin in Patients With Metastatic Breast Cancer

Condition:   Metastatic Breast Cancer
Interventions:   Drug: Paclitaxel;   Drug: Gemcitabine;   Drug: Avastin
Sponsors:   Barbara Ann Karmanos Cancer Institute;   Eli Lilly and Company;   Genentech, Inc.
Completed

Wed, 20 Feb 2008 12:00:00 EST

Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Conditions:   Platinum-Resistant Fallopian Tube Carcinoma;   Platinum-Resistant Ovarian Carcinoma;   Platinum-Resistant Primary Peritoneal Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Refractory Fallopian Tube Carcinoma;   Refractory Ovarian Carcinoma;   Refractory Primary Peritoneal Carcinoma
Interventions:   Biological: Bevacizumab;   Drug: Irinotecan Sucrosofate
Sponsors:   Northwestern University;   Ipsen Biopharmaceuticals
Not yet recruiting

Mon, 15 Feb 2021 12:00:00 EST

Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab

Condition:   Advanced Cancers
Interventions:   Drug: Oxaliplatin;   Drug: Capecitabine;   Drug: Bevacizumab
Sponsor:   M.D. Anderson Cancer Center
Completed

Fri, 01 Oct 2010 12:00:00 EDT

A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Participants With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer

Condition:   Non-Squamous Non-Small Cell Lung Cancer
Interventions:   Drug: Bevacizumab;   Drug: Carboplatin;   Drug: DNIB0600A
Sponsor:   Genentech, Inc.
Completed

Tue, 26 Nov 2013 12:00:00 EST

Bevacizumab Plus Capecitabin vs S-1 as Maintenance Treatment Following First-line Chemotherapy in the Patients With Advanced Colorectal Adenocarcinoma

Condition:   Colorectal Adenocarcinoma
Interventions:   Drug: S-1;   Drug: Bevacizumab;   Drug: Capecitabine
Sponsor:   Fujian Cancer Hospital
Withdrawn

Wed, 17 Oct 2018 12:00:00 EDT

Phase I/II Trial of Bevacizumab, Pemetrexed and Erlotinib in Elderly Patients With Non-Small Cell Lung Cancer

Condition:   Non-Small Cell Lung Cancer
Interventions:   Drug: Bevacizumab;   Drug: Erlotinib;   Drug: Pemetrexed
Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   Genentech, Inc.;   Eli Lilly and Company
Terminated

Wed, 12 Jul 2006 12:00:00 EDT

Blood-aqueous Barrier Integrity in Eyes Undergoing Intravitreal Bevacizumab Therapy to Treat Neovascular AMD

Condition:   Exudative Age-related Macular Degeneration
Intervention:   Drug: Bevacizumab Injection
Sponsor:   Medical University of Lublin
Completed

Fri, 16 Nov 2018 12:00:00 EST

Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma

Conditions:   Recurrent Melanoma;   Stage IV Skin Melanoma
Interventions:   Biological: Recombinant Interferon Alfa;   Biological: Bevacizumab
Sponsor:   National Cancer Institute (NCI)
Completed

Mon, 27 Jan 2003 12:00:00 EST

Efficacy and Safety of Intravitreal Bevacizumab in the Treatment of Choroidal Neovascular Membranes Associated to High Myopia

Conditions:   Myopia;   Choroidal Neovascularization
Interventions:   Drug: Intravitreal Injection;   Drug: Photodynamic Therapy (Visudyne)
Sponsors:   Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA;   Fondo de Investigacion Sanitaria
Completed

Fri, 28 Aug 2009 12:00:00 EDT

Combined Treatment of Camrelizumab and Bevacizumab for Adult Patients With Recurrent Glioblastoma (GBM)

Condition:   Recurrent Glioblastoma
Intervention:   Drug: Camrelizumab and Bevacizumab
Sponsor:   Beijing Sanbo Brain Hospital
Recruiting

Wed, 07 Jul 2021 12:00:00 EDT

Influence of Systemic Parameters in Diabetic Macular Edema - LIPSIA Study

Conditions:   Diabetic Macular Edema;   Macular Edema;   Retinal Vein Occlusion
Intervention:   Drug: Anti-VEGF
Sponsor:   University of Leipzig
Recruiting

Mon, 03 Dec 2018 12:00:00 EST

Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian

Conditions:   Ovarian Cancer;   Primary Peritoneal Cancer;   Fallopian Tube Cancer
Interventions:   Drug: carboplatin;   Drug: Bevacizumab;   Drug: Paclitaxel
Sponsors:   Ritu Salani;   Genentech, Inc.
Completed

Wed, 13 Oct 2010 12:00:00 EDT

Nivolumab and Bevacizumab in Patients With Advanced and or Metastatic Hepatocellular Carcinoma

Condition:   Hepatocellular Carcinoma
Interventions:   Drug: Nivolumab;   Drug: Bevacizumab
Sponsors:   University of Utah;   Bristol-Myers Squibb
Terminated

Tue, 26 Dec 2017 12:00:00 EST

Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery

Conditions:   Recurrent Glioblastoma;   Recurrent Adult Brain Tumor;   Gliosarcoma
Interventions:   Biological: HSPPC-96;   Drug: bevacizumab
Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Agenus Inc.
Active, not recruiting

Wed, 20 Mar 2013 12:00:00 EDT

Study of Cetuximab and Bevacizumab in Cancer of the Esophagus After Failure of Patient's First Therapy

Condition:   Esophageal Carcinoma
Intervention:   Drug: Bevacizumab, cetuximab
Sponsors:   Emory University;   Genentech, Inc.
Withdrawn

Fri, 14 Mar 2008 12:00:00 EDT

Gemcitabine, Bevacizumab, and Abdominal Radiation Therapy in Treating Patients With Localized Pancreatic Cancer

Condition:   Pancreatic Cancer
Interventions:   Biological: bevacizumab;   Drug: gemcitabine;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   Northwestern University;   National Cancer Institute (NCI)
Completed

Fri, 13 Apr 2007 12:00:00 EDT

Docetaxel With Bevacizumab as First-Line Therapy in Treating Women With Stage IV Breast Cancer

Condition:   Breast Cancer
Interventions:   Biological: bevacizumab;   Drug: Docetaxel
Sponsors:   Translational Oncology Research International;   University of California, Los Angeles
Completed

Thu, 22 Sep 2005 12:00:00 EDT

Sintilimab Plus Bevacizumab as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Curative Resection

Conditions:   HCC;   Adjuvant Therapy;   Immunotherapy
Interventions:   Drug: Sintilimab;   Drug: Bevacizumab
Sponsor:   Sun Yat-sen University
Not yet recruiting

Wed, 23 Dec 2020 12:00:00 EST

Study of Bevacizumab in Combination With Alternating Xeliri and Xelox in Metastatic Colorectal Cancer

Condition:   Metastatic Colorectal Cancer
Intervention:   Drug: Bevacizumab plus alternating Xelox/Xeliri
Sponsor:   Pia Osterlund
Recruiting

Mon, 13 Feb 2012 12:00:00 EST

Erlotinib and Bevacizumab in Treating Patients With Stage IV Melanoma

Condition:   Melanoma
Interventions:   Biological: bevacizumab;   Drug: erlotinib hydrochloride;   Genetic: fluorescence in situ hybridization;   Genetic: gene expression analysis;   Other: immunologic technique;   Other: laboratory biomarker analysis;   Procedure: biopsy
Sponsors:   Vanderbilt-Ingram Cancer Center;   National Cancer Institute (NCI)
Completed

Fri, 27 Apr 2007 12:00:00 EDT

Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors

Conditions:   Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Cancer;   Papillary Serous Mullerian Tumor;   Clear Cell Mullerian Tumor
Interventions:   Drug: bevacizumab;   Drug: erlotinib;   Drug: paclitaxel;   Drug: carboplatin
Sponsors:   Dana-Farber Cancer Institute;   Genentech, Inc.;   Beth Israel Deaconess Medical Center;   Brigham and Women's Hospital;   Massachusetts General Hospital
Completed

Thu, 23 Aug 2007 12:00:00 EDT

Phase II Avastin Trial for Stage IIIB/IV NSCLC

Conditions:   Non-small Cell Lung Cancer Stage IIIB;   Non-small Cell Lung Cancer Stage IV
Interventions:   Drug: bevacizumab;   Drug: docetaxel;   Drug: carboplatin
Sponsors:   Pharmatech;   Genentech, Inc.;   Sanofi
Terminated

Fri, 03 Oct 2008 12:00:00 EDT

A Clinical Study to Compare the Efficacy, Safety and Immunogenicity of HLX04 and Bevacizumab Combined XELOX or mFOLFOX6 in the First-line Treatment of mCRC

Condition:   Metastatic Colorectal Cancer (mCRC)
Interventions:   Drug: HLX04 100 mg in 4 ml Injection;   Drug: Avastin 100 mg in 4 ml Injection
Sponsor:   Shanghai Henlius Biotech
Active, not recruiting

Mon, 30 Apr 2018 12:00:00 EDT

Safety and Efficacy of Triamcinolone Acetonide Combined With Laser, Bevacizumab Combined With Laser Versus Laser Alone for the Treatment of Diffuse Non-tractional Diabetic Macular Edema

Condition:   Diabetic Macular Edema
Interventions:   Other: Grid laser;   Drug: Triamcinolone Acetonide;   Drug: Bevacizumab
Sponsor:   Hospital Universitario de Canarias
Completed

Fri, 06 Apr 2012 12:00:00 EDT

CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer

Conditions:   Esophageal Cancer;   Gastric Cancer
Interventions:   Drug: bevacizumab;   Drug: trastuzumab;   Drug: oxaliplatin;   Drug: capecitabine
Sponsors:   Dana-Farber Cancer Institute;   Brigham and Women's Hospital;   Massachusetts General Hospital;   Genentech, Inc.
Active, not recruiting

Tue, 31 Aug 2010 12:00:00 EDT

A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer

Condition:   Non-Small Cell Lung Cancer
Interventions:   Drug: bevacizumab;   Drug: erlotinib HCl;   Drug: placebo
Sponsor:   Genentech, Inc.
Completed

Tue, 16 Aug 2005 12:00:00 EDT

Clinical Trial in Chinese Healthy Volunteers of GB222

Condition:   Non-small Cell Lung Cancer
Interventions:   Biological: GB222;   Biological: Bevacizumab
Sponsor:   Genor Biopharma Co., Ltd.
Recruiting

Fri, 22 Nov 2019 12:00:00 EST

Sintilimab Plus Bevacizumab in Recurrent/Persistent Ovarian Clear Cell Carcinoma

Condition:   Ovarian Clear Cell Carcinoma
Interventions:   Drug: Sintilimab;   Drug: Bevacizumab Biosimilar IBI305
Sponsors:   Tongji Hospital;   Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology;   Qilu Hospital of Shandong University;   The First Affiliated Hospital of Zhengzhou University;   Henan Cancer Hospital;   Hubei Cancer Hospital;   Shengjing Hospital;   Anhui Provincial Cancer Hospital;   Wuhan University;   Jingzhou Central Hospital;   The First People's Hospital of Jingzhou;   Xiangyang Central Hospital
Recruiting

Wed, 03 Feb 2021 12:00:00 EST

2-arm Trial of Paclitaxel Plus Bevacizumab vs. Capecitabine Plus Bevacizumab

Condition:   Metastatic Breast Cancer
Interventions:   Biological: Bevacizumab and Paclitaxel;   Biological: Bevacizumab and Capecitabine
Sponsor:   Central European Cooperative Oncology Group
Completed

Fri, 25 Jan 2008 12:00:00 EST

Atezolizumab/Bevacizumab Followed by On-demand TACE or Initial Synchronous Treatment With TACE and Atezolizumab/Bevacizumab

Condition:   Hepatocellular Carcinoma Non-resectable
Intervention:   Combination Product: Atezolizumab Injection, Bevacizumab Injection
Sponsor:   Ludwig-Maximilians - University of Munich
Recruiting

Mon, 13 Jan 2020 12:00:00 EST

Effect of Sorafenib on ccRCC Uptake of Radiolabeled Bevacizumab or cG250

Condition:   Clear Cell Renal Cell Carcinoma
Interventions:   Drug: Sorafenib;   Drug: 111Indium-bevacizumab;   Drug: 111Indium-cG250
Sponsors:   Radboud University;   Dutch Cancer Society
Completed

Mon, 28 Jan 2008 12:00:00 EST

Bevacizumab Combined With Gefitinib in the Treatment of Advanced NSCLC

Condition:   PFS
Interventions:   Drug: Gefitinib;   Drug: Bevacizumab Combined With Gefitinib
Sponsor:   Fudan University
Recruiting

Thu, 11 Jun 2020 12:00:00 EDT

Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent Non-small Cell Lung Cancer

Conditions:   Locally Advanced Lung Non-Small Cell Carcinoma;   Metastatic Lung Non-Small Cell Carcinoma;   Recurrent Lung Non-Small Cell Carcinoma;   Stage III Lung Cancer AJCC v8;   Stage IIIA Lung Cancer AJCC v8;   Stage IIIB Lung Cancer AJCC v8;   Stage IIIC Lung Cancer AJCC v8;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
Interventions:   Biological: Bevacizumab;   Drug: Brigatinib
Sponsors:   Northwestern University;   National Cancer Institute (NCI)
Recruiting

Mon, 13 Jan 2020 12:00:00 EST

Bevacizumab in Combination With Vinorelbine and Trastuzumab for HER2-Positive, Metastatic Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: bevacizumab;   Drug: vinorelbine;   Drug: trastuzumab
Sponsors:   Harold J. Burstein, MD, PhD;   Brigham and Women's Hospital;   Beth Israel Deaconess Medical Center;   Massachusetts General Hospital;   Genentech, Inc.;   New Hampshire Oncology-Hematology PA;   Lowell General Hospital;   Hartford Hospital
Completed

Fri, 02 May 2008 12:00:00 EDT

Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2)

Conditions:   Vestibular Schwannoma;   Neurofibromatosis Type 2
Interventions:   Biological: bevacizumab;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment
Sponsor:   National Cancer Institute (NCI)
Completed

Thu, 23 Sep 2010 12:00:00 EDT

VEGF-targeted Fluorescent Tracer Imaging in Breast Cancer

Condition:   Breast Cancer
Intervention:   Drug: bevacizumab-IRDye800CW
Sponsors:   University Medical Center Groningen;   UMC Utrecht
Completed

Thu, 12 Jan 2012 12:00:00 EST

Bevacizumab/Doxorubicin/Radiation for Sarcoma

Condition:   Sarcoma
Interventions:   Drug: Bevacizumab;   Drug: Doxorubicin;   Radiation: Radiation Therapy
Sponsor:   Massachusetts General Hospital
Active, not recruiting

Mon, 10 Dec 2012 12:00:00 EST

Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Onartuzumab;   Drug: Bevacizumab;   Drug: Paclitaxel;   Drug: Bevacizumab Placebo;   Drug: Onartuzumab Placebo
Sponsors:   Genentech, Inc.;   Hoffmann-La Roche
Completed

Mon, 23 Aug 2010 12:00:00 EDT

Bevacizumab With or Without Docetaxel in Treating Patients With Previously Treated Metastatic Pancreatic Cancer

Condition:   Pancreatic Cancer
Interventions:   Drug: rhuMAB-VEGF;   Drug: docetaxel
Sponsors:   Fox Chase Cancer Center;   National Cancer Institute (NCI)
Terminated

Thu, 07 Aug 2003 12:00:00 EDT

Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors

Conditions:   Breast Cancer;   Ovarian Cancer;   Gynecological Cancer;   Head and Neck Carcinoma;   Non-small Cell Lung Cancer;   Small Cell Lung Cancer;   Non-squamous Cell Lung Cancer
Intervention:   Drug: PM01183 + paclitaxel +/- bevacizumab
Sponsor:   PharmaMar
Completed

Mon, 15 Apr 2013 12:00:00 EDT

Irinotecan, Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients

Condition:   Metastatic Colorectal Cancer
Intervention:   Drug: Capecitabine+Irinotecan+Bevacizumab
Sponsors:   Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD);   Hoffmann-La Roche
Completed

Fri, 03 Apr 2009 12:00:00 EDT

Radiation, Cetuximab and Pemetrexed With or Without Bevacizumab in Locally Advanced Head and Neck Cancer

Condition:   Cancer
Interventions:   Drug: Bevacizumab;   Drug: Cetuximab;   Drug: Pemetrexed;   Radiation: Radiation therapy
Sponsors:   University of Pittsburgh;   Eli Lilly and Company;   Genentech, Inc.
Completed

Tue, 24 Jun 2008 12:00:00 EDT

HAIC Combined With Bevacizumab and Toripalimab for Advanced Hepatocellular Carcinama

Conditions:   Hepatocellular Carcinoma;   Bevacizumab;   Liver Neoplasms;   Toripalimab;   Oxaliplatin
Interventions:   Procedure: Hepatic arterial infusion chemotherapy;   Drug: Bevacizumab;   Drug: Toripalimab
Sponsors:   Sun Yat-sen University;   Second Affiliated Hospital of Guangzhou Medical University
Not yet recruiting

Fri, 13 Nov 2020 12:00:00 EST

Safety of Intraperitoneal (IP) OXAliplatin (OXA) in Association With Systemic FOLFIRI Bevacizumab Chemotherapy in Patients With Peritoneal Carcinosis

Condition:   Peritoneal Carcinosis
Intervention:   Drug: intraperitoneal (IP) OXAliplatin (OXA) + systemic FOLFIRI bevacizumab chemotherapy
Sponsor:   Hospices Civils de Lyon
Unknown status

Mon, 15 Aug 2016 12:00:00 EDT

TACE Combined With Sintilimab Plus Bevacizumab Biosimilar in Hepatocellular Carcinoma (BCLC-C Stage ): a Prospective Single-arm Phase II Clinical Study

Condition:   Hepatocellular Carcinoma
Intervention:   Drug: Sintilimab; Bevacizumab Biosimilar
Sponsor:   Sun Yat-sen University
Recruiting

Fri, 12 Mar 2021 12:00:00 EST

A Study of Bevacizumab Therapy in Patients With Newly Diagnosed High-Grade Gliomas and Diffuse Intrinsic Pontine Gliomas

Conditions:   Newly Diagnosed High-Grade Gliomas;   Diffuse Intrinsic Pontine Glioma
Interventions:   Drug: Temozolomide;   Drug: Bevacizumab;   Drug: Irinotecan
Sponsors:   Children's Hospital Medical Center, Cincinnati;   Genentech, Inc.
Completed

Thu, 30 Apr 2009 12:00:00 EDT

A Study of Gemcitabine, Capecitabine and Bevacizumab to Treat Cancer of the Gall Bladder or Bile Ducts

Condition:   Cholangiocarcinoma
Intervention:   Drug: Gemcitabine, Capecitabine and Bevacizumab
Sponsors:   Roswell Park Cancer Institute;   Genentech, Inc.
Completed

Wed, 04 Nov 2009 12:00:00 EST

Molecular Fluorescence Endoscopy in Patients With Familial Adenomatous Polyposis, Using Bevacizumab-IRDye800CW

Condition:   Adenomatous Polyposis Coli
Interventions:   Drug: Bevacizumab-IRDye800CW;   Device: Near infrared fluorescence endoscopy platform
Sponsor:   University Medical Center Groningen
Completed

Mon, 14 Apr 2014 12:00:00 EDT

Imaging for Response Assessment of Neoadjuvant Chemotherapy in Primary Breast Cancer (GALADON)

Condition:   Breast Cancer
Interventions:   Drug: Docetaxel;   Drug: Trastuzumab;   Drug: Bevacizumab;   Drug: Epirubicin;   Drug: Cyclophosphamid
Sponsors:   West German Study Group;   Roche Pharma AG;   Sanofi
Terminated

Fri, 21 Sep 2012 12:00:00 EDT

A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Condition:   Renal Cell Cancer
Interventions:   Drug: Bevacizumab [Avastin];   Drug: Interferon alfa 2a [Roferon];   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed

Wed, 20 Aug 2008 12:00:00 EDT

First Line Metastatic Breast Cancer Treatment (ESMERALDA)

Condition:   Metastatic Breast Cancer
Intervention:   Drug: Eribulin
Sponsor:   ARCAGY/ GINECO GROUP
Completed

Fri, 13 Sep 2013 12:00:00 EDT

Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney

Condition:   Kidney Cancer
Interventions:   Biological: aldesleukin;   Biological: bevacizumab
Sponsors:   Jorge A. Garcia, MD;   National Cancer Institute (NCI)
Completed

Fri, 27 Feb 2009 12:00:00 EST

Bevacizumab, Erlotinib and Capecitabine for Advanced Pancreatic Cancer

Condition:   Pancreatic Cancer
Interventions:   Drug: Bevacizumab;   Drug: Erlotinib;   Drug: Capecitabine;   Radiation: Radiation Therapy
Sponsors:   M.D. Anderson Cancer Center;   Genentech, Inc.
Completed

Wed, 13 Feb 2008 12:00:00 EST

dMR During First Line Treatment of Non Squamous Lung Cancer: Time Course and Prognostic and Predictive Impact.

Condition:   Non-small Cell Lung Cancer
Interventions:   Device: dMRT;   Drug: Bevacizumab;   Drug: paclitaxel and carboplatin
Sponsor:   Karl Kölbeck
Unknown status

Mon, 21 Jul 2014 12:00:00 EDT

Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme

Condition:   Brain and Central Nervous System Tumors
Interventions:   Biological: bevacizumab;   Drug: sorafenib tosylate
Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
Completed

Fri, 22 Feb 2008 12:00:00 EST

Feasibility Study of Intraperitoneal Bevacizumab for Palliation of Intractable Malignant Ascites

Condition:   Malignant Ascites
Intervention:   Drug: Intraperitoneal Bevacizumab
Sponsor:   Eastern Regional Medical Center
Terminated

Tue, 14 Jul 2015 12:00:00 EDT

Pre-Operative Intravitreal Bevacizumab for Tractional Retinal Detachment Secondary to Proliferative Diabetic Retinopathy

Condition:   Tractional Retinal Detachment Secondary to Proliferative Diabetic Retinopathy
Interventions:   Drug: Intravitreal bevacizumab;   Procedure: Small-gauge pars plana vitrectomy
Sponsors:   J. Fernando Arevalo, MD FACS;   Pan American Collaborative Retina Study Group
Completed

Wed, 06 Nov 2013 12:00:00 EST

Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary

Conditions:   Malignant Ovarian Epithelial Tumor;   Ovarian Granulosa Cell Tumor;   Ovarian Gynandroblastoma;   Ovarian Sertoli-Leydig Cell Tumor;   Ovarian Sex Cord Tumor With Annular Tubules;   Ovarian Sex Cord-Stromal Tumor;   Ovarian Sex Cord-Stromal Tumor of Mixed or Unclassified Cell Types;   Ovarian Steroid Cell Tumor
Interventions:   Biological: Bevacizumab;   Other: Laboratory Biomarker Analysis
Sponsors:   National Cancer Institute (NCI);   NRG Oncology
Completed

Mon, 08 Sep 2008 12:00:00 EDT

A Study to Test the Safety and Efficacy of Erlotinib Plus Bevacizumab to Treat Advanced Thymoma and Thymic Cancer

Conditions:   Thymic Cancer;   Thymoma
Interventions:   Drug: bevacizumab;   Drug: Erlotinib
Sponsors:   Indiana University School of Medicine;   Genentech, Inc.
Completed

Wed, 30 Aug 2006 12:00:00 EDT

Bevacizumab Beyond Progression (BBP)

Conditions:   Malignant Glioma;   Grade 4 Malignant Glioma;   Glioblastoma;   Gliosarcoma
Interventions:   Radiation: Radiation Therapy;   Drug: Temozolomide;   Drug: Bevacizumab
Sponsors:   Duke University;   Genentech, Inc.
Completed

Tue, 04 Dec 2012 12:00:00 EST

Systemic Pharmacokinetics Following Intravitreal Injections of Anti-VEGF

Conditions:   Age-related Macular Degeneration;   Diabetic Macular Edema;   Retinal Vein Occlusion
Interventions:   Biological: Blood Sample Collection;   Drug: Aflibercept;   Drug: Bevacizumab;   Drug: Ranibizumab
Sponsor:   California Retina Consultants
Completed

Mon, 21 Apr 2014 12:00:00 EDT

Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab in Unresectable Biliary Tract Cancer

Conditions:   Biliary Tract Carcinoma;   Initially Unresectable
Intervention:   Drug: Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab
Sponsor:   Fudan University
Recruiting

Mon, 02 Aug 2021 12:00:00 EDT

Pemetrexed/Cisplatin With or Without Bevacizumab in Brain Metastases From Non Squamous Non-small Cell Lung Cancer

Conditions:   Non Squamous Non-small Cell Lung Cancer;   Brain Metastases;   Bevacizumab
Interventions:   Drug: Pemetrexed/cisplatin;   Drug: Bevacizumab and Pemetrexed/cisplatin
Sponsor:   Sun Yat-sen University
Unknown status

Thu, 26 Sep 2013 12:00:00 EDT

Preoperative Bevacizumab and Trastuzumab With ABI-007 and Carboplatin in HER2+ Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: nab-paclitaxel;   Drug: Bevacizumab;   Drug: Trastuzumab
Sponsors:   SCRI Development Innovations, LLC;   Celgene Corporation;   Genentech, Inc.
Completed

Thu, 26 Oct 2006 12:00:00 EDT

Neoadjuvant Therapy for Ovarian Cancer

Conditions:   Epithelial Ovarian Cancer;   Primary Peritoneal Cancer;   Fallopian Tube Cancer
Interventions:   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Bevacizumab
Sponsors:   Jason D. Wright;   Genentech, Inc.
Completed

Tue, 22 Jun 2010 12:00:00 EDT

Bevacizumab and Irinotecan or Bevacizumab and Temozolomide With Concomitant Radiotherapy for Primary Glioblastoma Multiforme (GBM)

Condition:   Glioblastoma Multiforme
Interventions:   Drug: bevacizumab and Irinotecan and radiotherapy;   Drug: Bevacizumab and Temozolomide and radiotherapy
Sponsor:   Ulrik Lassen
Completed

Tue, 06 Jan 2009 12:00:00 EST

Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas

Conditions:   Acoustic Schwannoma;   Adult Anaplastic Meningioma;   Adult Ependymoma;   Adult Grade I Meningioma;   Adult Grade II Meningioma;   Adult Meningeal Hemangiopericytoma;   Adult Papillary Meningioma;   Neurofibromatosis Type 1;   Neurofibromatosis Type 2;   Recurrent Adult Brain Tumor
Intervention:   Biological: bevacizumab
Sponsor:   Northwestern University
Completed

Tue, 18 May 2010 12:00:00 EDT

A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC

Condition:   Non-Small Cell Lung Cancer
Interventions:   Drug: Bevacizumab-Pfizer;   Drug: Bevacizumab-EU;   Drug: Paclitaxel;   Drug: Carboplatin
Sponsor:   Pfizer
Completed

Wed, 18 Feb 2015 12:00:00 EST

Feasibility Study of Using Molecular Fluorescence Guided Surgery in Endometriosis

Condition:   Endometriosis
Intervention:   Drug: Bevacizumab-800CW
Sponsor:   University Medical Center Groningen
Unknown status

Tue, 29 Nov 2016 12:00:00 EST

ME-344 in Early HER2-negative Breast Cancer With Antiangiogenic-induced Mitochondrial Metabolism

Conditions:   Breast Cancer;   Human Epidermal Growth Factor 2 Negative Carcinoma of Breast;   Early-Stage Breast Carcinoma
Interventions:   Drug: ME-344;   Drug: Bevacizumab;   Other: Normal saline
Sponsors:   Centro Nacional de Investigaciones Oncologicas CARLOS III;   Fundacion CRIS de Investigación para Vencer el Cáncer
Completed

Tue, 21 Jun 2016 12:00:00 EDT

Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and Leukemia

Conditions:   Refractory Solid Tumors;   Leukemia
Interventions:   Drug: Bevacizumab;   Drug: Sorafenib;   Drug: Cyclophosphamide
Sponsor:   St. Jude Children's Research Hospital
Completed

Thu, 24 Apr 2008 12:00:00 EDT

A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma

Conditions:   Glioblastoma;   Small Cell Glioblastoma;   Giant Cell Glioblastoma;   Gliosarcoma;   Glioblastoma With Oligodendroglial Component;   Recurrent Glioblastoma;   Relapsed Glioblastoma
Interventions:   Drug: Bevacizumab;   Drug: Rindopepimut (CDX-110) with GM-CSF;   Drug: KLH
Sponsor:   Celldex Therapeutics
Completed

Fri, 23 Dec 2011 12:00:00 EST

Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer

Condition:   Breast Cancer
Interventions:   Biological: bevacizumab;   Drug: fulvestrant
Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
Completed

Thu, 18 Jan 2007 12:00:00 EST

Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma

Conditions:   Macular Edema;   Cystoid Macular Edema;   Uveal Melanoma;   Radiation Maculopathy;   Radiation Retinopathy
Interventions:   Drug: Ozurdex;   Drug: Bevacizumab
Sponsors:   Arman Mashayekhi;   Allergan
Terminated

Fri, 11 Nov 2011 12:00:00 EST

Mesothelioma Avastin Plus Pemetrexed-cisplatin Study

Condition:   Mesothelioma
Interventions:   Drug: Standard Chemotherapy (Pemetrexed and Cisplatin);   Drug: Standard Chemotherapy (Pemetrexed and Cisplatin) + Bevacizumab
Sponsors:   Intergroupe Francophone de Cancerologie Thoracique;   University Hospital, Caen;   Groupe Francais De Pneumo-Cancerologie
Completed

Wed, 02 Apr 2008 12:00:00 EDT

Bevacizumab Plus Capecitabine (Xeloda) in Patients With Untreated Metastatic Colorectal Cancer

Condition:   Colorectal Cancer
Interventions:   Drug: Capecitabine (Xeloda);   Drug: Bevacizumab
Sponsors:   Translational Oncology Research International;   Genentech, Inc.
Completed

Tue, 20 Sep 2005 12:00:00 EDT

Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Condition:   Lung Cancer
Interventions:   Biological: bevacizumab;   Drug: carboplatin;   Drug: pemetrexed
Sponsors:   Northwestern University;   National Cancer Institute (NCI)
Completed

Thu, 06 Oct 2005 12:00:00 EDT

Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer

Condition:   Non-small Cell Lung Cancer Metastatic
Interventions:   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: ABP 215;   Drug: Bevacizumab
Sponsors:   Amgen;   Actavis Inc.
Completed

Mon, 21 Oct 2013 12:00:00 EDT

Predicting Response and Toxicity in Patients Receiving Paclitaxel and Avastin for Breast Cancer

Condition:   Breast Cancer
Interventions:   Procedure: Core Biopsy;   Procedure: Blood Collection;   Drug: Paclitaxel;   Drug: Avastin
Sponsors:   Hoosier Cancer Research Network;   United States Department of Defense;   Indiana University School of Medicine;   University of Colorado, Denver;   Baylor University;   McGill University
Terminated

Fri, 28 Sep 2007 12:00:00 EDT

Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer

Conditions:   Esophageal Cancer;   Stomach Cancer
Interventions:   Drug: Bevacizumab;   Drug: Docetaxel;   Drug: Cisplatin;   Drug: Irinotecan
Sponsors:   Dana-Farber Cancer Institute;   Brigham and Women's Hospital;   Massachusetts General Hospital;   Genentech, Inc.
Completed

Wed, 01 Nov 2006 12:00:00 EST

Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor

Conditions:   Sarcoma;   Desmoplastic Small Round Cell Tumor (DSRCT)
Intervention:   Drug: irinotecan, temozolomide, and bevacizumab incorporated into an existing schedule of high dose alkylator
Sponsors:   Memorial Sloan Kettering Cancer Center;   Genentech, Inc.
Active, not recruiting

Thu, 26 Aug 2010 12:00:00 EDT

Bevacizumab and Pembrolizumab Combination in EBER-ISH Positive NPC

Conditions:   Locally Recurrent Cancer;   Metastatic Nasopharyngeal Cancer
Interventions:   Drug: pembrolizumab;   Drug: bevacizumab
Sponsors:   National University Hospital, Singapore;   Merck Sharp & Dohme Corp.
Not yet recruiting

Wed, 23 Jan 2019 12:00:00 EST

Study of Combination Therapy of Carboplatin -Gemcitabine Plus Bevacizumab Beyond Progression in Patients With Locally Advanced and/or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Received Prior Systemic Therapy

Conditions:   Locally Advanced Non-Small Cell Lung Cancer;   NSCLC
Intervention:   Drug: Paclitaxel, Carboplatin and Bevacizumab,Erlotinib
Sponsor:   Radboud University
Completed

Fri, 20 Jun 2008 12:00:00 EDT

A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC

Conditions:   Colorectal Neoplasms;   Neoplasm Metastasis;   Intestinal Neoplasms;   Gastrointestinal Neoplasms;   Digestive System Neoplasms
Interventions:   Biological: Bevacizumab;   Drug: CPT-11;   Drug: 5-FU Bolus;   Drug: 5-FU Infusion;   Drug: l-LV (dl-LV)
Sponsor:   Sun Yat-sen University
Unknown status

Fri, 06 Oct 2017 12:00:00 EDT

Docetaxel/Epirubicin/Bevacizumab as First Line Therapy for Metastatic HER2 Negative Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Docetaxel;   Drug: Epirubicin;   Drug: Bevacizumab
Sponsor:   Hellenic Oncology Research Group
Completed

Thu, 26 Jun 2008 12:00:00 EDT

TACE Associated to Systemic Bevacizumab for the Treatment of Refractory Liver Metastases From Colorectal Cancer

Condition:   Liver Metastasis Colon Cancer
Interventions:   Device: TACE+ systemic Bevacizumab;   Drug: FOLFIRI+Bevacizumab;   Device: TACE
Sponsor:   Giammaria Fiorentini
Recruiting

Tue, 06 Nov 2018 12:00:00 EST

Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab in Patients With Resectable Liver Metastases

Conditions:   Colorectal Cancer Metastatic;   Liver Metastases;   KRAS Wild Type Colorectal Cancer
Interventions:   Drug: FOLFOX6;   Biological: Bevacizumab;   Biological: Panitumumab;   Procedure: Surgery
Sponsors:   European Organisation for Research and Treatment of Cancer - EORTC;   Amgen;   Roche Pharma AG
Terminated

Wed, 11 Jan 2012 12:00:00 EST

A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients

Condition:   Recurrent Glioblastoma
Interventions:   Biological: Nivolumab;   Biological: Bevacizumab;   Biological: Ipilimumab
Sponsor:   Bristol-Myers Squibb
Active, not recruiting

Mon, 23 Dec 2013 12:00:00 EST

Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme

Condition:   Glioblastoma Multiforme
Intervention:   Drug: Temozolomide, bevacizumab and bortezomib
Sponsors:   Emory University;   Schering-Plough;   Genentech, Inc.;   Millennium Pharmaceuticals, Inc.
Completed

Fri, 16 Sep 2011 12:00:00 EDT

Pemetrexed Disodium and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Condition:   Lung Cancer
Interventions:   Biological: bevacizumab;   Drug: pemetrexed disodium
Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
Completed

Thu, 22 Dec 2005 12:00:00 EST

A Study of Bevacizumab in Previously Untreated Extensive-Stage Small Cell Lung Cancer (SALUTE)

Condition:   Small Cell Lung Cancer
Interventions:   Drug: Bevacizumab;   Drug: Chemotherapy;   Drug: Placebo
Sponsor:   Genentech, Inc.
Completed

Thu, 23 Nov 2006 12:00:00 EST

A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer

Condition:   Biliary Tract Cancer
Interventions:   Drug: Atezolizumab;   Drug: Bevacizumab;   Other: Placebo;   Drug: Cisplatin;   Drug: Gemcitabine
Sponsor:   Hoffmann-La Roche
Active, not recruiting

Mon, 21 Dec 2020 12:00:00 EST

Bevacizumab and Doxorubicin Hydrochloride Liposome in Treating Women With Locally Recurrent or Metastatic Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: bevacizumab + doxorubin hydrochloride liposme;   Drug: Bevacizumab
Sponsor:   Swiss Group for Clinical Cancer Research
Completed

Fri, 09 Mar 2007 12:00:00 EST

Gemcitabine, Infusional 5 Fluorouracil and Bevacizumab in Patients With Advanced Pancreas Cancer

Condition:   Pancreatic Cancer
Interventions:   Drug: Gemcitabine;   Drug: Bevacizumab;   Drug: Infusional 5-Fluorouracil
Sponsors:   Tony Bekaii-Saab;   Genentech, Inc.
Completed

Thu, 04 Jan 2007 12:00:00 EST

Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors

Condition:   Colorectal Cancer
Interventions:   Drug: Atezolizumab;   Drug: Bevacizumab;   Drug: Cobimetinib
Sponsor:   Hoffmann-La Roche
Completed

Tue, 23 Aug 2016 12:00:00 EDT

Bevacizumab in Treating Patients With Relapsed Prostate Cancer That Did Not Respond to Hormone Therapy

Conditions:   Adenocarcinoma of the Prostate;   Recurrent Prostate Cancer;   Stage I Prostate Cancer;   Stage IIA Prostate Cancer;   Stage IIB Prostate Cancer;   Stage III Prostate Cancer
Interventions:   Biological: bevacizumab;   Other: laboratory biomarker analysis
Sponsors:   Barbara Ann Karmanos Cancer Institute;   Genentech, Inc.
Completed

Thu, 02 Aug 2012 12:00:00 EDT

Bevacizumab vs Dacarbazine in Metastatic Melanoma

Conditions:   Metastatic Malignant Melanoma;   Unresectable Malignant Melanoma
Interventions:   Drug: Bevacizumab;   Drug: Propranolol;   Drug: Enalapril;   Drug: Dacarbazine
Sponsors:   Haukeland University Hospital;   The Norwegian Melanoma Group;   Norwegian Cancer Society
Terminated

Fri, 12 Oct 2012 12:00:00 EDT

A Phase I Study of Bevacizumab and Sunitinib in Metastatic Renal Cell Carcinoma Patients

Conditions:   Metastatic Renal Cell Carcinoma;   Kidney Cancer
Intervention:   Drug: Bevacizumab and Sunitinib
Sponsor:   Memorial Sloan Kettering Cancer Center
Completed

Fri, 12 Jan 2007 12:00:00 EST

A Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (AMBER)

Condition:   Multiple Myeloma
Interventions:   Drug: Bevacizumab;   Drug: Bortezomib;   Drug: placebo
Sponsor:   Genentech, Inc.
Completed

Tue, 15 May 2007 12:00:00 EDT

Cisplatin, Bevacizumab, and Gemcitabine Followed by Surgery, Bevacizumab, and Paclitaxel in Treating Patients With Locally Advanced Nonmetastatic Bladder Cancer That Can Be Removed By Surgery

Condition:   Bladder Cancer
Interventions:   Biological: bevacizumab;   Drug: cisplatin;   Drug: gemcitabine hydrochloride;   Drug: paclitaxel;   Procedure: cysectomy
Sponsor:   Medical University of South Carolina
Terminated

Thu, 22 Dec 2005 12:00:00 EST

Hypertension in Breast Cancer Patients Receiving Bevacizumab

Condition:   Breast Cancer
Intervention:   Drug: Bevacizumab
Sponsors:   Dana-Farber Cancer Institute;   Brigham and Women's Hospital
Terminated

Wed, 07 May 2008 12:00:00 EDT

Chemoradiation for Locally Advanced and Low Rectal Cancers: Avastin-Capecitabine-Oxaliplatin-Radiation REctal Cancer Trial

Condition:   Advanced Colorectal Cancer
Intervention:   Drug: Bevacizumab:
Sponsor:   British Columbia Cancer Agency
Completed

Thu, 12 Oct 2006 12:00:00 EDT

The Efficacy of Subconjunctival Bevacizumab in Diabetic Macular Edema

Condition:   Diabetic Macular Edema
Intervention:   Drug: Subconjunctival bevacizumab (Altuzan)
Sponsors:   Neon Hospital;   Ondokuz Mayıs University
Completed

Fri, 10 Jun 2016 12:00:00 EDT

Fluorescence Endoscopy of Esophageal Carcinoma

Condition:   Esophageal Cancer
Interventions:   Drug: Bevacizumab-IRDye800CW;   Device: Molecular Fluorescence Endoscopy platform
Sponsor:   University Medical Center Groningen
Recruiting

Fri, 15 Jun 2018 12:00:00 EDT

Aflibercept or Bevacizumab as Second-line Treatment of RAS Mutated Metastatic Colorectal Cancer

Condition:   Metastatic Colorectal Cancer
Interventions:   Drug: Folfiri/Bevacizumab;   Drug: Folfiri/Aflibercept
Sponsor:   National Cancer Institute, Naples
Recruiting

Thu, 21 May 2020 12:00:00 EDT

A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer

Conditions:   Metastatic Non-small Cell Lung Cancer (NSCLC);   Non-squamous NSCLC
Interventions:   Drug: ABP 215;   Drug: Bevacizumab;   Drug: Paclitaxel;   Drug: Carboplatin
Sponsors:   Amgen;   Parexel
Withdrawn

Fri, 10 Jul 2020 12:00:00 EDT

Bevacizumab and Trastuzumab With Weekly Paclitaxel Followed, After Surgery, by Encapsuled Liposomal Doxorubicin, Cyclophosphamide and Trastuzumab as Adjuvant Treatment After Surgery on Women With Her2+ Breast Cancer

Condition:   Breast Cancer
Intervention:   Drug: Bevacizumab,Trastuzumab,Paclitaxel,Cyclophosphamide,Myocet
Sponsor:   Hospital Universitario Madrid Sanchinarro
Unknown status

Thu, 24 Mar 2011 12:00:00 EDT

Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Metastatic Pancreatic Cancer

Condition:   Metastatic Pancreatic Cancer
Interventions:   Biological: cetuximab;   Biological: bevacizumab;   Drug: gemcitabine
Sponsor:   Eli Lilly and Company
Terminated

Wed, 17 May 2006 12:00:00 EDT

Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas

Conditions:   Sarcoma;   Soft Tissue Sarcoma;   Locally Advanced Sarcoma;   Unresectable Sarcoma;   Metastatic Sarcoma
Intervention:   Drug: Bevacizumab, Gemcitabine, Docetaxel and Valproic Acid
Sponsors:   Mohammed M Milhem;   Genentech, Inc.
Completed

Tue, 20 Apr 2010 12:00:00 EDT

Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary Site

Condition:   Neoplasm, Unknown Primary
Interventions:   Drug: paclitaxel;   Drug: carboplatin;   Drug: bevacizumab;   Drug: erlotinib
Sponsors:   SCRI Development Innovations, LLC;   Genentech, Inc.
Completed

Fri, 04 Aug 2006 12:00:00 EDT

A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab

Condition:   Glioma
Interventions:   Drug: Bevacizumab;   Radiation: PRDR
Sponsors:   University of Wisconsin, Madison;   Genentech, Inc.;   National Cancer Institute (NCI)
Recruiting

Thu, 06 Dec 2012 12:00:00 EST

To Compare Therapeutic Effect of Intravitreal Bevacizumab and Triamcinolone in Resistant Uveitic Cystoid Macular Edema

Condition:   Resistant Cystoid Macular Edema
Interventions:   Drug: Intravitreal injection of Triamcinolone;   Drug: Intravitreal injection of Avastin
Sponsor:   Shahid Beheshti University of Medical Sciences
Unknown status

Fri, 01 Sep 2006 12:00:00 EDT

A Phase I Study of High-dose L-methylfolate in Combination With Temozolomide and Bevacizumab in Recurrent High Grade Glioma

Condition:   Malignant Glioma
Interventions:   Drug: Bevacizumab;   Drug: Temozolomide;   Dietary Supplement: Vitamin C
Sponsor:   Vanderbilt-Ingram Cancer Center
Active, not recruiting

Wed, 03 Jul 2013 12:00:00 EDT

VEGFRs Predict Bevacizumab Benefit in Advanced Non Small Cell Lung Cancer

Conditions:   Non Small Cell Lung Cancer;   Brain Metastasis
Intervention:   Other: bevacizumab, standard chemotherapy and radiation
Sponsor:   Li Liu
Unknown status

Wed, 03 Jul 2013 12:00:00 EDT

Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma

Conditions:   Metastatic Cancer;   Renal Cancer
Interventions:   Drug: Atezolizumab;   Drug: Bevacizumab;   Drug: Entinostat
Sponsors:   Roberto Pili;   Genentech, Inc.;   Syndax Pharmaceuticals
Active, not recruiting

Wed, 18 Jan 2017 12:00:00 EST

Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC

Condition:   Non-squamous Non-small-cell Lung Cancer
Interventions:   Drug: Tiragolumab;   Drug: Atezolizumab;   Drug: Bevacizumab
Sponsors:   Georgetown University;   Genentech, Inc.
Not yet recruiting

Mon, 12 Jul 2021 12:00:00 EDT

Rapamycin Plus Bevacizumab in Advanced Cancers

Conditions:   Advanced Cancer;   Metastatic Cancer
Interventions:   Drug: Rapamycin (liquid);   Drug: Bevacizumab;   Drug: Rapamycin (Tablets)
Sponsors:   University of Chicago;   Genentech, Inc.
Completed

Mon, 28 Apr 2008 12:00:00 EDT

Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases

Conditions:   Radionecrosis;   Brain Metastases
Interventions:   Drug: bevacizumab;   Drug: corticosteroids;   Other: placebo
Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Genentech, Inc.
Terminated

Tue, 07 Jul 2015 12:00:00 EDT

Soluble Vascular Endothelial Growth Factor Receptor 2 as Predictor of Benefit From Bevacizumab Beyond Progression in Metastatic Colorectal Cancer

Condition:   Metastatic Colorectal Cancer
Intervention:   Drug: chemotherapy plus bevacizumab
Sponsor:   Azienda Ospedaliero, Universitaria Pisana
Completed

Tue, 08 Dec 2015 12:00:00 EST

Bevacizumab Plus Vinorelbine in Treating Patients With Stage IV Breast Cancer

Conditions:   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions:   Biological: bevacizumab;   Drug: vinorelbine tartrate;   Other: laboratory biomarker analysis
Sponsor:   National Cancer Institute (NCI)
Completed

Thu, 12 Jun 2003 12:00:00 EDT

HAI Abraxane With Gemcitabine and Bevacizumab

Condition:   Advanced Cancers
Interventions:   Drug: HAI Abraxane;   Drug: Gemcitabine;   Drug: Bevacizumab;   Drug: Filgrastim
Sponsor:   M.D. Anderson Cancer Center
Completed

Wed, 27 Jan 2010 12:00:00 EST

A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies

Conditions:   NSCLC Stage IIIB;   NSCLC Stage IV;   EGFR Gene Mutation;   ALK Gene Rearrangement Positive;   ROS1 Gene Mutation
Interventions:   Drug: Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab;   Drug: Carboplatin + Pemetrexed + Atezolizumab
Sponsors:   Centre Francois Baclesse;   GFPC
Recruiting

Fri, 02 Aug 2019 12:00:00 EDT

A Study of Avastin (Bevacizumab) in Combination With Platinum-Based Chemotherapy in Patients With Advanced or Recurrent Squamous Non-Small Cell Lung Cancer

Condition:   Non-Small Cell Lung Cancer
Interventions:   Drug: bevacizumab [Avastin];   Drug: Platinum-based chemotherapy
Sponsor:   Hoffmann-La Roche
Terminated

Wed, 29 Nov 2006 12:00:00 EST

Sirolimus and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Condition:   Liver Cancer
Interventions:   Drug: Rapamycin;   Drug: Bevacizumab
Sponsor:   National Cancer Centre, Singapore
Completed

Fri, 27 Apr 2007 12:00:00 EDT

Influence of BRAF and PIK3K Status on the Efficacy of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFIRI) Plus Bevacizumab or Cetuximab in Patients With RAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells (CTC)

Condition:   Colorectal Cancer Metastatic
Interventions:   Drug: FOLFIRI + bevacizumab;   Drug: FOLFIRI + cetuximab
Sponsors:   Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD);   Roche Pharma AG
Completed

Fri, 13 Jul 2012 12:00:00 EDT

Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer

Conditions:   Adult Hepatocellular Carcinoma;   Advanced Adult Hepatocellular Carcinoma;   Endometrial Serous Adenocarcinoma;   Localized Non-Resectable Adult Liver Carcinoma;   Lung Carcinoid Tumor;   Malignant Pancreatic Gastrinoma;   Malignant Pancreatic Glucagonoma;   Malignant Pancreatic Insulinoma;   Malignant Pancreatic Somatostatinoma;   Metastatic Digestive System Neuroendocrine Tumor G1;   Ovarian Carcinosarcoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Seromucinous Carcinoma;   Ovarian Serous Surface Papillary Adenocarcinoma;   Pancreatic Alpha Cell Adenoma;   Pancreatic Beta Cell Adenoma;   Pancreatic Delta Cell Adenoma;   Pancreatic G-Cell Adenoma;   Pancreatic Polypeptide Tumor;   Recurrent Adult Liver Carcinoma;   Recurrent Digestive System Neuroendocrine Tumor G1;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Pancreatic Neuroendocrine Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Recurrent Uterine Corpus Carcinoma;   Regional Digestive System Neuroendocrine Tumor G1;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Primary Peritoneal Cancer;   Stage IIIA Uterine Corpus Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Primary Peritoneal Cancer;   Stage IIIB Uterine Corpus Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cancer;   Stage IIIC Uterine Corpus Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer;   Stage IVA Uterine Corpus Cancer;   Stage IVB Uterine Corpus Cancer;   Uterine Carcinosarcoma
Interventions:   Biological: Bevacizumab;   Drug: Temsirolimus
Sponsor:   National Cancer Institute (NCI)
Completed

Mon, 09 Nov 2009 12:00:00 EST

Study of Biweekly Capecitabine Dosing With Bevacizumab for the Treatment of Metastatic Breast Cancer Based Upon the Norton-Simon Mathematical Model

Condition:   Breast Cancer
Interventions:   Drug: Capecitabine;   Drug: Bevacizumab
Sponsor:   Memorial Sloan Kettering Cancer Center
Completed

Thu, 03 May 2007 12:00:00 EDT

A Phase II Study of Optune (NovoTTF) in Combination With Bevacizumab (BEV) and Temozolomide (TMZ) in Patients With Newly Diagnosed Unresectable Glioblastoma (GBM)

Condition:   Cancer of Brain and Nervous System
Interventions:   Device: NovoTTF100A;   Drug: Bevacizumab;   Drug: Temozolomide
Sponsors:   Ashley Love Sumrall;   NovoCure Ltd.
Terminated

Thu, 22 Jan 2015 12:00:00 EST

A Study Comparing SIBP-04 and Bevacizumab in Healthy Male Subjects

Condition:   Healthy Male
Interventions:   Drug: SIBP-04;   Drug: Bevacizumab
Sponsor:   Shanghai Institute Of Biological Products
Unknown status

Wed, 23 Oct 2019 12:00:00 EDT

Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix

Condition:   Carcinoma of the Cervix, Stage IVB
Interventions:   Drug: Atezolizumab;   Drug: Bevacizumab;   Drug: Cisplatin/Carboplatin;   Drug: Paclitaxel
Sponsors:   Grupo Español de Investigación en Cáncer de Ovario;   Hoffmann-La Roche;   ARCAGY/ GINECO GROUP;   Multicenter Italian Trials in Ovarian cancer and gynecologic malignancies;   MaNGO;   NSGO;   Japanese Gynecologic Oncology Group;   Gynecologic Oncology Group Foundation;   AGO Study Group
Active, not recruiting

Thu, 14 Jun 2018 12:00:00 EDT

Niraparib and Bevacizumab Maintenance Therapy in Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor

Condition:   Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor
Intervention:   Drug: Niraparib-Bevacizumab
Sponsors:   Yonsei University;   Takeda
Recruiting

Tue, 02 Feb 2021 12:00:00 EST

Salvage Ovarian FANG™ Vaccine + Bevacizumab

Conditions:   Stage III Ovarian Cancer;   Stage IV Ovarian Cancer
Interventions:   Biological: Vigil™ Vaccine;   Drug: Bevacizumab
Sponsor:   Gradalis, Inc.
Completed

Tue, 13 Mar 2012 12:00:00 EDT

First-line Therapy of Stage IV Colorectal Cancer

Condition:   Stage IV Colorectal Cancer
Intervention:   Drug: Oxaliplatin, Capecitabine, Bevacizumab, Imatinib
Sponsors:   University of Cologne;   Roche Pharma AG;   Novartis;   Sanofi
Completed

Tue, 04 Nov 2008 12:00:00 EST

TF (SENSIMED Triggerfish) in Intraocular Anti-VEGF (Vascular Endothelial Growth Factor) Injection

Conditions:   Neovascular Age Related Macular Degeneration (AMD);   Open Angle Glaucoma
Interventions:   Procedure: Intraocular anti-VEGF injection;   Device: SENSIMED Triggerfish
Sponsor:   Sensimed AG
Terminated

Thu, 14 Nov 2013 12:00:00 EST

A Study to Develop Predictive and Prognostic Tools for Optimizing Therapy With Bevacizumab Frontline Cancer Therapy in Participants With HER 2-Negative Aggressive Metastatic Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Bevacizumab;   Drug: Paclitaxel
Sponsor:   Hoffmann-La Roche
Completed

Tue, 24 Nov 2015 12:00:00 EST

A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors.

Condition:   NSCLC Stage IIIB~IV
Intervention:   Drug: Atezolizumab Injection; bevacizumab Injection
Sponsor:   National Taiwan University Hospital
Recruiting

Fri, 01 Nov 2019 12:00:00 EDT

Phase 2 Randomized Clinical Trial of Luminate® as Compared to Avastin® in the Treatment of Diabetic Macular Edema

Condition:   Diabetic Macular Edema
Interventions:   Drug: Luminate 1.0mg;   Drug: Luminate 2.0mg;   Drug: Luminate 3.0mg;   Drug: Avastin;   Drug: Luminate 0.5mg
Sponsors:   Allegro Ophthalmics, LLC;   Trial Runners, LLC;   Duke University
Completed

Wed, 28 Jan 2015 12:00:00 EST

Safety and Efficacy Study to Compare Capecitabine + Bevacizumab Versus Capecitabine, Concomitantly With Radiotherapy as Neoadjuvant Treatment for Patients With Localized and Resectable Rectal Cancer

Condition:   Rectal Cancer
Interventions:   Drug: Bevacizumab + Capecitabine + Radiotherapy;   Drug: Capecitabine + Radiotherapy
Sponsors:   Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD);   Hoffmann-La Roche
Completed

Wed, 06 Jan 2010 12:00:00 EST

A Single-arm, Open-label, Multi-center Phase II Clinical Study to Evaluate the Safety and Efficacy of Toripalimab Injection (JS001) Combined With Bevacizumab as the First-line Therapy for Advanced Hepatocellular Carcinoma (HCC)

Condition:   Advanced Hepatocellular Carcinoma (HCC)
Intervention:   Combination Product: Toripalimab combined with Bevacizumab
Sponsor:   Shanghai Junshi Bioscience Co., Ltd.
Recruiting

Wed, 28 Oct 2020 12:00:00 EDT

Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer

Condition:   Untreated Metastatic Colorectal Cancer
Interventions:   Drug: Veliparib;   Drug: Placebo;   Drug: Modified FOLFIRI;   Drug: FOLFIRI;   Drug: Bevacizumab;   Drug: Fluorouracil infusion
Sponsor:   AbbVie
Completed

Wed, 03 Dec 2014 12:00:00 EST

Study of FOLFIRI Plus Bevacizumab in Colorectal Cancer Patients

Condition:   Colorectal Cancer
Interventions:   Drug: 5-Fluorouracil;   Drug: Bevacizumab;   Drug: Leucovorin;   Drug: Irinotecan
Sponsors:   M.D. Anderson Cancer Center;   Genentech, Inc.;   Pfizer
Completed

Thu, 20 Jul 2006 12:00:00 EDT

A Study of Avastin (Bevacizumab) in Combination With Fotemustine in Patients With Metastatic Melanoma

Condition:   Malignant Melanoma
Interventions:   Drug: bevacizumab [Avastin];   Drug: fotemustine
Sponsor:   Hoffmann-La Roche
Completed

Wed, 17 Feb 2010 12:00:00 EST

Bevacizumab, Erlotinib, and Capecitabine for Locally Advanced Rectal Cancer

Condition:   Rectal Cancer
Interventions:   Drug: Bevacizumab;   Drug: Capecitabine;   Drug: Erlotinib;   Radiation: Radiation Therapy;   Procedure: Surgery
Sponsors:   M.D. Anderson Cancer Center;   Genentech, Inc.
Completed

Mon, 15 Oct 2007 12:00:00 EDT

Temsirolimus and Bevacizumab in Hormone-Resistant Metastatic Prostate Cancer That Did Not Respond to Chemotherapy

Condition:   Prostate Cancer
Interventions:   Drug: temsirolimus;   Biological: bevacizumab;   Genetic: polymorphism analysis;   Other: laboratory biomarker analysis
Sponsor:   Case Comprehensive Cancer Center
Completed

Tue, 09 Mar 2010 12:00:00 EST

Efficacy of Docetaxel, Capecitabine, Cisplatin, and Bevacizumab in Patients With Unresectable Advanced Gastric Cancer

Condition:   Advanced Gastric Cancer
Intervention:   Drug: Docetaxel, Capecitabine, Cisplatin, Bevacizumab
Sponsors:   Asan Medical Center;   Roche Pharma AG
Completed

Tue, 15 Nov 2011 12:00:00 EST

Detection of Early Esophageal Cancer by NIR-FME.

Condition:   Barrett Esophagus
Interventions:   Drug: Bevacizumab-IRDye800CW;   Diagnostic Test: Fluorescence endoscopy
Sponsors:   University Medical Center Groningen;   Helmholtz Zentrum München
Recruiting

Fri, 15 Mar 2019 12:00:00 EDT

Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer

Condition:   Colorectal Cancer
Interventions:   Biological: Bevacizumab;   Drug: Floxuridine;   Drug: Irinotecan;   Drug: Leucovorin
Sponsor:   University of Miami
Terminated

Mon, 19 Mar 2007 12:00:00 EDT

Mebendazole as Adjuvant Treatment for Colon Cancer

Condition:   Colorectal Cancer
Interventions:   Drug: Folfox with avastin;   Drug: Mebendazole
Sponsor:   Sherief Abd-Elsalam
Recruiting

Wed, 24 Apr 2019 12:00:00 EDT

Multimodal Imaging Analysis During Treatment With Bevacizumab in Patients With Recurrent Glioblastoma

Condition:   Glioblastoma
Interventions:   Drug: F-MISO;   Other: Cerebral magnetic resonance imagery;   Drug: Bevacizumab;   Other: Clinical examination
Sponsor:   University Hospital, Toulouse
Terminated

Fri, 22 Jul 2016 12:00:00 EDT

Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors

Condition:   Solid Tumors
Interventions:   Drug: Bevacizumab;   Drug: Dasatinib
Sponsor:   National Cancer Institute (NCI)
Completed

Mon, 03 Oct 2011 12:00:00 EDT

Bevacizumab Versus Micropulse in Central Serous Chorioretinopathy (CSC)

Condition:   Central Serous Chorioretinopathy
Interventions:   Device: subthreshold micropulselaser;   Drug: bevacizumab
Sponsor:   Johann Wolfgang Goethe University Hospital
Completed

Fri, 05 Dec 2008 12:00:00 EST

A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell Carcinoma

Condition:   Carcinoma, Renal Cell
Intervention:   Drug: combination of gemcitabine, capecitabine, and bevacizumab
Sponsors:   University of Chicago;   Genentech, Inc.;   Eli Lilly and Company
Terminated

Fri, 31 Aug 2007 12:00:00 EDT

PD-1 Immune Checkpoint Inhibitor Combined With Bevacizumab for Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of First Line Chemotherapy

Conditions:   Recurrent Nasopharyngeal Carcinoma;   Metastatic Nasopharyngeal Carcinoma;   Chemotherapy Effect
Intervention:   Drug: PD-1 Immune Checkpoint Inhibitor Combined With Bevacizumab
Sponsor:   XIANG YANQUN
Recruiting

Tue, 04 May 2021 12:00:00 EDT

Bevacizumab and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer

Conditions:   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions:   Biological: bevacizumab;   Drug: docetaxel;   Other: laboratory biomarker analysis
Sponsor:   National Cancer Institute (NCI)
Completed

Fri, 07 Mar 2003 12:00:00 EST

QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer

Conditions:   Refractory Metastatic Colorectal Cancer;   pMMR;   MSS
Interventions:   Drug: Bevacizumab;   Drug: Tripleitriumab
Sponsors:   Second Affiliated Hospital, School of Medicine, Zhejiang University;   Qilu Pharmaceutical Co., Ltd.;   Shanghai Junshi Bioscience Co., Ltd.
Not yet recruiting

Wed, 26 Aug 2020 12:00:00 EDT

N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma

Condition:   Neuroblastoma
Interventions:   Drug: Bevacizumab;   Drug: cyclophosphamide;   Drug: zoledronic acid
Sponsors:   New Approaches to Neuroblastoma Therapy Consortium;   National Cancer Institute (NCI)
Completed

Tue, 21 Apr 2009 12:00:00 EDT

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

Conditions:   Advanced Lung Non-Squamous Non-Small Cell Carcinoma;   Metastatic Lung Non-Squamous Non-Small Cell Carcinoma;   Recurrent Lung Non-Squamous Non-Small Cell Carcinoma;   Stage IIIB Lung Cancer AJCC v8;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
Interventions:   Biological: Bevacizumab;   Drug: Osimertinib
Sponsor:   National Cancer Institute (NCI)
Recruiting

Fri, 29 Nov 2019 12:00:00 EST

First-line FOLFOXIRI Plus Bevacizumab in BRAF Mutant Metastatic Colorectal Cancer

Condition:   Metastatic Colorectal Cancer
Intervention:   Drug: FOLFOXIRI plus bevacizumab
Sponsor:   Azienda Ospedaliero, Universitaria Pisana
Completed

Wed, 21 Sep 2011 12:00:00 EDT

Study to Evaluate Markers of Response in Locally Advanced Breast Cancer

Condition:   Breast Neoplasms
Intervention:   Other: Bevacizumab, docetaxel and doxorubicin followed by surgery
Sponsors:   Clinica Universidad de Navarra, Universidad de Navarra;   Roche Farma, S.A
Completed

Tue, 19 Apr 2011 12:00:00 EDT

FMISO PET Study of Glioblastoma

Condition:   Recurrent Glioblastoma
Interventions:   Device: FMISO PET;   Device: MRI;   Drug: Bevacizumab;   Drug: CCNU
Sponsors:   Massachusetts General Hospital;   National Cancer Institute (NCI)
Completed

Mon, 03 Mar 2014 12:00:00 EST

A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injections for Retinal Vein Occlusion or Diabetic Macular Edema

Conditions:   Retinal Vein Occlusion;   Macular Edema
Intervention:   Drug: Anti-VEGF
Sponsor:   Allergan
Completed

Wed, 07 Aug 2013 12:00:00 EDT

The Effects of Bevacizumab and Ranibizumab on Ocular Pulse Amplitude in Neovascular Age Related Macular Degeneration (AMD)

Condition:   Neovascular Age Related Macular Degeneration
Interventions:   Device: Pascal Dynamic Contour Tonometer;   Drug: Ranibizumab;   Drug: Bevacizumab
Sponsors:   Sheba Medical Center;   Universitaire Ziekenhuizen Leuven
Unknown status

Fri, 21 Mar 2008 12:00:00 EDT

A Clinical Study to Evaluate Efficacy and Safety of HLX10 Combined With HLX04 and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC)

Condition:   Metastatic Colorectal Cancer
Interventions:   Drug: HLX10/Placebo;   Drug: HLX04/Avastin
Sponsor:   Shanghai Henlius Biotech
Not yet recruiting

Mon, 14 Sep 2020 12:00:00 EDT

Open Label Trial for Post-Menopausal Women With Newly Diagnosed Operable Breast Cancer

Condition:   Breast Cancer
Intervention:   Drug: Letrozole in combination with Bevacizumab
Sponsors:   University of Alabama at Birmingham;   Genentech, Inc.
Completed

Mon, 12 Sep 2005 12:00:00 EDT

Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Conditions:   Fallopian Tube Cancer;   Primary Peritoneal Cavity Cancer;   Recurrent Ovarian Epithelial Cancer;   Stage IV Ovarian Epithelial Cancer
Interventions:   Biological: bevacizumab;   Drug: erlotinib hydrochloride;   Other: laboratory biomarker analysis
Sponsor:   National Cancer Institute (NCI)
Completed

Thu, 04 Aug 2005 12:00:00 EDT

PRIMADOS Study:A Study of Avastin (Bevacizumab) Plus Docetaxel for First Line Treatment of Patients With Metastatic Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: bevacizumab [Avastin];   Drug: docetaxel
Sponsor:   Hoffmann-La Roche
Withdrawn

Fri, 17 Oct 2008 12:00:00 EDT

A Study of The Safety Profile of First-line Avastin (Bevacizumab) in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Her2-negative Breast Cancer (AVATAX)

Condition:   Breast Cancer
Interventions:   Drug: bevacizumab [Avastin];   Drug: paclitaxel
Sponsor:   Hoffmann-La Roche
Withdrawn

Mon, 05 Jul 2010 12:00:00 EDT

Avastin and Chemotherapy Followed by a KRAS Stratified Randomization to Maintenance Treatment for First Line Treatment of Metastatic Colorectal Cancer.

Condition:   Colorectal Cancer
Interventions:   Drug: bevacizumab, erlotinib;   Drug: bevacizumab;   Drug: low dose capecitabine
Sponsors:   Lund University Hospital;   Hoffmann-La Roche
Completed

Thu, 28 Oct 2010 12:00:00 EDT

Comparison of Interval Variation and Dosage in Preoperative Bevacizumab and Ziv-Aflibercept Administration in Proliferative Diabetic Retinopathy Undergoing Vitrectomy

Condition:   Diabetic Retinopathy
Intervention:   Drug: Intravitreal bevacizumab or intravitreal ziv-aflibercept
Sponsor:   Panhandle Eye Group, LLP
Recruiting

Wed, 28 Oct 2015 12:00:00 EDT

A Translational Trial on Molecular Markers and Functional Imaging to Predict Response of Preoperative Treatment of Breast Cancer Early

Condition:   Breast Cancer
Interventions:   Drug: Epirubicin;   Drug: Docetaxel;   Drug: Bevacizumab
Sponsor:   Thomas Hatschek
Unknown status

Wed, 12 Aug 2009 12:00:00 EDT

A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLC

Condition:   Advanced Non-squamous NSCLC
Interventions:   Biological: Bevacizumab;   Drug: AMG 706;   Drug: Paclitaxel;   Drug: Carboplatin
Sponsor:   Amgen
Terminated

Tue, 29 Aug 2006 12:00:00 EDT

LEAC-102 for Advanced Colorectal Cancer

Condition:   Advanced Colorectal Cancer
Intervention:   Drug: LEAC-102 500mg capsule and FOLFOX + Bevacizumab/Cetuximab
Sponsor:   Taiwan Leader Biotech Corp.
Not yet recruiting

Mon, 11 Jul 2016 12:00:00 EDT

Intravitreal Bevacizumab Combined With PDT Versus Bevacizumab to Treat Exudative AMD

Condition:   Macular Degeneration
Interventions:   Drug: bevacizumab;   Drug: vetaporfin
Sponsor:   Federal University of São Paulo
Unknown status

Wed, 28 May 2008 12:00:00 EDT

Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes

Conditions:   Sarcoma;   Leiomyosarcoma;   Malignant Fibrous;   Histiocytoma;   Angiosarcoma
Interventions:   Drug: gemcitabine;   Drug: docetaxel;   Drug: bevacizumab
Sponsors:   Memorial Sloan Kettering Cancer Center;   Genentech, Inc.
Completed

Fri, 24 Apr 2009 12:00:00 EDT

A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast Cancer

Conditions:   Breast Neoplasms;   Breast Tumors;   Breast Cancer;   Locally Recurrent and Metastatic Breast Cancer
Interventions:   Drug: AMG 706 placebo;   Drug: Bevacizumab;   Drug: AMG 706;   Drug: Paclitaxel
Sponsor:   Amgen
Terminated

Wed, 26 Jul 2006 12:00:00 EDT

A Study of Avastin (Bevacizumab) Plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.

Condition:   Breast Cancer
Interventions:   Drug: bevacizumab [Avastin];   Drug: Taxane-based chemotherapy
Sponsor:   Hoffmann-La Roche
Completed

Mon, 19 Mar 2007 12:00:00 EDT